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Abstract 
Introduction 
HIV -associated facial lipoatrophy is a stigmatizing condition associated with 
significant psychological morbidity. The condition may be treated with soft tissue 
fillers, although quantification of objective and patient- reported outcomes is lacking. 
The primary aim of this study was to evaluate change in facial volume and 
psychological morbidity following treatment for HIV lipodystrophy with autologous fat 
transfer, Newfill and Bio- alcamid. An additional aim of the study was to compare 
psychological characteristics between HIV seropositive patients with lipodystrophy 
(HIV LD) and without lipodystrophy (HIV non -LD) and HIV seronegative men who 
have sex with men (MSM). 
Methods 
HIV LD patients were treated with autologous fat, Newfill or Bio- alcamid based on a 
clinical assessment in a prospective, observational study. The Colemnan technique of 
fat transfer was utilised. Newfill injections were carried out at monthly intervals using 
1 vial per cheek. Bio- alcamid was injected subcutaneously under aseptic technique to 
achieve the desired cheek augmentation. 3 -D images were obtained pre- operatively 
then at 2, 6 and 12 months post -operatively using the DI3D system. Volume changes in 
treated areas were measured using DI3D software. The DAS -24 and HADS were used 
to assess psychological morbidity at similar time intervals. 
An additional case -control study was conducted to measure psychological morbidity in 
HIV LD, HIV non -LD and MSM groups utilising the Derriford Appearance Scale 
(DAS -24) and Hospital Anxiety and Depression Scale (HADS). 
Data was analyzed using appropriate statistical tests. 
Results 
ANOVA tests demonstrated significantly higher DAS -24 scores in the HIV -LD group 
compared to the HIV non -LD and MSM groups. No difference in HADS -A scores was 
seen between groups. 
48 patients with HIV LD were treated: 16 patients had Bio- alcamid augmentation, 20 
patients received Newfill injections and 12 patients underwent fat transfer. The mean 
injected volume of Bio- alcamid was 25.5cc The Wilcoxin test demonstrated no 
significant difference in mean volume change relative to zero at 2, 6 and 12 months. 
The mean injected volume of fat was 20.1cc, which did not differ from the measured 
volumes at 2 months (1)= 0.15). There was a mean reduction in measured volume of 
7.3cc at 6 months and 9cc at 12 months (p <0.001). 
For Newfill, the mean volume change compared to baseline was 8.7cc at 2months, 
increasing to 12.6cc at 6 months and 12.3cc at 12 months. 
ANOVA tests demonstrated no difference in psychological outcomes between groups. 
There was a significant improvement in DAS -24 scores compared too baseline for all 3 
groups throughout follow -up. For Bio- alcamid, a significant improvement in HADS -A 
and HADS -D scores were seen at 2 months but mean scores increased at 6 and 12 
months. In the fat group, some improvement in HADS -A and HADS -D scores were 
seen at follow -up, although values only reached significance at 6 months. In the 
Newfill group, small improvements in both HADS -A and HADS -D were demonstrated 
in the post -treatment scores, although these did not reach significance. No correlation 
between change in facial volume and psychological measures was demonstrated. 
Conclusions 
The case control study demonstrated that patients with HIV lipodystrophy have greater 
distress relating to body image and depression compared to HIV -seropositive patients 
without lipodstrophy and HIV -seronegative MSM control groups. 
The prospective study of the HIV LD treatment cohort demonstrated a change in 3 -D 
measured facial volume for all 3 groups. Bio- alcamid produced the greatest, permanent 
volume change but was associated with the most complications. Newfill was associated 
with a moderate, delayed volume augmentation but was insufficient for some patients 
with severe lipoatrophy. Volume enhancement with autologous fat was good 
immediately post -operatively but variable degrees of fat resorption occurred. Treatment 
was associated with improved body image perception. However, initial improvements 
in anxiety and depression symptoms were not maintained in the long term. 
CHAPTER 1 Introduction 
1.1. Hypotheses 
The hypotheses of this study were that: 
1. HIV lipodystrophy is associated with psychological morbidity relating to body 
image, anxiety and depression. 
2. Treatment of HIV lipodystrophy using autologous fat transfer, Newfill® or Bio- 
alcamid®, is associated with an improvement in psychological morbidity and 
anatomical volume of treated areas. 
3. The DI3D system is a valid and reproducible method of recording and measuring 
facial 3 -D volume. 
1.2. Overview of HIV Lipodystrophy 
HIV -associated lipodystrophy is a syndrome of morphological changes (central fat 
accumulation and peripheral fat atrophy) and metabolic changes (hyperlipidaemia and 
insulin resistance) which has been increasingly reported in patients since 1998 (Carr, 
Samaras et al. 1998). The consequence of altered body fat morphology is social 
stigmatization that may lead to poorer adherence and the failure of anti -retroviral 
therapy. Moreover, metabolic abnormalities may increase the risk of cardiovascular 
disease (Carr, Samaras et al. 1999). 
1.2.1 Definition 
At least five definitions of lipodystrophy have been proposed (Carr, Miller et al. 2000; 
Martinez, L et al. 2000; Saint -Marc, Partisani et al. 2000), and although HIV 
investigators have attempted to develop meaningful case definitions for changes in 
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scan for assessment of extremity fat. These are not modalities available to the general 
HIV population for the purposes of diagnosis of HIV lipodystrophy. Given the need for 
rationing of resources, it may be inappropriate to perform tests which are expensive, 
require expertise and do not lead to a direct intervention. 
1.2.2. Prevalence 
From the era of Highly Active Antiretroviral Therapy (HAART), a spectrum of 
changes in body fat have been reported to occur in 20 -80% of subjects receiving these 
therapies (Carr, Law et al. 2003; Miller, Carr et al. 2003; Sattler 2003). The wide 
variability in prevalence is mostly related to an absence of standardized case definitions 
but also inclusion of cases based on patients' self -report of changes, variability in the 
way different physicians clinically assess fat distribution, and extraction of data from 
chart reviews. In a review of 15 studies with over 100 HIV patients who reported 
features of HIV -associated adipose redistribution syndrome (HARS), HARS was 
reported in 9 -48% patients (mean 32 %)(Lichtenstein, Wanke et al. 2004). 
1.2.3. Clinical features 
Table 1.1 summarizes the morphological and metabolic changes associated with HIV - 
associated lipodystrophy. 
Table 1.1. Clinical features of HIV -associated lipodystrophy 
Morphological 
Peripheral lipoatrophy: 
Face, arms, legs, buttocks 
 Central fat accumulation 




Insulin resistance (increased insulin, C- peptide) 
Type II diabetes mellitus/ impaired glucose tolerance 
Lactic acidaemia 
1.2.3.1. Morphological changes 
Changes in body fat distribution are characteristic of HIV associated lipodystrophy. 
On body shape changes alone, three different patterns of lipodystrophy have been 
described: 
signs of peripheral fat atrophy alone 
signs of lipohypertrophy alone 
a mixed type involving both lipoatrophy and fat accumulation 
There is now accumulating evidence that lipoatrophy, central adiposity and the 
combination of both result from different pathogenetic developmental 
processes.(Behrens and Schmidt 2003) 
The most prominent clinical sign is a loss of subcutaneous fat in the face and 
extremities. Facial atrophy characterized by sunken cheeks, hollow temples, sunken 
eyes, and prominent zygomatic arch has been attributed to the loss of buccal, parotid, 
and pre -auricular fat pads. Adipose tissue loss from the peripheral regions occasionally 
leads to prominent veins resembling varicosities. The most common site for 
lipoatrophy is the face, and is often the most distressing for the patient as it identifies 
them as being affected by HIV. Central facial wasting may also be accentuated by 
parotid hypertrophy in some patients. 
Anatomically, facial fat lies in three planes: subcutaneous fat, fat within the superficial 
musculo -aponeurotic system (SMAS) layer and the deep fat pads. The deep fat of the 
cheek constitutes the Bichat fat sack, which has three branches: temporal, buccinator 
and retromandibular. In the literature, facial atrophy has been attributed to either 
atrophy of the deep facial fat pads, or atrophy of all layers of facial fat (Serra -Renom 
and Fontdevila 2004). However, one recent study which evaluated the anatomy of the 
buccal fat pad of Bichat in HIV -related facial atrophy reported normal position and 
thickness of the fat pad and suggests that the cachectic appearance of the face is likely 
secondary to profound atrophy of the subcutaneous tissues in these areas (Talmor, 
Hoffman et al. 2002). 
A classification of facial lipoatrophy has been proposed to assist in treatment decisions 
(James, Carruthers et al. 2002). Grade 1 is mild and localized, and the appearance is 
almost normal. Grade 2 has longer and deeper central cheek atrophy, with the facial 
muscles (especially zygomaticus major) beginning to show through. In grade 3, the 
atrophic area is even deeper and wider with the muscles clearly showing and in grade 4, 
atrophy covers a wide area and extends up towards the orbit. 
Some patients have concomitant deposition of excess adipose tissue around the neck, 
over the dorsocervical spine (buffalo hump), upper torso and intra- abdominal region 
(Talmor, Hoffman et al. 2002). Dorsocervical fat accumulation can be disfiguring and 
is associated with the development of neck pain and sleep apnoea (Piliero, Hubbard et 
al. 2003). Fat accumulation at the occipital region may also occur. Breast enlargement 
has been reported in both sexes, although it is unclear whether this is due to excess 
subcutaneous fat, glandular hypertrophy or both.(Paech, Lorenzen et al. 2002) 
Other possible related symptoms include dry skin or lips, nail dystrophy, hair loss or 
brittleness, dysmenorrhoea, impotence, avascular osteonecrosis, osteoporosis, liver 
steatosis, cardiovascular disease, and increased bleeding in haemophiliacs (Can and 
Cooper 2000). Visceral fat accumulation has also been reported to cause distension and 
abdominal cramps. A few cases of thrombosis and pancreatitis have been reported 
related to high triglyceride levels. 
Several techniques are suitable for measuring regional fat distribution including dual 
energy x -ray absorptiometry (DEXA), computer tomography (CT), magnetic resonance 
imaging (MRI) and ultrasound. Anthropometric measurements, including waist 
circumference, sagittal diameter, and skin fold thickness are cheaper and easier to 
perform than imaging techniques but are operator dependent.(Behrens and Schmidt 
2003) Three -dimensional laser scans have been used for measurement of facial 
volumes (Ras, Habets et al. 1996; Hajeer MY 2002) and may provide an objective tool 
for monitoring changes in facial lipoatrophy (Benn, Ruff et al. 2003). 
Sonography has been used in HIV lipodystrophy to quantify subcutaneous 
fat(Martinez, L et al. 2000), and in intervention studies to quantify facial tissue 
thickness changes (Valantin, Aubron -Olivier et al. 2003; Moyle, Lysakova et al. 2004). 
Martinez et al measured subcutaneous fat thickness at three reference skin points 
(periumbilical, brachial, and malar) and infra- abdominal fat thickness in HIV -1- 
infected patients with and without lipodystrophy and in healthy controls. Measurement 
of subcutaneous facial and arm fat was simpler, less variable, and more discriminative 
to diagnose abnormal regional fat distribution than that of intra- abdominal fat. They 
concluded that sonography was useful in quantifying regional fat distribution in HIV -1- 
infected patients. Its potential advantages include simplicity, availability, safety, patient 
tolerance, and low cost compared with DEXA, computed tomography, and MRI. 
However, the use of ultrasonography to measure malar fat is not advocated by Carey et 
al who assessed facial lipoatrophy changes in HIV -infected adults receiving 
antiretroviral therapy who participated in a 48 -week, randomized, placebo -controlled 
trial of rosiglitazone.(Carey, Wand et al. 2005) Ultrasound was performed at weeks 0, 
24 and 48 to determine the subcutaneous fat thickness over the malar bone. No 
significant correlation was found between between malar sonographic measures and 
body composition parameters assessed by DEXA and CT. They conclude that 
sonography may be subject to measurement error, correlates poorly with more 
established objective measures of lipoatrophy, and is therefore not recommended. 
However, these studies compare facial ultrasound with DEXA and CT measurements 
of non -facial body parts. There are no studies to compare the efficacy of facial 
ultrasound and other imaging modalities in the assessment of HIV -associated facial 
lipoatrophy. These studies also demonstrated the need for non -invasive technology to 
quantify facial lipoatrophy. 
1.2.3.2. Metabolic changes 
Frequently, complex metabolic alterations are associated with the described body shape 
alterations. These include peripheral and hepatic insulin resistance, impaired glucose 
tolerance, type II diabetes, hypertriglyceridaemia, hypercholesterolaemia, increased 
free fatty acids, and reduced high density lipoproteins.(Sekhar, Jahoor et al. 2002) The 
prevalence of insulin resistance and glucose tolerance is reported in the literature at 20- 
50% depending on study design and measurement methods (Carr, Samaras et al. 1999). 
1.2.4. Pathogenesis and associated risk factors 
The pathogenesis of HIV lipodystrophy is complex and the aetiology is likely to be 
multi -factoral. Published studies provide evidence for two assumptions: firstly, 
lipoatrophy and lipoaccumulation result from divergent mechanisms. Secondly, the 
various classes of anti -retroviral drugs contribute to the lipodystrophy syndrome by 
different and probably overlapping mechanisms. 
1.2.4.1 Protease Inhibitors 
Many studies have suggested a link between the use of protease inhibitors and the 
development of lipodystrophy. Carr and Cooper performed two studies and found that 
64% of patients receiving protease inhibitor (PI) therapy developed lipodystrophy, 
compared to 3% of protease inhibitor -naïve patients.(Carr and Cooper 2000) One year 
later, Carr et al reported 83% of subjects receiving PI therapy developed lipodystrophy, 
while only 4% of those not receiving PI therapy developed lipodystrophy.(Carr, 
Samaras et al. 1999) They estimated that the mean time to lipodystrophy was 10 
months after commencing protease inhibitor treatment. An increased duration of PI 
therapy has been shown to increase the odds of fat wasting and the probability of intra- 
abdominal fat accumulation.(Carr, Samaras et al. 1998) Protease inhibitors account for 
the majority of metabolic abnormalities associated with the lipodystrophy syndrome. 
Numerous studies report increases in the levels of total triglycerides and triglyceride- 
rich lipoproteins (VLDL) accompanied by raised LDL levels after initiation of PI 
therapy. These changes are frequently associated with hyperinsulinaemia and/ or 
insulin resistance (Walli, Herfort et al. 1998). 
The underlying mechanisms for fat depletion and accumulation in HIV- infected 
patients receiving antiretroviral therapy remain unclear. One hypothesis proposes that 
protease inhibitors bind to and inhibit proteins involved in lipid metabolism. (Carr, 
Samaras et al. 1998) There is homology between the amino acid sequences of the 
catalytic site of HIV protease and two proteins involved in lipid metabolism regulation: 
low- density lipoprotein receptor -related protein (LRP) and cytoplasmic retinoic -acid 
binding protein type 1 (CRABP -1). Protease inhibitor binding of LRP reduces 
postprandial chylomicron clearance which leads to hyperlipidaemia. Binding of 
protease inbibitors to CRABP -1 prevents binding of retinoic acid which diminishes the 
production of cis -9- retinoic acid. This reduces differentiation and increases apoptosis of 
peripheral adipocytes and leads to impaired fat storage and lipid release. An alternative 
suggested mechanism is that PI therapy inhibits adipogenesis by a process involving 
sterol regulatory element binding proteins (SREBPs), which are membrane bound 
transcription factors that play a central role in cellular lipid homeostasis. (Caron, 
Auclair et al. 2001) 
Differences in the metabolic activity of central, dorso- cervical and peripheral 
adipocytes has been proposed. Thus, the impaired fat storage and hyperlipidaemia 
associated with protease inhibitor treatment may lead to preferential central 
accumulation of fat. A link between PI therapy and altered apolipoprotein (B and C -III) 
synthesis has been postulated.(Carr, Samaras et al. 1998) 
1.2.4.2. Nucleoside/ non -nucleoside reverse transcriptase inhibitors 
Some have suggested that the real risk of developing lipodystrophy is associated with 
nucleoside reverse transcriptase inhibitors (NRTI) therapy, not PI therapy. NRTIs are 
phosphorylated and incorporated into new DNA, resulting in HIV DNA termination. 
Mitochondrial toxicity associated with non -nucleoside reverse transcription inhibitors 
has been well established and is thought to contribute to the fat redistribution syndrome 
seen in patients with HIV infection (McComsey and Walker 2004). It is thought that the 
toxicity of these drugs is due to inhibition of mitochondrial DNA polymerase gamma 
resulting in impaired synthesis of mitochondrial enzymes that generate ATP. (Hadigan, 
Miller et al. 1999) Decreased levels of mitochondrial DNA were found in the blood 
cells of NRTI- treated patients (Cote, Brumme et al. 2002). Depletion of mtDNA and 
structural changes in the mitochondria are thought to result in increased rates of 
apoptosis in subcutaneous adipocytes. The resulting apoptosis or complement (C3) 
deficiency can lead to abnormal fat distribution. 
Several retrospective cohort studies demonstrate an association between HIV 
lipodystrophy and NRTIs, most notably stavudine (Can, Miller et al. 2000). Exclusive 
NRTI therapy seems to have minor impact on lipid metabolism. Although fat 
redistribution has been observed in patients treated with NRTIs alone, the addition of a 
PI to the regimen substantially increases the risk of lipoatrophy.(Madge, Kinloch -de- 
Loes et al. 1999) It has been suggested that the pattern of lipodystrophy varies with 
drug therapy: NRTIs are associated with lipoatrophy alone, whilst NRTI combined 
with PI therapy is associated with lipoatrophy and lipohypertrophy. However, the wide 
variety of drug combinations used make it difficult to identify risk associated with 
particular drugs. Can et al demonstrated no significant difference in physical or body 
composition parameters between patients with NRTI -lipodystrophy syndrome and 
those with protease inhibitor- associated lipodystrophy syndrome. However, NRTI- 
lipodystrophy syndrome had more recent onset of symptoms and weight loss, higher 
lactate and alanine aminotransferase, and lower albumin, cholesterol and triglycerides, 
glucose and insulin compared to protease inhibitor- associated lipodystrophy 
syndrome.(Carr, Samaras et al. 1999) 
1.2.4.3. HIV infection 
The development of HIV lipodystrophy has been positively associated with the 
duration of HIV infection, negatively associated with previous HIV viral load, and both 
positively and negatively associated with blood CD4 lymphocyte counts in various 
studies.(Chen, Misra et al. 2002) 
1.2.4.4. Nutritional status, age and adiposity 
Body adiposity before receiving antiretroviral therapy may also affect features of 
lipodystrophy. In one cross sectional study, patients with Body Mass Index (BM) 
greater than 28 kg /m2 had higher prevalence of buffalo hump and breast enlargement, 
but a lower prevalence of facial and gluteal fat loss compared with underweight 
patients (BMI <20 kg /m2).(Pettit, Kotler et al. 1999) Older people tend to have greater 
body fat mass, particularly intraabdominal fat, which may contribute to the body fat 
changes seen in HIV lipodystrophy.(Mercie, Tchamgoue et al. 1999) 
1.2.4.5. Female sex 
Trunk obesity rather than subcutaneous fat wasting appears to be more common in 
women than in men (Hadigan, Miller et al. 1999) although prospective studies are 
required to evaluate whether there are true differences between the sexes. 
1.2.4.6. Cytokines 
There is an association between lipodystrophy and levels of serum inflammatory 
factors. One study analyzed the mRNA expression of adipocytokines and 
transcriptional factors in fat samples from 26 patients with peripheral lipoatrophy.(Jan, 
Cervera et al. 2004) The patients' fat showed higher values of apoptosis, fibrosis, 
vessel density and macrophage infiltration than the controls' fat, together with lower 
adiponectin and leptin mRNA levels and higher interleukin (IL) -6 and tumour necrosis 
factor (TNF)alpha mRNA levels. Elevated levels of the soluble type 2 tumour necrosis 
factor -alpha receptor has been linked with insulin resistance associated with 
lipodystrophy. C- peptide has been shown to be the strongest metabolic predictor of 
future LD severity in patients receiving combines NRTI and protease inhibitor 
therapy.(James, Carruthers et al. 2002) 
t 2.5. Management of HIV Lipodystrophy 
1.2.5.1. Non -surgical management 
To date, there has been no adequate treatment to resolve lipodystrophy. Various 
therapeutic options are summarized in table three. Dietary modification is ineffective. 
Exercise may lead to partial beneficial decrease in central fat accumulation and 
triglyceride levels but at the expense of increased peripheral fat wasting(Milinkovie and 
Martinez 2005). The use of recombinant growth hormone can be beneficial in patients 
with visceral abdominal fat or dorso- cervical fat pad. However, it is not recommended 
for the treatment of patients with features of lipoatrophy as it may lead to a reduction in 
peripheral fat. The impact of switching anti -retrovirals that are implicated in the 
lipodystrophy syndrome has been commonly assessed in different studies. In general, 
switching antiretroviral regimes may improve metabolic abnormalities but the impact 
on body fat is very small. 
Table 1.2. Therapeutic options for HIV -associated lipodystrophy and related metabolic 
complications 
Lifestyle changes (reduce saturated fat and cholesterol intake, increase physical 
activity, cessation of smoking) 




Recombinant human growth hormone 
Surgical intervention 
1.2.5.1 Surgical management of HIV lipodystrophy 
There are various described surgical techniques for the treatment of lipodystrophy and 
these can be divided into treatments for lipoatrophy or treatments for lipohypertrophy 
and have been summarized in our paper entitled Plastic surgical options for HIV - 
associated lipodystrophy' (Nelson and Stewart 2008) In this section, the treatment 
options for this study shall be described, namely: autologous fat injections, Newfill®, 
Bio- alcamid® and liposuction. The published literature on other plastic surgery 
options for HIV lipodystrophy shall also be summarized. 
1.3. Treatment Options for Facial Lipoatrophy 
The surgical techniques described for HIV -associated facial lipoatrophy include; 
autologous fat transfer, dermis -fat grafts, rhytidectomy, flaps, soft tissue fillers and 
implants. 
1.3.1 Autologous fat transfer 
The technique of soft tissue augmentation with centrifuge prepared autologous fat 
grafting has been developed by Coleman and is now being used in the treatment of 
HIV -related facial lipoatrophy. (Coleman 2004; Serra -Renom and Fontdevila 2004) 
Autologous tissue is the ideal tissue filler for physiological reasons. The potential 
advantages include biocompatibility, versatility, stability, and a natural appearance. 
(Niechajev and Sevcuk 1994) The Coleman technique involves harvesting fat by 
aspiration, which is then centrifuged and re- injected to augment areas of facial wasting. 
Longevity of correction depends on the tissue, mobility and vascularity of the recipient 
site. The various techniques for fat transfer and controversies surrounding technique 
shall be discussed in this section. 
1.3.1.1. History of Autologous fat transfer 
Autologous transplantation of adipose tissue is a technique that has gained increasing 
popularity over the past two decades. However, the concept of fat transfer is not new. 
The earliest recorded human free fat transfer was by Neuber in 1893, who reported 
using upper extremity fat to recontour soft- tissue facial defects, and emphasised the 
importance of small grafts for more predictable results (Neuber 1893). This was 
followed by reports of free fat autographs to fill soft- tissue defects by Czerny (1895), 
Lexer (1910), and Rehn (1912). In 1911, Bruning was the first to inject autologous fat 
into the subcutaneous tissue for the purpose of soft tissue augmentation. In 1912, 
Hollander published photographs showing the results of fat infiltration into two patients 
with lipoatrophy of the face (Hollander 1910). In 1926, Miller wrote about his 
experiences with infiltration of fatty tissue through cannulas. Early optimism was 
tempered by Peer, who demonstrated histologically that fat grafts lost approximately 45 
percent of their weight and mass one year or more after transplantation (Peer 1956). 
Interest in autologous fat transfer diminished until the advent of liposuction surgery in 
the 1980s which provided plastic surgeons with semi -liquid fat which could be grafted 
with relative ease. In the 1980s, Illouz and Fournier developed an approach to fat 
transfer by syringe harvesting called `microlipoinjection'(Illouz 1985; Fourneir 1986). 
Initial experimentation with this new technique yielded variable results. In the early 
1990s, Ersek reported disappointing results, with fat loss ranging from 20 -90 percent, 
which generated a widespread negative perception of the technique(Ersek 1991). Since 
the mid 1990s, Coleman has confirmed the efficacy and permanence of grafted fat, but 
stresses that this is dependent on the harvesting and grafting technique adopted 
(Coleman 2001). Indeed, ongoing variability in results has been reported depending on 
choice of technique, the area treated, patient factors and surgical experience. In recent 
years, many different techniques have evolved and a standard procedure that is adopted 
by all practitioners has not yet been developed. 
1.3.1.2. Theories of fat graft survival 
There have been two major theories proposed for the survival of fat grafts. The `host 
cell replacement theory' was based on the work of Neuhof and Hirshfeld in 1923. It 
postulated that transplanted fat undergoes complete cell death and that histiocytes 
would scavenge lipid material and eventually replace all the host tissue. The more 
popular theory in recent years is the cell survival theory, which states that some of the 
graft adipose tissue survives after the host reaction subsides and is based on the work of 
Peer. The graft of adipose tissue goes through an initial period of ischaemia and obtains 
nutrition through plasmatic imbibition. Circulation is restored to the grafted fat cells in 
a manner similar to the revascularization of a skin graft. In the first 4 days, host cells, 
such as polymorphonuclear leukocytes (PMNs), plasma cells, lymphocytes, and 
eosinophils, infiltrate the graft. On or about the fourth day, neovascularization is 
evident. Histiocytes act only to remove fat from disrupted cells (Peer 1955). 
More recently, the role of adipose- derived stem cells and preadipocytes in transplanted 
fat has been investigated. These cells appear to be more resistant to trauma than mature 
adipocytes due to lower oxygen consumption requirements. Some researchers have 
proposed that survival of adipose -derived stem cells in the stromal cell fraction of 
transplanted fat is a major factor and may account for the variability in survival of fat 
grafts between individuals.(Billings and May 1989) 
1.3.1.3. Histological evaluation of transplanted fat 
Multiple animal models have been proposed to study the technique of autologous fat 
transfer. Recent histological evaluation of transplanted fat grafts to the lips of rabbits 
has demonstrated an early inflammatory response to the injected fat followed by 
sequestration of nonviable tissue. The transplanted fat remained viable at one year, with 
good overall survivability and minimal fibrosis.(Brucker, Sati et al. 2008) However, 
there are few studies to evaluate the histologic fate of reinjected fat in humans. 
Niechajev et al obtained biopsies of transplanted fat to the cheeks of 9 patients with 
subcutaneous fat atrophy, 7 to 36 months after transplantation. Histologic analysis 
showed an organised lobular structure of transplanted fat at 7 months with more 
pronounced fibrosis between lobuli in the specimens obtained at 36 months. (Niechajev 
and Sevcuk 1994) Carpaneda studied collagen alterations in adipose tissue transplanted 
to abdominal subcutaneous fat prior to abdominoplasty.(Carpaneda 1994) He found a 
type 1 collagen capsule around the grafted fat and several alterations to type 1 and type 
3 collagen synthesis, degradation and remodelling. A shift in the inflammatory process 
from the peripheral viable region to the central unviable region was also demonstrated, 
where pseudocysts were present. Chajchir et al performed biopsies on the sites of 
grafted fat at intervals. Three months after transfer, zones of cytosteatonecrosis, 
lipophagic granulomas, lymphocytes, adipocytes, giant multinucleated cells, and new 
vessels were found. At 6 -8 months, the specimens were infiltrated heavily by PMNs in 
a fibrotic matrix, and, at 1 year, a large amount of connective tissue and fibrotic 
reaction was present. Some fat was still present, but the authors felt that the 
inflammatory reaction may contribute more to the long -term result (Chajchir, 
Benzaquen et al. 1990). There is some disagreement about the role of fibrosis. Some 
authors believe that fibroblasts cause contraction, whilst others believe that they can 
provide augmentation. A fibrous host reaction may be all that occurs in some patients 
although it may be argued that it ultimately fulfilled the role of soft tissue 
augmentation. 
1.3.1.4. Surgical technique and modifications 
A greater understanding of how to maintain viable fat has led to modifications in 
technique that are believed to improve clinical results. These modifications are 
intended to preserve the delicate structure of adipocytes and provide a robust blood 
supply on which fat cells are extremely dependent. However, there is little objective 
scientific evidence and studies are difficult to compare as authors use different 
harvesting techniques, re- injection techniques and means of evaluating the outcome. 
1.3.1.5. Anaesthesia of the donor site 
The use of local anaesthesia at the harvest site has been debated. Whilst some 
practitioners argue that vasoconstriction by local application of epinephrine may have a 
detrimental effect on the graft, others believe that reduced bleeding helps to maintain 
viability.(Sommer and Sattler 200) Some studies have also shown that lidocaine may 
potentially inhibit adipocyte metabolism in culture, but this effect persists only as long 
as the lidocaine is present and has not been demonstrated in vivo.(Moore, Kolaczynski 
et al. 2005) According to a recent survey of American plastic surgeons (Kaufman, 
Bradley et al. 2007), the majority of practitioners use a wetting solution of with a 
mixture of lidocaine and epinephrine (e.g. 50m11% lidocaine plus 1ml of epinephrine 
1:1000 plus 1 litre of normal saline). 
1.3.1.6. Choice of donor site 
The most common sites for fat harvest include the abdomen, thigh, flank, gluteal region 
and knee. In patients with HIV associated lipodystrophy, sites of lipohyperlrophy such 
as the dorso- cervical fat pad may also be utilised for fat harvest. When assessing central 
adiposity, it is important to evaluate whether the fat accumulation lies within the 
subcutaneous tissue or peritoneum. Abdominal computed tomography scans have 
shown that the increase in girth in patients with HIV lipodystrophy is largely due to fat 
accumulation in the peri- visceral region, which is less accessible for harvesting of fat 
grafts. Some authors have suggested that adipocytes from the gluteal- femoral region 
are larger and have greater lipogenic activity, making them the ideal choice for donor 
fat (Hudson, Lambert et al. 1990). However, other studies have shown no difference 
between choice of donor site following assessment of histological parameters 
(Ullmann, Shoshani et al. 2005) or adipocyte viability using cell proliferation 
techniques (Rohrich, Sorokin et al. 2004). Thus, the donor site may be chosen based on 
surgeon or patient preference. The solutions are infiltrated in a ratio of roughly 1 cc of 
solution per cubic centimetre of fat to be harvested. 
1.3.1.7. Harvesting method 
Common harvesting techniques used for fat isolation include syringe aspiration and 
lipoaspiration. It has been hypothesized that liposuction may be more detrimental to the 
fat cells than syringe aspiration. However, laboratory studies comparing the techniques 
have reported contradictory results. Various studies have shown no difference in fat cell 
viability, as assessed by cell proliferation, graft weight maintenance or histological 
evaluations (Smith, Adams et al. 2006; Pu, Coleman et al. 2008). Some investigators 
argue that adipose aspirates from conventional liposuction have sub -optimal levels of 
cellular function despite maintenance of normal structure and numbers of viable fat 
cells, and therefore may not survive well after transplantation (Pu, Cui et al. 2005). The 
negative pressure applied using either technique appears to determine the extent of cell 
damage. A number of authors recommend using half the normal suction pressure to 
avoid mechanical injury to adipocytes during aspiration (Niechajev and Sevcuk 1994). 
Nguyen et al showed 90% adipocyte injury at -760 mmHg on histological sections 
compared to 5% injury after gentle syringe aspiration (Nguyen, Pasyk et al. 1990). It is 
estimated that the pressure when a syringe plunger is pulled, is 40% of liposuction 
pressures. However, it has been demonstrated that negative pressures can reach 100% 
of liposuction pressures when a 10 -cc syringe plunger is pulled maximally (Smith, 
Adams et al. 2006). 
The Coleman technique is now the most popular method of autologous fat transfer. It 
was first described in 1994 using a syringe, cannula, and centrifuge and later refined 
with the use of Coleman instruments (Coleman 1997). For harvesting fat, Coleman 
recommends a 3mm diameter, 2 -hole Coleman harvesting cannula attached to a 10 -ml 
Luer -Lok syringe. Via a small stab incision, the blunt cannula is advanced and retracted 
through the harvest site using digital manipulation of the plunger to create gentle 
negative pressure. Parcels of fat are delivered to the cannula and once full, the syringe 
and plunger are disconnected and a plug is attached before placement in the centrifuge. 
1.3.1.8. Method of refinement 
There are various methods of fat refinement advocated to improve the long -term take of 
fat grafts. These include centrifugation, washing, rolling and treatment with other 
substances ranging from growth factors to growth medium (Yuksel, Weinfeld et al. 
2000). 
Washing liposuction aspirate with saline, Ringer's lactate or sterile water is felt by 
some authors to obtain the highest proportion of viable cells (Rubin and Hoefflin 
2002). However, Coleman argues that washing of harvested tissue may disrupt the 
fragile fatty tissue architecture and also remove fibrin, thus hampering anchorage of fat 
to the surrounding tissues (Coleman 2002). 
Centrifugation, popularised by the Coleman technique remains the most widely 
practised method of fat purification. The rationale for centrifugation is to remove 
excess blood, oil and local infiltration fluid. Thus a purified, predictable volume of fat 
may be re- injected. Prevention of inflammatory reaction to debris by centrifugation or 
washing is also an intuitive argument. Studies to evaluate adipocyte viability between 
centrifuged and non -centrifuged fat samples are also conflicting. One study 
investigating cell proliferation has shown no difference between groups although the 
authors acknowledge that evaluation of long -term cell viability requires an in vivo 
animal model (Rohrich, Sorokin et al. 2004). Further scientific studies are required to 
determine the best method of cell isolation whether by centrifugation or other means. 
The Coleman protocol for centrifugation involves centrifuging syringes of fat at 3000 
rpm for 3 minutes, which separates the harvested material into three layers. The upper 
layer is composed of oil from ruptured adipocytes and should be decanted. Absorbent 
material can be used to wick off any remaining oil. The bottom layer is composed of 
blood, water and local anaesthesia, and is allowed to drain by gravity after the plug is 
removed. The middle layer is composed of refined fat, which is transferred to 1 -cc 
Luer -Lok syringes for infiltration. During the transfer process, most authors favour a 
closed technique. Advantages include maintenance of sterility and avoidance of 
exposure to air, which may lead to desiccation of adipocytes. 
1.3.1.9. Placement 
Infiltration cannulas devised by Coleman are commonly used for placement of fat 
grafts. For the treatment of facial lipoatrophy, a blunt 17 -gauge cannula is 
recommended. The cannula is inserted to the recipient tissues via 2 -mm incisions and 
fat is injected on withdrawal of the cannula into multiple planes. In the face, the 
maximum amount of fat deposited with each withdrawal should be 1 /10th ml. 
Placement of small parcels of fat is recommended to maximise the surface area of 
contact between the harvested fat and recipient site. Studies have shown that only 40% 
of grafted fat tissue is viable 1mm from the edge of the graft at 60 days (Coleman 
2002). Therefore, decreasing the diameter of the grafted fat parcels ensures adequate 
blood supply to central adipocytes for nutrition and respiration. Ideally, the threads of 
fat should not exceed 3mm diameter. An additional benefit of maximising the surface 
area of grafted fat is increased stability and fat anchorage via host fibrin (Coleman 
2002). 
Although some authors believe that injection of fat graft into muscle is associated with 
increased viability due to improved vascularity, clinical evidence shows good survival 
in scarred tissue despite reduced vascularity in these conditions (Rigotti, Marchi et al. 
2007). 
Because of the tendency for fat resorption, many surgeons believe it is necessary to 
overcorrect the soft tissue defect. For surgeons who follow this practise, the amount of 
overcorrection thought to be required varies between 10 - 50% (Kaufman, Bradley et 
al. 2007). 
1.3.1.10. Post -operative care 
Elevation, cold therapy and external pressure with elastic tape may be used to minimize 
oedema although compression to the grafted area should be avoided to prevent 
migration of fat. 
1.3.1.11. Complications 
Fat grafting is considered to be a relatively safe procedure with few serious 
complications. The most common complications are aesthetic. Undercorrection may 
result from insufficient volume correction intraoperatively or resorption of grafted fat 
over time. Overcorrection can lead to several problems and is generally more difficult 
to resolve than undercorrection. Placement of excess adipose tissue in a particular area 
can lead to graft necrosis through failure of revascularisation. Fat migration may also 
be related to overcorrection of an area as pressure and insufficient blood supply force 
the graft into an undesirable site. 
Contour irregularities may develop as a consequence of graft necrosis, surgical 
technique, or migration of grafted fat. Clumping can be corrected to some extent by 
scar massage. 
Fat graft hypertrophy has been documented by several authors (Latoni, Marshall et al. 
2000; Miller 2002), and is a problem particularly noted in patients with HIV -associated 
lipodystrophy. 
Damage to underlying structures such as nerves, muscles, glands and blood vessels is 
rare although can result from this technique. In particular, intra- arterial injection is a 
potentially devastating complication. Reports of unilateral blindness following 
treatment of glabellar frown lines have been documented as a result of intravascular 
emboli (Niechajev and Sevcuk 1994). The use of a blunt cannula is recommended to 
avoid these complications. Donor site contour irregularities can result from overly 
aggressive harvesting in a small area. Another problem relating to patients with HIV 
lipodystrophy is insufficient subcutaneous fat reserves in some patients secondary to 
generalized lipoatrophy. In patients with HIV lipodystrophy, fat is often harvested from 
areas of dystrophic fat (e.g. the dorso- cervical fat pad) which is extremely fibrous and 
often requires multiple aspirations. 
Variable degrees of oedema can result from the procedure depending on the amount 
and location grafted fat. is usually evident for 2 weeks after the procedure; 
however, may be prolonged and troubling to the patient. 
Bleeding complications and bruising may also occur but are usually associated with the 
use of sharp needles for fat graft placement. 
Although rare, infections can occur wherever the skin envelope is violated. The most 
common source of infection is the oral mucosa. 
1.3.1.12. Evidence for the use of autologus fat in HIV lipodystrophy 
Quantification of surgical outcome in HIV -infected patients undergoing autologous fat 
transfer for facial lipoatrophy is lacking, and studies are limited by small numbers, 
subjective assessment and lack of long -term data. In one study, 38 patients received 
autologous fat injections using the Coleman technique for HIV facial lipoatrophy 
(Serra -Renom and Fontdevila 2004). The cosmetic result was evaluated at six months, 
after which 12 patients required a new injection of fat to improve symmetry and 
resorption. At one year, the cosmetic result was rated as good to excellent by the 
patient, the clinic nurse and the surgeon. Less resorption was reported in cases where 
the fat was not centrifuged and the authors suggest that this may be due to decreased 
trauma to the fat. In another study, the outcome of the Coleman technique was 
evaluated in 33 HIV -infected patients by clinical examination, biochemical data, 
patient satisfaction and standardized photographs at baseline and one year following 
lipostructure (Burnouf, Buffet et al. 2005). Improvement was found in 12 patients by 3 
independent evaluators at 12 months and 93% of patients were satisfied with the 
results. The authors also report that quantity of fat injected and low serum triglyceride 
level before surgery were significantly associated with improvement of facial 
lipoatrophy. Similar outcome measures were evaluated in two further studies to 
demonstrate the efficacy of lipostructure in HIV -infected patients using the Coleman 
technique for facial lipoatrophy. Levan et al (2002) reported 93% patient satisfaction 
and `acceptable', `good' or `very good' results in 13 out of 14 patients evaluated by a 
5- member jury 6 months following the procedure. Caye et al (2003) evaluated 29 HIV - 
infected patients treated using the Coleman technique and reports durability of fat 
grafts at 6 months based on serial photography. The results were deemed good in 
72.4 %, acceptable in 13.8% and poor in 13.8 %. Davison et al (2007) have utilized 
lipoaspirate in patients undergoing suction- assisted liposuction for buffalo hump 
deformities to correct associated facial wasting. In these cases, the fat grafts were not 
centrifuged to avoid aerosolization of the virus. The authors report graft take of 
approximately 40 to 50 percent based on subjective assessment, and postulate that fat 
harvested from dystrophic sites possesses different biochemical properties from non- 
hypertrophic fat and may lead to more sustained results in these patients. However, 
Talmor et al feel that the quality of fat rendered from dystrophic sites makes it 
unsuitable for transfer due to its extremely fibrous nature (Talmor, Hoffman et al. 
2002). The potential for fat graft hypertrophy when utilized from dystrophic sites 
should also be considered. Since HIV lipodystrophy is a systemic, metabolic disease, 
the effect of transferring dystrophic fat can be unpredictable. In one study of 41 patients 
who received autologous fat injections for HIV- associated lipoatrophy, four patients 
developed disfiguring facial lipohypertrophy at the injection site (Guaraldi, De Fazio et 
al. 2005). The fat source was the dorso- cervical fat pad in three of these patients. The 
pathogenic mechanism for this is unknown. The authors hypothesize that the 
mechanism may be related to adipocyte receptors and mitochondrial toxicity: receptor 
expression could be transferred from the harvest site and remain sensitive to 
lipohypertrophy determinants. Alternatively, lipohypertrophy of the cheeks may be the 
result of expansion of brown fat that is transferred with the intervention. Histological 
examination of hypertrophied fat graft to the nasogenian area was carried out following 
surgical resection in one patient. Fibroadipose tissue and dystrophic adipocytes of 
various sizes were demonstrated. The authors postulate that a nonadaptive response 
could be partly related to dysfunction of adipocyte receptor expression and a mutated 
DNA toxicity- related mechanism. 
Despite the reported success of fat transfer, there is a lack of objective evidence; 
measurement to date has been subjective and based on patient and surgeon satisfaction. 
Although patient satisfaction is a key factor in determining outcome in aesthetic 
surgery, a more objective measure of fat transfer is required. Measurement of facial 
volume using three -dimensional imaging is an ideal modality and the technique shall be 
described further in the following chapter. 
1.3.2. Dermis -fat graft 
The use of free fat grafts with overlying dermis for patients with soft -tissue defects was 
advocated by Peer in 1956. The results of dermafat graft transfer to the malar area in 
patients with HIV -associated lipodystrophy have been variable. Dermafat grafts were 
transferred from the abdominal wall to malar pockets through a trans -oral approach 
technique in five patients with antiretroviral- induced lipodystrophy of the face. (Stauch, 
Baum et al. 2004) Patients were overcorrected to twice the expected final volume and 
they reached final volume (50% of initial augmentation) in three to five months. The 
aesthetic results were maintained during the follow -up period of fourteen to thirty 
months. However, another report of the use of a dermis -fat graft in a patient with HIV - 
associated lipodystrophy is slightly less favourable (Wechselberger, Sarcletti et al. 
2001). In this case, dermis -fat grafts were harvested from the buttocks to augment the 
nasolabial and temporal regions with overcorrection of the defect in a female patient 
with facial lipoatrophy. The patient was unhappy with the overcorrection at four weeks 
post -op and underwent removal of the bulky tissue, during which the parotid duct was 
lacerated on the right side. Despite an acceptable aesthetic result at 17 months, the 
authors remain skeptical about the technique. 
1.3.3. Rhytidectomy 
Rhytidectomy can ameliorate the disfigurement due to loss of facial volume by 
tightening the skin envelope although long -term follow -up results in patients with HIV - 
associated facial lipoatrophy are lacking. 
1.3.4. Temporary soft tissue fillers 
Filler substances play an important role in the treatment of the aging face and the 
correction of soft tissue defects. A significant body of evidence supports the use of 
fillers in the management of HIV lipodystrophy. Fillers can be classified as temporary, 
semi -permanent or permanent. Temporary fillers which have been utilized to treat HIV - 
associated facial lipoatrophy are discussed as follows. In general, recurrence of 
symptoms with the use of temporary fillers may either be treated by repeat injections of 
the filler or an alternative product, depending on patient and or practitioner preference. 
1.3.4.1. Collagen fillers (Bovine: Zyderm® and Zyblast ®; Human: CosmoDerm® 
and CosmoPlast ®) 
Collagen has been used for over 25 years for cosmetic purposes. Large volumes of 
collagen may be needed to restore facial volume in patients with severe HIV -associated 
lipoatrophy, so this option is probably best for people with mild to moderate facial 
lipoatrophy. 
More recently, several collagen- derived fillers have emerged (including Dermalogen ®, 
Fascian®, Isolagen ®, Autologen® and AlloDerm ®). To date, there have been few 
studies investigating the use of these products in the treatment of patients with HIV - 
associated lipodystrophy. In addition, information on long -term effects and duration of 
correction are limited. 
1.3.4.2. Calcium hydroxylapatite (Radiance®, Radiesse ®) 
Calcium hydroxylapatite consists of microspheres of calcium hydroxyapatite in a 
carboxymethylcellulose gel carrier. When injected into dermis, collagen forms around 
the calcium hydroxylapatite, providing long -term, natural -looking fullness. Eviatar et al 
have evaluated the safety and efficacy of Radiesse® in 100 patients with HIV - 
associated facial lipoatrophy. Eighty -five percent of patients received touch up 
injections at one month following initial treatment. The study demonstrated that all 
patients had improved aesthetic outcomes at six months follow -up as scored on a facial 
global aesthetic improvement rating scale by a panel of plastic surgeons; more than 
90% of patients were scored as Very Much Improved or Much Improved. Adverse 
events were minor and included transient injection site reactions. There were no reports 
of granulomas or migration of the product (Eviatar, Silvers et al. 2005). 
1.3.4.3. Hyaluronic acid (Restylane ®, Perlane ®, Hylaform ®) 
Hyaluronic acid is a naturally occurring polysaccharide component of the intercellular 
matrix. The use of hyaluronic acid has been evaluated for soft tissue augmentation of 
HIV -associated facial lipodystrophy in five patients (Gooderham and Solish 2005). 
Each patient received approximately 5 -6 mls in total of hyaluronic acid in the malar 
area via intradermal injection. The technique was found to provide a good cosmetic 
result for at least six months, with high patient satisfaction and no adverse events. 
Another study of seven patients with HIV- associated facial lipodystrophy treated with 
hyaluronic acid revealed high patient satisfaction with regards to cosmetic 
improvement, and no side effects of treatment (Riff, Hillebrand- Haverkort et al. 2001). 
1.3.4.4. Poly -L- lactic acid (Newfill® Sculptra®) 
Poly -L- lactic acid was approved by the FDA in August 2004 for treatment of HIV 
associated facial atrophy. Poly -L- lactic acid (PLLA) (NewFill ®, Sculptra® in the US) 
is a biocompatible, bioabsorbable synthetic polymer from the alpha- hydroxy -acid 
family. Injectable PLLA is composed of crystalline, irregularly sized microparticles of 
poly -L- lactic acid. The product is supplied as a sterile, freeze -dried preparation which 
also contains carboxymethylcellulose as a suspending agent to maintain even 
distribution of poly -L- lactic acid particles and nonpyrogenic mannitol that enhances the 
lyophilization process. The mechanism by which injectable poly -L- lactic acid produces 
the observed volume change is related to a foreign body giant cell reaction that occurs 
several weeks to months after injection. This is followed by a progressive increase in 
collagen deposition as the bioactive material is degraded and undergoes resorption. 
This neocollagenesis is thought to account for the gradual and volumizing effect of 
PLLA. Poly -L- lactic acid polymers degrade through nonenzymatic hydrolysis to lactic 
acid monomers, which are in turn metabolised into carbon dioxide or incorporated into 
glucose (Borelli, Kunte et al. 2005). Poly -L- lactic acid differs from other dermal fillers 
in that it leads to gradual volumetric expansion over time, and the objective of 
treatment is to enhance volume- deficient areas rather than correct discrete facial 
deficiencies such as lines and folds. 
There is a growing body of literature on the use of PLLA in the correction of facial 
lipoatrophy. To date, there have been four principal clinical studies involving PLLA for 
the correction of HIV -associated facial lipoatrophy: VEGA, Chelsea and Westminister, 
APEX002 and Blue Pacific. 
The VEGA study evaluated the safety and efficacy of Poly -L- lactic acid injections 
(Newfill®) in 50 patients with HIV- associated lipoatrophy by means of an open -label, 
single -arm pilot study over 96 weeks (Valantin, Aubron -Olivier et al. 2003). Patients 
received four sets of injections given every 2 weeks: at day 0 and at weeks 2, 4, and 6. 
One vial of PLLA per cheek per treatment session was utilised and reconstituted with 
3 -4 ml of water for injection. Clinical endpoints included: change in total cutaneous 
thickness from baseline; improvement in quality of life; change in viral load, CD4 
count and blood chemistry parameters; and incidence of adverse events. All patients 
experienced increases in skin thickness in the treatment area. Statistically significant 
increases above baseline values of mean skin thickness were noted at all time points 
(weeks 8, 24, 48, 72, 96) during the study. Based on results of the visual analogue 
scale, there was a significant improvement in quality of life compared with baseline 
values. There were no serious adverse events, although in 44% of patients, palpable but 
non -visible subcutaneous nodules developed. 
Similar results were found by Moyle et al, who conducted a 24 -week open -label, study 
in 30 HIV patients with facial lipoatrophy, designed to compare immediate treatment 
with delayed treatment of PLLA (Moyle, Lysakova et al. 2004). Patients randomized to 
the immediate treatment group received PLLA injections on day 1 and at weeks 2 and 
4. Patients in the delayed group received injections at weeks 12, 14 and 16. Clinical 
endpoints included ultrasound measurement of skin thickness, assessment of anxiety 
and depression, visual analogue scale of patient satisfaction, and changes in laboratory 
values. Ultrasonographic assessment revealed significant changes from baseline in the 
areas treated with Newfill® in all patients. A mean increase in dermal thickness of 4 to 
5mm within 12 weeks of treatment was reported with effects persisting at least 18 
weeks beyond the last injection. Statistically significant improvements in anxiety and 
depression and patient- assessed visual analogue scores were also demonstrated. 
APEX002 and Blue Pacific were open -label, single centre studies aiming to assess 
safety and efficacy of PLLA over 12 months. During the APEX002 trial, 99 patients 
were given 1 -6 treatment sessions, 4 -6 weeks apart. Treatment efficacy was measured 
by patient and investigator satisfaction and digital photography. Patients and physicians 
rated the degree of lipoatrophy on a scale of 1 -5 (1 =mild, 5= severe) and patient 
satisfaction was also rated on a scale of 1 -5 (1= dissatisfied, 5=very satisfied). Mean 
lipoatrophy at baseline was 3.58 in the cheeks, decreasing to 1.51 prior to fmal 
treatment, then 0.87 and 0.88 and 6 and 12 months respectively. At the fmal treatment 
the average satisfaction rating was 4.71. In the Blue Pacific study, 97 patients received 
1 -6 treatment sessions three weeks apart (Mest and Humble 2006). Clinical endpoints 
included measurement of total cutaneous thickness by skin callipers, assessment of 
serial photographs and patient satisfaction. At the final treatment visit, mean skin 
thickness increased by 65.1% from baseline. At 6 and 12 months following treatment, 
skin thickness had increased by 68.8% and 73% respectively. High levels of patient and 
investigator satisfaction were also reported. The main drawback of this study relates to 
the use of skin capilers as an outcome measure of cutaneous thickness, which is highly 
operator dependent. Also no precise surface landmarks for measurements are identified. 
Based on clinical impression and patient observation, one author reports stability of 
PLA until 30 months in 2131 patients treated for facial rejuvenation, although these 
results have not been substantiated using objective measures in a clinical trial 
(Vleggaar 2006). 
Adverse events from treatment can be divided into injection- related and device -related. 
Injection related side effects were similar across the studies and included pain, 
swelling, bruising, erythema, haematoma, and inflammation which resolved 
spontaneously within 24 -48 hours in most cases. The most important device -related 
adverse event was the formation of small, subcutaneous papules (SPs) which can be 
classified as visible or non -visible, temporary or permanent or early or late. 
Histologically, the nodule consists of fluid droplets or microparticles surrounded by a 
normal foreign body reaction. It is claimed that they may arise as a result of technical 
error, uneven distribution of PLLA in suspension, or uneven dispersal in the injected 
areas(Lam, Azizzadeh et al. 2006). In the VEGA study, 44% of patients developed SPs 
on average 7 months after initial injection (range 0.3 -25 months); however, in 27% of 
those patients, the SPs had disappeared at week 96. Thirty-one percent of the patients in 
the Chelsea and Westminster study developed SPs, whereas 6% of patients in the 
APEX002 study and 12% of patients in the Blue Pacific study developed this 
complication. None of the study protocols describe evaluation or treatment of papules. 
Lam et al suggest that early nodules (that appear within several weeks of treatment) 
should be treated by needle fragmentation and late nodules (that appear within several 
months of treatment) by intralesional steroid injection. Failure to respond to these 
treatments may require local excision of the papule. 
Granuloma formation represents another device -related adverse event with the reported 
incidence ranging from 0.2 -12 %. They typically arise throughout the treated area 
rather than at discrete sites several months to years following injection. Local excision 
fails to address the problem as the borders of a granuloma are seldom well defined. 
Steroid therapy with or without immune -modulating medications is the mainstay of 
intervention (Vleggaar 2006). 
Some authors now recommend that the incidence of SPs may be reduced by increasing 
the volume of dilution, reconstituting a minimum of 12 hours prior to use, 
subcutaneous injection, and increasing the treatment interval to 4 -6 weeks (Borelli, 
Kunte et al. 2005; Lam, Azizzadeh et al. 2006). 
Several published studies have utilised ultrasound to measure cutaneous thickness; 
however, prior to commencement of trial, there were no published studies to evaluate 
outcome using three -dimensional imaging. In the VEGA study, patients were assessed 
using an unspecified `quality of life' scale. In the Chelsea and Westminister study, 
patients were assessed using the Hospital Anxiety and Depression Scale (Zigmond, 
Snaith et al. 1983) and a self -devised visual analogue scale to measure change in body 
shape. Neither of the studies used a validated measure of body image assessment, such 
as the Derriford Appearance Scale.(Carr, Moss et al. 2005) 
1.3.5. Semi -permanent and permanent fillers 
The use of semi -permanent and permanent fillers may present an attractive treatment 
option for both cosmetic and reconstructive patients who desire a long -term aesthetic 
outcome. However, the decreased immunity inherent to the HIV -positive surgical 
patient represents a significant concern. The self evident concern for any surgeon is the 
ongoing risk of peri- implant infection in a patient cohort who may become infection 
prone and subject to a high incidence of dental caries and skin disease. 
1.3.5.1. Silicone oil 
Silicone oil has been used for facial lipoatrophy but its safety and effectiveness for 
cosmetic purposes remain controversial. A ten -year follow -up of silicone injections for 
facial atrophy revealed that silicone oil is safe and effective when injected in very small 
amounts, dispersed throughout the tissue planes (Rees, Ashley et al. 1973). 
Disadvantages of using silicone include risks of infection, granulomas, migration of 
silicone droplets and inability to remove the product. There have been reports on the 
use of liquid injectable silicone in patients with HIV -associated facial lipoatrophy 
including a case report of one patient (Orentreich and Leone 2004) and larger study of 
77 patients (Jones, Carruthers et al. 2004). In both papers, 1000 -cs liquid injectable 
silicone was administered using the microdroplet serial puncture technique. Both 
papers conclude that silicone oil is a safe and effective treatment for HIV -associated 
facial lipoatrophy. Facial contours were restored and significant patient satisfaction was 
achieved with no adverse events noted. However, longer -term safety and efficacy in 
HIV patients remains to be proven. 
1.3.5.2. Polyalkylamide gel (Bio- Alcamid)® 
Bio- Alcamid® is a relatively new hydrogel polymer that is used for cosmetic and 
reconstructive purposes. It is an alkylic resin containing 96% pyrogen -free water and 
4% alkylimide -amide groups. The product is considered to be a permanent filler due to 
the stability of its chemical properties and resistance to hydrolysis (Ramires, Miccoli et 
al. 2005). Once injected, Bio- alcamid becomes enclosed within a thin (0.02mm) 
collagen capsule (Protopapa, Sito et al. 2003). The process commences within a few 
days of injection and is completed by 6 weeks. Electron microscopy analysis of skin 
biopsy specimens three months after Bio- alcamid implantation revealed fibroblasts 
arranged around the injected material, with no signs of inflammation (Formigli, Zecchi 
et al. 2004). Bio- alcamid is thus considered to be an endoprosthesis (an intermediate 
between an injectable filler and a prosthesis) due to the encapsulation process which 
isolates the injected material from surrounding host tissues. This is reported to 
contribute to the safety of the product and prevent migration of injected material 
(Formigli, Zecchi et al. 2004). A number of safety studies have shown Bio- alcamid to 
be non -toxic, non -allergenic, non -reactive, biocompatible and non -biodegradable 
(Pacini, Ruggiero et al. 2003). Studies by Lotti et al have suggested a weak 
inflammatory reaction of cellular tissue surrounding the implant, with diminishing 
numbers of CD68 macrophages after 4 months in the upper perivascular dermis. 
Immune -histochemical studies have also demonstrated a lack of fibroblast induction. 
Several advantages of Bio- alcamid have been proposed. Once injected and settled, the 
implant has the consistency of the normal tissues and a total, permanent correction can 
be achieved in just one or two sessions. The procedure requires no surgical incisions, 
and is minimally invasive. When compared to other fillers, polyalkylimide gel can be 
used in large quantities, and if lipoatrophy continues or the patient is overcorrected, it 
can be partially or totally removed to obtain a more natural or symmetrical look 
(Pacini, Ruggiero et al. 2003). 
Studies providing clinical evidence for the use of Bio- alcamid in cosmetic and 
reconstructive practice have been published. The largest multicentre study of 2000 
otherwise healthy patients reported excellent cosmetic results with only 12 
complications.(Pacini, Ruggiero et al. 2002) These results have also been replicated in 
several case series of patients with HIV -associated facial lipoatrophy. One Italian study 
has reported stability, tolerance and safety of Bio- Alcamid® with permanent, 
satisfactory improvement in appearance for patients with lipodystrophy (Protopapa, 
Sito et al. 2003). In this study, 90% of the 73 patients required a second injection of 
Bio- Alcamid® (four weeks after the first injection) to improve implant appearance. The 
aesthetic results were deemed excellent by both physicians and patients at follow -up of 
three years. Favourable clinical experience with Bio- alcamid was reported by Lahiri et 
al for a variety of reconstructive purposes including 15 patients with HIV facial 
lipoatrophy, although one patient developed infection with Staphylococcus aureus 
(Lahiri, Waters et al. 2007). High patient and physician satisfaction were reported 
following treatment of thirteen patients with HIV facial lipoatrophy in another study, 
with no major complications (Ramon, Lucian et al. 2007). However, all of these reports 
are based on subjective outcomes only. In addition to photographic assessment, some 
studies utilising quality of life (QoL) measures as treatment outcomes for HIV 
lipoatrophy have been published. In one study of 31 patients randomised to immediate 
or delayed injections to correct facial lipodystrophy, 2 QoL questionnaires (Medical 
Outcomes Study HIV Health Survey and the modified Dermatology Quality of Life 
Survey) and the Hospital Anxiety and Depression scale (HADS) were completed 
(Loufty, Raboud et al. 2007). Compared with the delayed group, patients in the 
immediate therapy group had significantly lower physician- related lipoatrophy scores, 
improved QoL and lower anxiety scores. Significant improvements in patient anxiety 
and depression were observed from baseline to week 48. Three QoL measures were 
assessed in another study of 17 patients receiving treatment for HIV facial 
lipodystrophy with Bio- alcamid.(Karim, deLlnt et al. 2008) Relevant parts of the Short 
Form 36 -item health survey, the Medical Outcomes Study HIV Health Survey, and the 
Centre for epidemiological Studies were used to assess outcome. QoL improved 
significantly from baseline over 48 weeks for mental health and social functioning and 
depression was significantly correlated with the extent to which lipoatrophy had 
disappeared at week 48. Although early published studies demonstrated the safety and 
efficacy of Bio- alcamid®, the clinical follow -up period was limited. Longer -term 
complications relating to the use of the product including infection, migration and 
capsule formation are beginning to emerge (Karim, Hage et al. 2006; Jones, Carruthers 
et al. 2007) and shall be monitored in this study. 
To date, there are no studies to evaluate the outcome of treatment with Bio- alcamid® 
using the Derriford Appearance Scale or 3 -D imaging techniques. 
1.3.5.3. Polymethylmethacraylate (PMMA; Artecoll®, Artefill®) 
Artecoll® consists of polymethylmethacrylate suspended in bovine collagen, which is 
degraded and replaced by autologous collagen approximately three months after 
injection (Alster and West 2000). Side effects of Artecoll® include erythema, swelling, 
moderate pain lasting an average of 48 hours, and mild pruritis at the implantation site 
for several weeks. It has been suggested that correct placement of the implant between 
the dermis and subcutaneous fat rather than within the dermis may avoid some of these 
problems (McClelland, Egbert et al. 1997). The use of polymethylmethacrylate for 
HAART- associated lipoatrophy has been reported from Brazil, but no structured 
studies have been performed (Serra, Oyafuso et al. 2004). 
1.3.6. Implants 
1.3.6.1. Silicone implants 
The use of submalar silicone implants has been evaluated in patients with HIV - 
associated lipodystrophy. In one study, three patients with facial lipoatrophy underwent 
reconstruction with submalar silicone implants via an infra -oral approach (Talmor, 
Hoffman et al. 2002). Two patients required additional soft -tissue augmentation; one 
patient received collagen augmentation of the nasolabial fold at an unspecified post- 
operative interval, and the other patient received collagen and autologous fat 
augmentation after progression of atrophy at fifteen months. No infection or extrusion 
was encountered, although one patient required implant repositioning on one side. At 
15 months follow -up, both patients and surgeons were satisfied with the results. The 
advantages of this technique are that silicone implants provide a durable surgical 
reconstruction, the procedure can be performed on an outpatient basis under local 
anaesthetic, and the implant can be easily removed if necessary compared to an injected 
material. The main disadvantages include infection and displacement of the implant. 
1.3.6.2. Polytetraflouroethylene Facial Implants 
The use of e -PTFE soft tissue augmentation in plastic and reconstructive surgery has 
been favourable, with a high degree of patient and surgeon satisfaction (Levine and 
Berman 1995). However, larger series with longer follow -ups are necessary to assess 
safety and efficacy, and studies specifically in HIV lipodystrophy patients are lacking. 
1.3.7. Flaps 
With the advent of microvascular surgery and free flap transfer, numerous flaps have 
been used to augment facial soft tissue deformities. One patient with lipodystrophy is 
reported to have undergone facial contour reconstruction using a double paddle dermis- 
fat forearm free flap (Endo, Nakayama et al. 1994). Another option described for 
patients with lipodystrophy is the adipofascial free radial forearm flap (Koshy and 
Evans 1998). Since dermis is not incorporated, the flap is malleable, enabling it to be 
contoured to the shape of the defect. It is also reported to maintain bulk after five years 
follow -up in two patients. 
A temporalis muscle rotation flap has also been described to augment the cheeks and 
upper lip in a patient with lipodystrophy (van der Wal and Mulder 1998). Potential 
disadvantages with free tissue transfer include multiple procedures, lengthy operation, 
flap failure, haematoma, and donor site defects. 
1.4. Measures of psychological outcome 
1.4.1. Psychological aspects of HIV lipodystrophy 
The psychological consequences of HIV lipodystrophy are well recognized amongst 
practitioners involved in the management of patients with HIV lipodystrophy. The 
stigmatizing effect of body changes may influence health -related quality of life 
(incorporating self -image, self -esteem, social interaction and sexual relations), and 
anxiety and depression (Colins, Wagner et al. 2000). Facial lipoatrophy, in particular 
appears to be associated with the most detrimental psychological effects. This is in 
keeping with other psychological studies evaluating facial disfigurement and is due to 
the unique importance of our facial appearance in terms of our `identity'. The face is 
exposed and is the focus of communication as well as being central in others' 
perception of an individual (Tebble, Thomas et al. 2004). For some patients, the 
negative impact of lipodystrophy leads to non -compliance with antiretroviral therapy 
(Corless, KM et al. 2005). Although several studies have attempted to quantify 
psychological distress, these often rely on non -standardized methods. Reynolds et al 
conducted a qualitative study to capture the psychosocial dimensions of HIV 
lipodystrophy. They reported physical, psychological and social distress across sex, 
sexual orientation and geographic subgroup, but highlighted that the greatest fear for 
patients was unintentional disclosure of their HIV status. Whilst this study provides 
descriptive evidence for psychosocial impairment, it does not attempt to quantify these 
elements (Reynolds, Neidig et al. 2006). Goetzenich et al evaluated the correlation 
between body habitus changes and specific areas of health related quality of life 
(HRQL). They found that a diagnosis of lipodystrophy was correlated with decreased 
social contact, changes in daily performance, changes in sexual functioning and 
decreased self -esteem, although the study lacked a standardized HRQL measure 
(Goetzenich, Corzillius et al. 2000). A study by Falutz found that 70% of 82 patients 
with HIV lipodystrophy reported depressed mood, with facial lipoatrophy having the 
greatest impact on patients (Falutz 2003). However, a standardized measure of 
depression was not used; therefore, the criteria to diagnose mood alterations is 
uncertain. Although the body of published literature report negative psychological 
sequelae of lipodystrophy, one study has found no associated between lipodystrophy 
and HRQL or depression (Oette, Juretzko et al. 2002). 
Plastic surgery is now the mainstay of treatment for established lipodystrophy as 
studies have shown that medical intervention is generally ineffective. Several authors 
have reported improvements in psychological wellbeing in patients undergoing 
treatment for HIV lipodystrophy using a variety of validated and non -validated scales. 
Studies evaluating the outcome of treatment with polylactic acid, such as the VEGA 
trial, have reported improved quality of life extending to 48 weeks post -treatment 
(Valantin, Aubron -Olivier et al. 2003). However, a non -standardized visual analogue 
scale was used and the particular elements assessed are not described. Some authors 
have incorporated validated tools (such as the Short Form 36 -item health survey, the 
Medical Outcomes Study HIV Health Survey, the Centre for epidemiological Studies, 
and the Hospital Anxiety and Depression Scale) to assess psychological outcome 
following treatment with polyalkylimide gel and report significant improvement in 
quality of life, anxiety and depression extending to 48 weeks (Karim, Hage et al. 2006; 
Loufty, Raboud et al. 2007). However, the selected measures were developed and 
validated in the pre -HAART era, at a time when the lipodystrophy was not yet 
recognized and the clinical picture of HIV was different to the present day. Two further 
studies comparing autologous fat transfer, polylactic acid and polyalkylimide gel have 
found improved quality of life in all three treatment groups (Guaraldi, Orlando et al. 
2005; Negredo, Higueras et al. 2006). Measures used in these studies included the 
Assessment of Body Change and Distress questionnaire (ABCD) and the Beck 
Depression Inventory. Although, the ABCD was specifically designed to analyze the 
impact of HIV -related lipodystrophy, this questionnaire has no specific items referring 
to facial lipoatrophy. Therefore, none of the scales employed to assess quality of life 
address concern over physical appearance specifically relating to the face. Traditionally 
the outcomes of aesthetic surgery have relied on subjective measures such as patient or 
surgeon satisfaction. The need for more objective outcomes is becoming increasingly 
recognized. This requirement is particularly important when assessing the benefits and 
consequences of treatment for HIV lipodystrophy. 
Price has developed a model of body image with 3 related components: body reality 
(the way our body really is), body ideal (our perception of how our body should look) 
and body presentation (how we present our body to others)(Price 1995). The balance of 
these components leading to normal body image is influenced by individual coping 
strategies and social support network. An altered body image occurs when the body no 
longer supports self -esteem, is dysfunctional and limits social activity. Price 
emphasizes that a change in appearance does not necessarily lead to a state of altered 
body image, but that the interpretation of change is the determining factor. 
Previous research has suggested a number of factors may influence psychological 
outcome and body image perception in disfiguring conditions including age, sex, ethnic 
origin, socio- economic class, site of disfigurement and cause of the injury. Social 
influences vary depending on age (Janelli 1986), and women may be more sensitive 
than men to changes in body image (Anderson and Maksud 1994). It has been reported 
that patients in low socio- economic classes are more affected by their state of health. 
Partridge has also reported that the site of facial disfigurement is important; with 
disfigurements in the communication triangle (between the eyes and mouth) provoking 
more negative reactions than elsewhere in the face (Partridge 1993). Interestingly, this 
is the area mainly affected in patients suffering from HIV facial lipoatrophy. In terms 
of aetiology of injuries, accidents and assault have the greatest psychological impact. In 
patients with HIV associated lipoatrophy, the impact of HIV infection and other health - 
related concerns clearly may also influence body image assessment and general 
psychological wellbeing. In addition, a high proportion of HIV patients seeking 
treatment for HIV lipodystrophy are men who have sex with men (MSM). There is a 
paucity of research which utilizes standardized measures to compare psychological 
distress between HIV seropositive patients with and without lipodystrophy. In addition, 
there is little published evidence evaluating the relationship between sexual orientation 
and psychological morbidity in an MSM control group. 
1.5. Three -dimensional Imaging 
1.5.1. Three -dimensional Imaging Techniques 
Methods to record facial dimensions are useful to study morphology, to develop 
treatment plans and to evaluate treatment outcomes. There are advantages and 
disadvantages of each of the registration methods which have evolved. 
1.5.1.1. Anthropometry 
Anthropometrical measurements may be used to study facial morphology and have 
been used extensively to collect normative data (Farkas and Posnick 1992) and to study 
craniofacial abnormalities such as cleft lip and palate in adolescent and adult 
populations (Farkas, Hajnis et al. 1993). Ghoddousi et al also demonstrated good levels 
of repeatability of the technique when compared with 3D stereophotogrammetry and 
2D photography (Ghoddousi, Edler et al. 2007). The technique has some advantages 
including the ability to locate landmarks by palpation. However the analysis is limited 
to linear and angular measurements. The technique is highly operator dependent, time - 
consuming and requires a great deal of subject co- operation. In addition, 
anthropometrical instruments may introduce deformation of the surface of the face and 
are unable to measure some structures such as the eyes. 
1.5.1.2. Facial casts 
Plaster casts obtained via impression may be used to obtain a 3 -D model of the face. 
Applications of this technique include the creation of facial casts for burns patients and 
anthropometric analysis of the cleft infant face (Krimmel, Kluba et al. 2006). This 
method demands full co- operation of the patient during the session of impression and is 
usually performed under general anaesthesia in children. Inaccuracy due to deformation 
of soft tissues may occur during the procedure. Holberg et al have demonstrated 
marked differences between the cast and facial surfaces using a three -dimensional laser 
scanner (Holberg, Schwenzer et al. 2006). 
1.5.1.3. 3 -D Cephalometry 
3 -D cephalometry is a technique of manually abstracting 3 -D co- ordinate data from 
lateral and anteroposterior cephalometric films. The concept was introduced by 
Broadbent and first implemented by Singh and Savara (Singh and Savara 1966). The 
advantage of using radiographs is that the morphology of the underlying hard tissues 
can be registered (Ras, Habets et al. 1996). The disadvantages of this technique include 
radiation exposure, inaccuracy of landmark location and the time required to extract 
data. Computer programs can now extract three- dimensional co- ordinates from digital 
cephalogram images (Dean, Hans et al. 2000). 
1.5.1.4. Morphanalysis 
Morphoanalysis is a technique promoted by Rabey which utilizes photographs, 
radiographs and study casts of a patient to obtain 3 -D information (Rabey 1971). It is 
claimed to be accurate and statistically valid; however, the required equipment is 
expensive and the process is time -consuming. 
1.5.1.5. 3 -D Facial Morphometry 
Ferrario et al have described a system for recording three -dimensional co- ordinates of 
facial landmarks (Ferrario, Sforza et al. 1994). The system consisted of two charged 
coupled device (CCD) cameras, real time hardware for the recognition of markers and 
software for the 3D reconstruction of the landmark coordinates. The process is time - 
consuming, requires considerable patient cooperation, and landmark placement is 
restricted due to the size of the markers necessitating 2 mm separation between the 
landmarks. The technique also lacks a 3D facial image display since only the 
landmarks are recorded. 
1.5.1.6. Electromagnetic digitisation 
Electromagnetic three- dimensional digitisers can be used directly on facial soft tissues 
to supply the coordinates of facial landmarks (Ferrario, Sforza et al. 1997). A hand -held 
probe is used to locate facial landmarks and 3 -D co- ordinates are produced. This 
method has the advantage that the landmarks are identified directly on the subjects' 
face rather than on a reconstruction of the face. Its main disadvantage is the compliance 
required which makes its use in infants impractical. 
1.5.1.7. 3 -D CT scanning 
The first commercial CT scanner appeared in 1972 and its' potential to generate 3D 
information was quickly recognized. In the 1980s, CT- assisted 3D imaging was 
introduced for use in maxillo- facial surgery (McCance, Moss et al. 1992). Since then, 
the applications and popularity of this technique have increased dramatically. CT 
scanning makes it possible to analyze the soft and hard tissues of the head. Computer 
software can reconstruct a 3D image from successive slices. The error of 3 dimensional 
CT data is considered to be minimal, although the accuracy of reconstructed 3D images 
depends on the thickness of the original slices (Ras, Habets et al. 1996). It is useful in 
diagnosis and treatment planning of patients with craniofacial abnormalities (Fisher, Lo 
et al. 1999). Stereolithographic techniques can be used to manufacture models for 
surgery but require experienced operators (Burke and Beard 1967). The technique may 
also be used in the production of various prostheses, including ear prostheses (Watson, 
Coward et al. 1993). However, there are several drawbacks of 3D CT scanning 
including: (1) patient exposure to a high dose of ionizing radiation; (2) limited 
resolution of facial soft tissues due to slice spacing; (3) the possibility of artifact form 
metal objects; (4) patient co- operation during long scanning periods. Sedation or 
anaesthesia may be required to obtain images of infants. 
1.5.1.8. MRI 
Three -dimensional images can also be reconstructed from magnetic resonance imaging 
(MRI) (Moss 2006). This is a useful technique for 3D imaging of soft tissues and may 
be used to estimate tissue depth in human faces with precision. (13) Its main advantage 
is that it does not involve a radiation dose. The drawbacks of this technique include: 
cost relative to other techniques; artifacts from metal objects; unable to differentiate 
between air and bone; and discomfort for patients who feel claustrophobic in an 
enclosed environment (Browne, Golding et al. 2001). Similar to CT, sedation or 
anaesthesia may be required to obtain images of infants. 
1.5.1.9. Moire topography and contour photography 
Both Moire topography and contour photography use grid projections during exposure, 
resulting in standardized contour lines on the face (Kawai, Natsume et al. 1990). A grid 
with known projections is projected onto the face and transforms into an image of 
contour lines on the face. The contour lines can then be used to calculate the depth of 
the image based on contour fringes and fringe intervals. These methods are better 
suited to use on smoothly contoured faces as difficulties are encountered if a surface 
has sharp features. Also a small change in head position can result in a large change in 
fringe pattern, thus accurate head positioning is critical (Rabey 1971). 
1.5.1.10. 3 -D Laser scanning 
Laser scanning techniques provide a less invasive method for capturing the face in 
three dimensions. These methods make use of the detection of a reflected laser beam to 
reconstruct 3 -D images of the surface of objects. The earliest descriptions of this 
technique was in 1985 (Arridge, Moss et al.). A low- energy laser light beam is passed 
through a cylindrical lens so that a vertical line is projected onto the surface. A video 
camera at an angle to the light source records the image of this line and the camera 
output is digitized into a set of 3 -D co- ordinates. The patient is rotated in a motorized 
chair in order to scan the whole face. The laser scanning system was subsequently used 
to describe changes in facial morphology following a variety of orthognathic 
procedures (McCance, Moss et al. 1992). 
The accuracy of this system was evaluated by comparison of laser -scanned landmarks 
with direct anthropometric measurements. The most reliable measurements were in the 
nasal and circumoral regions, with a mean difference of less that 1.0mm (Aung, Ngim 
et al. 1995). More recently, a study of 3 -D laser -scanned images of a mannequin head 
demonstrated a mean error of the scanned image of 0.37mm. Kau et al analyzed 38 
adults one week apart using a 3 -D laser imaging system. The mean difference of 
superimposed images was 0.37mm and 0.35mm for males and females respectively, 
indicating reproducibility of the system within one week of initial records (Kau, 
Richmond et al. 2006). The 3 -D laser system has the advantage of capturing an image 
in a simple and rapid manner, with the ability to immediately view the image at any 
preferred angle and position. The data can be easily retrieved and repeated scans can be 
performed without radiation hazards making it useful for long -term studies. Several 
models of the face scanned at different angles can be computed into a composite image 
to create a 360° 3D image. 
A major drawback of this technique is the time required to capture image, during which 
the patient must not change his or her facial expression. Improvements in technology 
have reduced the time to capture images from 10 seconds with the earlier systems to 
around 1 second (Da Silveira, Daw et al. 2003). 
However, difficulties remain when capturing images of young children, as any 
movement during the scanning interval results in distortion of the image. Another 
drawback of this system is that patient's eyes are required to remain closed during 
capture for protection, although a system has been described which allows image 
capture with the eyes open (Bush and Antonyshyn 1996). A further disadvantage is the 
inability of the system to capture the soft tissue surface texture, which can result in 
difficulties of landmark identification. 
The cost of this system also remains a drawback. 
1.5.1.11. 3 -D Ultrasonography 
Three -dimensional ultrasonography delivers a reflection picture which is transformed 
into digital information using a specific contact probe to generate a 3 -D database (Hell 
1995). This system produces 3 -D co- ordinates of selected landmarks but does not 
create a 3 -D image. The procedure requires a skilled operator as well as a co- operative 
patient. Also distortion of facial soft tissues with the probe may occur which alters their 
spatial positions. 
1.5.1.12. Stereophotogrammetry 
Photogrammetry is defined as `the science or art of obtaining reliable measurements by 
means of photographs' (Hajeer MY 2002). Stereophotogrammetry utilizes 2 cameras, 
configured as a stereo -pair, to recover the 3D distance to features on the surface of the 
face by triangulation. It was first described in the medical literature in 1967 (Burke and 
Beard 1967). Contemporary digital stereophotogrammetry incorporates advances in 
computer science technology to convert simple photographs to 3 -D images based on 
complex algorithms. Various systems applied to capture the face have been described. 
These include the Spatial Vision System (Bowskill, Baldock et al. 1997) 
stereophotogrammetry systems (Rasse, Forkert et al. 1991; Ras, Habets et al. 1996) and 
video -based stereophotogrammetry (Stevens 1997). 
The C3D® imaging system was developed as a result of collaboration between 
Glasgow University Dental School and the Turning Institute. The system was based on 
the Active Stereo Probe which employed a new image- matching algorithm and consists 
of two stereo digital cameras and special textured illumination. It has been used to 
record 3D records of study models (Ayoub, Garrahy et al. 2003) and to study the facial 
soft tissue changes following orthognathic surgery (Hajeer, Mao et al. 2005). A 
drawback of this system is the requirement for the scene to be bathed in `textured light' 
to capture the natural surface appearance of the patient's skin. This technique is termed 
`active stereophotogrammetry'. A new system has been developed by Dimensional 
Imaging, a company branched from C3D Limited, which is able to extract 3 -D models 
from stereo -pair images without restoring to bathing the scene in speckle illumination. 
This technique, termed `passive stereophotogrammetry', is possible due to the 
development of high- resolution digital cameras which can accurately capture surface 
texture. 
1.5.2. Facial volume measurement 
The assessment of facial morphology using 3 -D imaging has often relied on the 
measurement of distances, angles, and curves between defined facial landmarks. Other 
techniques using statistical analysis are based on geometric morphometrics. This is a 
method where the coordinates of the landmarks are statistically analysed rather than 
interlandmark distances (O'Higgins and Jones 1998). Three- dimensional coordinates 
are defined in three planes; the x axis is the horizontal plane, the y axis the vertical 
plane and the z axis the anteroposterior plane. 
Changes have been described in terms of 3D facial soft tissue landmark displacement 
(Berkowitz and Cuzzi 1977), 3 -D interlandmark distances and angles (Ras, Habets et 
al. 1996), 3 -D mesh diagram analysis (Ferrario, Sforza et al. 1998), colour -coded 
millimetric maps of changes on 3 -D soft tissue models (McCance, Moss et al. 1992) , 
and other 3 -D shape analyses such as Euclidean distance matrix analysis (O'Grady and 
Antonyshyn 1999). 
The development of software to measure facial volume is still under investigation by 
researchers but represents a key application of 3D imaging. The problem with all 
methods of facial volume assessment is that the area under measurement needs to be 
closed. The surface of the face does not have an inherent volume therefore a plane has 
to be constructed to form the posterior border of a face and close the volume. When 
examining pre and post- operative swelling, if the swelling is localised, the overlap of 
the two images may give a closed volume. However, if a border has to be constructed 
to close the volume between two models, the location of this plane could have a 
dramatic effect on the volume and render the analysis meaningless. 
A method of measuring the volume of a facial swelling has been described (Bowskill, 
Baldock et al. 1997) using a Spatial Visual System (SVS). The SVS acquires four video 
images (two stereo -pairs) and constructs a 3 -D surface representation using stereo - 
matching of spatial features using `speckled' illumination. A simulated pre- operative 
and post- operative volume was imaged using a plaster head onto which a quantity of 
padding was added over the left cheek. Volumetric quantification was achieved by 
volume differencing and the mean error in repeated measurement of volume was found 
to be within 3.5 %. The authors advised that this was a `best case' error since the images 
were of a cast and not a live subject. Another method of measuring facial swelling has 
been described (Yip, Smith et al. 2004) which evaluated the accuracy and 
reproducibility of the Fiore" 3 -D range camera by simulating facial swellings on a 
mannequin head and 20 human subjects. Image registration was carried out by 
adjusting the second image over the first image using the forehead as a control area. A 
colour- graded format was used to display regions of facial swelling, and volume was 
calculated after drawing a mask over the area. In a validation of this method the overall 
percentage difference for the volumetric comparisons ranged from 0.1% to 2.3 %. 
Validation of the C3D system for facial volume analysis was conducted in vitro using a 
mannequin head and in vivo with a male- subject head (Hajeer, Mao et al. 2005). Thirty 
facial silicone moulds were applied to various regions of the face and their volumes 
were calculated using three different algorithms (the `tetrahedron formulation', the 
`projection' method and the `back -plane construction' method.) The least mean error, 
found with the tetrahedron formulation, was 0.071 cm3 in vitro and 0.314cm3 in vivo. 
A further method of measuring volume, as a measure of asymmetry, has been described 
(O'Grady and Antonyshyn 1999). In this method, a laser -scanned plaster model with 
and without a silicone cheek implant was used to simulate facial asymmetry. The 
volume was determined by superimposing and subtracting one facial half from a mirror 
image of the contralateral half. However, an error of about 16.2% was found. Facial 
volume analysis has also been applied to study facial growth (Ferrario, Sforza et al. 
1998). This technique involved locating 3D landmarks on the face and connecting them 
in a series of triangles with a posterior plane. Only the approximate volume of the face 
is therefore quantified and the results cannot be compared to other techniques which 
measure the whole surface of the face. Kobayashi et al carried out volumetric changes 
in the lower face before and after orthognathic surgery by dividing the 3D model into 
eight sites, with six intersecting planes (Kobayashi, Ueda et al. 1990). The drawbacks 
of this study are that these mathematically constructed volumes are not clinically 
applicable, and the accuracy and reproducibility of the imaging technique were not 
evaluated. 
Clinical studies to evaluate facial soft tissue volume change following treatment with 
fillers are lacking, particularly in patients with HIV lipodystrophy. Therefore, this study 
will provide objective analysis of facial changes secondary to injection of biological 
fillers and fat. 
1.5.3. DI3D Facial Camera 
1.5.3.1. Description of DI3D Facial Camera system 
The DI3D Facial Camera is a precision 3D surface -image capture device which was 
used in this study to capture 3 -D facial images. The system consists of two pods, each 
pod containing two 10 megapixel digital cameras, attached to a base and tripod stand. 
The cameras are assembled vertically (right top and bottom and left top and bottom) on 
either side of the base which measures 87 cm in width. The cameras are positioned at 
angles of 30 degrees. The system is attached to a laptop computer for image capture. 
(Figure 1.1) 
Figure 1.1. DI3D Facial Capture System 
1.5.3.2. Principles of Stereophotogrammetry 
The DI3D system uses a passive stereo photogrammetry technique using SLR (single 
lens reflex) digital cameras to produce high- resolution 3D surface images. Passive 
stereo photogrammetry utilizes the subject's skin pattern to triangulate the geometry 
from each surface point. There are several processes are required to produce the 3 -D 
surface model. 
1. Capture 
The DI3D system captures two stereo -pairs of images using four cameras (Figure 1.2). 
Figure 1.2. Images captured from each pod. 
This increases the number of 3 -D measurements that can be obtained to compute a 3 -D 
facial surface model. With a synchronized trigger, the four images are captured 
simultaneously, which reduces the inaccuracy due to movement. 
2. Triangulation and stereo 
DI3D creates a depth map by decoding parallaxes from a stereo -pair of images. This is 
similar to human vision in that we perceive depth from slight parallaxes present 
between the views observed in each eye. Figure 1.3 illustrates this principal. 







Point P in space will project onto the left and right cameras in slightly different 
locations. The difference is termed parallax or disparity, and increases as point P moves 
further from the convergence point C of the camera stereo -pair. Similarly, the sign of 
disparity reverses depending on whether point P lies in front or behind point C. The 
DI3D software is able to produce depth values based on the size and sign of the 
disparity values. 
3. Stereo matching 
The next stage in the process is to determine for each point imaged in the left camera, 
the corresponding point in the right camera. This process, termed stereo matching, 
produces an (x,y) disparity map. This maps the values of each pixel co- ordinate of the 
left image to the right image for each stereo -pair. A confidence map is also produced 
which gives an indication of the reliability of each matched value. The process of stereo 
matching also utilizes the geometry of the camera system deduced by calibration. A 
calibration target, comprising a series of black dots on a white background, of known 
dimensions and location is imaged in a series of different angles to the cameras. The 
geometric configuration the cameras can be determined by processing images of the 
target from each camera to find the central location of the dots. By computing 
disparities from stereo matching with calibration data (a process termed space 
intersection) a cloud point is produced. (Figure 1.4) 
Figure 1.4. Cloud point images 
4. Model construction and integration 
The point cloud (also called a range model) comprises only 2.5D information but can 
be easily warped to fit a triangulated mesh. The point clouds from each pod (each set of 
cameras) can be integrated to create the 3D image. During calibration, the orientation 
of each pod with respect to the calibration target is calculated. This process enables the 
point cloud captured from each pod to be transferred into the same coordinate frame. 
The point clouds are merged into a single triangulated polygon mesh using the 
marching cubes algorithm. The final 3 -D model can be seen as a solid, shaded, or 
wireframe model (Figurel.5). 
This method is non -invasive, captures the face in 50 milliseconds and does not expose 
the patient to harmful radiation. Therefore, this system was chosen as the most useful 
tool to capture facial images in a clinical trial. When the study was initiated, the DI3D 
system required development of volume software to analyze the change in measured 
outcomes following surgery. A software package was developed by the Dimensional 
Imaging engineers and tailored to the specific requirements of the study. However, 
validation studies to evaluate the accuracy and reliability of the system and software to 
measure facial volume was required and shall be described in the following chapter. 
Chapter 2. Surgical technique and outcome 
following treatment for HIV facial lipoatrophy 
2.1. Aim 
The aim of this study was to evaluate three different treatments for HIV facial 
lipoatrophy with regards to surgical technique, complications and patient satisfaction. 
2.2. Method 
2.2.1. Design 
This was a prospective, follow -up study in a cohort of patients undergoing 3 treatments 
for HIV associated facial lipoatrophy: autologous fat transfer, Newfill and Bio- alcamid. 
2.2.2. Sample Size 
A retrospective review of all patients with HIV lipodystrophy treated within the 
Edinburgh unit prior to commencement of the trial was conducted to evaluate local 
demographic data and treatment outcomes. Thirty -two patients with HIV lipodystrophy 
were treated within the Edinburgh unit between March 2003 and March 2006 and 
identified using the hospital coding system. Thus, a sample size of 50 HIV 
lipodystrophy patients was chosen to allow the study to be completed within a 
reasonable timescale whilst providing useful information for future studies. 
With 50 patients followed up post -operatively, the standard deviation of a continuous 
outcome can be estimated with a 95% confidence of ±20 %. There was likely to be 
some loss to follow -up, but by collecting data at several time points and analysing with 
repeated measures techniques, the study would provide sufficient data to obtain 
accurate estimates of post- operative outcome distributions. 
2.2.3. Ethical Approval 
Full ethical approval was granted from the Multi Centre Research Ethics Committee for 
Scotland for the project to be carried out at multiple clinical sites within NHS Lothian 
and Greater Glasgow. In addition, Research and Development approval at each site was 
awarded. 
This study also received funding from the following charities: 
Henry Smith Charity 
NHS Lothian Endownments 
William Rooney Charity 
Sick Kids Foundation, Edinburgh 
2.2.4. Recruitement 
Patients and physicians were made aware of the trial via the SHIVAG (Scottish HIV 
and Aids Group) website and annual meeting. Posters to advertise the trial were also 
placed in HIV clinics in Edinburgh and Glasgow. Patients seeking treatment for HIV 
lipodystrophy were referred by their HIV physician to the Plastic Surgery Unit in either 
Edinburgh or Glasgow. Referred patients were appointed to the out -patient clinic of the 
lead consultant involved in the trial from each unit. At the out -patient clinic, patients 
were assessed by the Plastic Surgery Consultant and lead researcher. A full medical 
history and clinical examination was carried out, incorporating the patient and 
physician assessment of lipodystrophy devised by Carr et al (Appendix 3). Patients 
were recruited to the trial if the eligibility criteria were satisfied. A patient information 
sheet was provided and informed consent was obtained. The patients' HIV physician 
and general practitioner were informed by letter, only if patient consent was obtained. 
Inclusion Criteria: 
1 Patients over 18 years of age. 
2 Male or female. 
3 HIV positive. 
4 Patient and physician agreed body changes attributable to lipodystrophy and 
amenable to surgical treatment. 
5 Undetectable viral load and CD4 count > 200 cells /mm3 
Exclusion Criteria: 
1 Pregnancy. 
2 Inflammation/ infection of skin at site of treatment. 
3 Concurrent illness/ medical problems precluding general anaesthetic. 
4 Concurrent treatment with anti -coagulants. 
5 Any known psychiatric disorder 
2.2.5. Data Collection 
Demographic data was collected including the patients' age and ethnic status. Data 
relating to the patients' HIV status was recorded including; date of diagnosis, mode of 
HIV acquisition, current medication and treatment history, viral load/ CD4 count. 
Information on the patients' past medical history, drug history and relevant social 
history were also collected. 
The patient and physician assessment of lipodystrophy (Carr, Law et al. 2003) was used 
to collect information on clinical features of lipodystrophy (Appendix 1). Each patient 
completed a lipodystrophy- specific questionnaire and underwent a lipodystrophy- 
specific examination by the lead researcher. Both assessments recorded independently 
any lipoatrophy or fat accumulation in each of the face, neck, dorsocervical spine, 
arms, breasts, abdomen, buttocks, and legs, as well as the presence of any lipomata. 
The degree of lipoatrophy or fat accumulation at each region was rated as absent = 0, 
mild =1 (noticeable on close inspection), moderate = 2 (readily noticeable by patient 
and physician) or severe = 3 (readily noticeable to a casual observer) by both the 
patient and surgeon. 
Anthropometric measurements obtained for each patient included height, weight and 
skin -fold thickness. The height and weight were used to calculate the Body Mass Index 
(BMI = weight (kg)/ height (m) 2. Measurements of skin -fold thickness were obtained 
from five sites (triceps, biceps, abdomen, thigh and medial calf) and recorded in 
accordance with the International Standards for Anthropometric Assessment by the 
lead researcher using the Accu- Meaure Fitness 3000 body fat caliper. 
2.2.6. Treatment of HIV patients with facial lipoatrophy 
Three treatment options were available for patients presenting with facial lipoatrophy: 
autologous fat injections, Newfill or Bio- alcamid. During the clinical examination, 
potential donor sites for autologous fat transfer were assessed. Patients with sufficient 
subcutaneous fat were offered treatment with autologous fat injections. Patients with 
insufficient fat resources to facilitate autologous fat transfer, received treatment with 
either Newfill or Bio- alcamid. Patient preference was taken into account when 
choosing a treatment option. 
2.2.6.1. Autologous fat transfer 
Prior to theatre, patients underwent pre -assessment including medical history, 
examination, blood tests (FBC, U &E, LFT, clotting, G &S), ECG, and anaesthetic 
review. Lipoatrophic areas of the face and potential sites for fat harvesting were 
marked by the Consultant Plastic Surgeon, and informed consent for the procedure was 
obtained. 
Under general anaesthetic, a solution containing 1L saline, 40mg marcaine and lmg 
adrenaline, was infiltrated to the subcutaneous fat of the periumbilical region, and/or 
areas of fat accumulation requiring liposuction. 
Fat was harvested using a Coleman cannula and 10m1 syringe via small stab incisions 
(Figure 2.1), then centrifuged for 3 minutes at low speed using the Coleman centrifuge 
machine. 
Figure 2.1 Fat harvest from the periumbilical region 
After centrifugation, the aspirate was divided into 3 layers (Figure 2.2): the top layer, 
consisting of free oil from ruptured fat cells, and the bottom layer, consisting of 
tumescent fluid and blood, were decanted. The middle layer, consisting of fat cells for 
grafting, was transferred to lml syringes for injection. 
Figure 2.2. Centrifuged fat 
Fat was injected, via small stab incisions (at the nasolabial area, lateral zygoma and 
lateral eyebrow) to affected lipoatrophic areas using a blunt 2mm Coleman cannula 
(Figure 2.3). Fat was injected using a tunnelling technique. Multiple threads of 3mm 
diameter fat were deposited in a retrograde fashion to multiple subcutaneous planes. 
Figure 2.3. Fat injection technique 
Some patients with areas of fat accumulation (such as the dorsocervical fat pad, 
anterior neck, gynaecomastia) had liposuction carried out during the same procedure. 
Occasionally, areas of fat accumulation were used as the donor site for fat transfer if 
subcutaneous fat from the abdomen was deemed insufficient. In these cases, harvested 
fat was aspirated using the method described to avoid excess trauma to the fat from 
mechanical aspiration. 
Steri- strips were applied to all stab incisions and areas of liposuction were dressed with 
swabs and mefix tape. 
Patients were observed in hospital overnight then reviewed in the out -patient clinic 2 
weeks post -operatively to check the donor and recipient sites. 
2.2.6.2. Newfill 
Newfill injections were carried out by a trained nurse specialist in the out -patient clinic. 
At the initial consultation, the patient was asked to identify the lipoatrophic areas of the 
face causing concern. The product is supplied as a sterile freeze -dried preparation in a 
clear glass vial. At each treatment session, one vial of Newfill per cheek was 
reconstituted with 3mls sterile water and 2mls 1% lignocaine into lml syringes. 
Reconstitution was carried out 2 hours prior to injection to ensure complete hydration, 
as per the manufacturer's recommendations. The product was then agitated 
immediately prior to use until a uniform translucent suspension was obtained. 
The patients' face was prepared using sterile water, and the injection session was 
conducted using aseptic technique. Injection was carried out using a 26G sterile needle 
to the deep dermis of affected areas. The needle was introduced, bevel up, at an angle 
of 30 -40 degrees until the desired skin depth was reached. For lipoatrophy affecting the 
malar area, a tunnelling technique for injection was used. The needle was advanced in 
the appropriate dermal plane, and the product was deposited as the needle was 
withdrawn. The volume of Newfill per injection was 0.1 -0.2mL and up to 20 injections 
were required per cheek. The depot injection technique was used for the temple area. 
Multiple small boluses of approximately 0.05mL were injected to the temporal fascia 
and the area was massaged following each injection. 
After the injection session, the treatment area was massaged to evenly distribute the 
product. Patients were advised to massage the treatment area daily for several days 
after the injection session to promote a natural -looking correction. Patients were 
advised about potential side -effects of treatment and given contact details to report 
problems. 
Treatments were carried out at intervals of one month. At each session, the patient was 
re- evaluated to determine which areas required further correction. Up to 7 treatment 
sessions were required by some patients depending on the severity of facial 
lipoatrophy. 
2.2.6.3. Bio- alcamid 
Initially Bio- alcamid injections were carried out under general anaesthetic. Thus, 
patients required pre- operative assessment including medical history, examination, 
blood tests (FBC, U &E, LFT, clotting, G &S), ECG and anaesthetic review. In some 
patients, Bio- alcamid injections were performed using a regional nerve block. The 
areas of the patient's face requiring augmentation were delineated using a permanent 
marker pen pre -operatively. 
The procedure was carried out in the operating theatre under aseptic technique. 
Betadine solution was used to clean the patient's face and surgical drapes were applied. 
The head of the operating table was raised to 50 degrees to create an upright position. 
Antibiotic prophylaxis with augmentin was administered intraoperatively for patients 
having the procedure performed under general anaesthetic; or given as a 3 -day post- 
operative course for patients having the procedure under local anaesthetic. 
The product is supplied in pre -filled 3m1 syringes and an 18 G needle was used for 
injection (Figure 2.4). 
Figure 2.4. Bio- alcamid syringes 
A hollow, beveled needle was used to pierce the skin then exchanged for a blunt 
needle. Injection sites for the cheek were the nasolabial fold and lateral zygoma at the 
pre -auricular region (Figure 2.5). For the temple region, the lateral brow or pre - 
auricular injection sites were used. Prior to deposition of the material, the blunt needle 
was used to create a pocket by fanning in the hypodermis of affected areas. 
Figure 2.5. Bio- alcamid injection technique 
The product was injected until total correction of the deficit was obtained. Histoacryl 
glue was used to seal the injection sites. Patients were discharged from hospital on the 
day of the procedure and warned to avoid applying pressure or UV light to the treated 
area. 
2.2.7. Clinical Follow -up 
All patients were invited for clinical review at 2 months, 6 months and 12 months 
following treatment. This was undertaken either by the lead researcher or by lead 
consultant involved in the trail. Patients were asked about their satisfaction with the 
results of treatment, and about any complications following treatment. A subjective 
opinion of the patient was sought regarding recurrence of fat resorption or fat 
accumulation in treated areas and whether the results of treatment were maintained. 
Patients were examined for asymmetry or irregularity in treated areas and also assessed 
for complications such as bruising, swelling, infection, nodules/ granulomas, migration, 
capsular contraction, and fistulae. 
2.2.8. Patient Satisfaction 
A series of visual analogue scales were designed for the study to assess patient 
satisfaction with treatment. Four questions were included (Appendix 2), intended to 
assess satisfaction with overall treatment, appearance improvement and patient 
expectations. Patients were asked to mark along a horizontal line with word descriptors 
at each end the point which they felt represented their current perception. The numbers 
one and ten were also placed at each end of the scale to facilitate the measurement of 
responses in an ordinal fashion. Scores were determined either by measuring in 
millimetres from the left hand end of the line to the point that the patient marked or 
recording the numerical value given by some patients on the scale. 
2.2.9. Statistical analysis 
Patient demographics, HIV -related factors and clinical features were summarised by 
treatment group (Autologous Fat Transfer, NewFill or Bio- alcamid) for patients 
undergoing treatment for facial lipoatrophy, and compared using analysis of variance 
(ANOVA) for continuous measures and Fishers exact test for categorical variables. 
Clinical features were summarised by gender. A descriptive summary of complications 
and their management was collated. Summary statistics were presented for the number 
of NewFill treatment sessions and displayed in a histogram. 
Patient satisfaction scores were subdivided according to treatment group and summary 
statistics were also measured. 
2.3. Results 
2.3.1. Baseline characteristics of treatment groups 
Forty-eight patients with HIV lipodystrophy underwent treatment for facial 
lipoatrophy. Three patients decided against treatment and one patient was excluded due 
to deteriorating HIV control and subsequent medical problems. 12 patients underwent 
Autologous Fat Transfer (AFT), 20 were treated with NewFill, and 16 with Bio- 
alcamid. 
The groups were well matched with regards to baseline age and HIV history (Table 
2.1). The majority of patients were male. Only one (6 %) of the Bio- alcamid patients 
was female; a greater proportion of NewFill (20 %) and AFT (33 %) patients were 
female. 
Similarly, the majority of patients were MSM in the Newfill and Bio- alcamid groups 
compared to 50% in the AFT group (reflecting the greater proportion of females in this 
group). Average BMI and skin fold thickness measurements were greater in the AFT 
group. Baseline mean clinical grading of facial lipoatrophy was greater for patient 
versus surgeon assessment for all groups and was significantly higher in the Bio- 
alcamid group. Lipoatrophy only was present in 65% and 50% of patients treated with 
Newfill and Bio- alcamid respectively. However, 92% of patients in the AFT group 
demonstrated a mixed morphological pattern. 
Table 2.1. Demographics of fat, Newfill and Bio -alcamid treatment groups 
AFT Newfill Bio -alcamid 
(n =12) (n =20) (n =16) 
P value 
Gender 
N ( %) Male 8 (67) 16 (80) 
15 




N Edinburgh 11 11 15 
N Glasgow 1 9 1 
Age (years) 
Mean +- SD 
43.4 45.5 +- 45.3 




N ( %) MSM 
N ( %) IVDA 
N ( %) Heterosexual 
N ( %) Other 












2 (13) 0.758 
HIV infection (years) 
11.4 10.7 +- 12.2 
Mean +- SD +- 5.2 6.4 +- 3.9 
0.72 
HAART duration (years) 
Mean +- SD 
9 +- 7.1 +- 9.2 +- 
0.28 
3.8 4.6 3.5 
CD4 count (cell /mm3) 
595 +- 551 +- 548 +- Mean +- SD 0.91 
287 239 287 




19 (95) 100) 1.000 
BMI (kg/m2) 
23.5 20.6 +- 21.4 
Mean + - SD + -2.2 2.9 + -3.2 0.08 
Skin fold thickness (mean of 5 areas, mm) 
Mean +- SD 8.3 
+- 5.3 + 5.1 +- 
0.008 
3.3 2.3 2.7 
Clinical grade 
Mean, Patient 2.1 2.1 2.7 0.016 
Mean, Surgeon 1.7 1.6 2.1 0.06 
Clinical pattern 
N ( %) Lipoatrophy only 
N ( %) Lipohyertrophy only 





13 (65) 8 (50) 
0 0 0.005 
7 (35) 8 (50) 
Table 2.2 summarizes the morphological pattern of HIV -associated lipodystrophy in 
patients referred for treatment. The pattern varied between male and female patients: 
87% of females presented with a mixed morphology whereas male patients 
demonstrated either lipoatrophy alone (45 %) or mixed morphology (48 %). 
Table 2.2 Clinical patterns of HIV -associated lipodystrophy in patients 
referred for treatment. 















N (%) 3 (7) 0 
Gynaecomastia 1 0 
DCFP 1 0 






























2.3.2. Complications of treatment 
2.3.2.1. Bio -alcamid 
The majority of post- operative complications occurred with the use of Bio -alcamid and 
are summarised in Table 2.3. 





Complication Onset Treatment 
1. 




12 months Expression of Bio- alcamid via 
Inferior stab incision. 
migration 





Removal Bio- alcamid & 
migration Coleman fat transfer. 
3. 
2 attempts at removal via needle 




Surgical removal by stab 




Asymmetry 1 month 
















Surgical removal by stab 
incisions, curettage & irrigation. 
I.V. antibiotics & long -term oral 
antibiotics. 
Revision by aspiration & further 
injection of Bio- alcamid. 
I.V. flucloxicillin & 
benzlypenecillin 
Revision by 
Asymmetry 1 month aspiration & further injection of 










3 years Removal of Bio -alcamid. 
of the right cheek one week following a minor revision procedure. An ultrasound scan 
of the cheek demonstrated soft tissue swelling but no collection of pus. The most 
serious complications relating to infection were seen in a patient who developed 
chronic swelling of the left temple fourteen months post -operatively. Viscous fluid was 
present surrounding the capsule suggesting low -grade infection, although pus was 
subsequently aspirated from this region and both cheeks. Two months later, the patient 
presented with an acute abscess of the right cheek requiring incision and drainage. 
Microbiological assessment isolated clostridium perfringens and the patient was 
commenced on a prolonged course of oral metronidazole. At follow -up assessment, pus 
discharging from a sinus tract at the right cheek was discovered (Figure 2.6). 
Figure 2.6. Sinus of right cheek 
Therefore, all remaining Bio- alcamid® was removed from the right cheek and temple 
via stab incisions, curettage and irrigation. The patient refused removal of the product 
from the left side of his face and long -term oral metronidazole therapy was continued. 
Four months later, the areas of inflammation remained quiescent but resulted in 
undesirable facial scarring (Figure 2.7). 
Figure 2.7. Post -operative scarring following removal of Bio -alcamid 
In addition, the patient also developed problematic metronidazole- induced paraesthesia. 
Extrusion of Bio- alcamid to the buccal mucosa of the right cheek was seen in one 
patient, 6 months following 2 revision procedures to correct minor asymmetry (Figure 
2.8). Manual expression of Bio- alcamid via the fistula tract combined with antibiotic 
prophylaxis was attempted on two occasions. However, the patient subsequently 
required removal of all remaining product via stab incisions and curettage. 
Figure 2.8. Extrusion of Bio -alcamid 
Inferior migration of the product from the malar region to the jowls occurred in 3 
patients, 12 months to 3 years following treatment, and required further surgery (Figure 
2.9). 
Two patients developed firm, non -inflammatory swellings in treated areas which 
persisted despite aspiration of the product, and excess capsule formation was suspected 
to account for this contour abnormality. 
Figure 2.9. Migration of Bio -alcamid 
2.3.2.2. Newfill 
Patients treated with Newfill experienced mild injection -related side -effects of 
treatment such as swelling and or bruising which settled within one week. There were 
six patients who developed palpable subcutaneous nodules but these were not visible 
and therefore did not require treatment. Three patients complained of minor asymmetry 
in treated areas. 
Table 3.13 and Figure 2.10 show the number of treatment sessions and top -up 
treatments for Newfill. 
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Seven treatment sessions were required for almost 50% of patients. Two patients with 
severe lipoatrophy required nine treatment sessions and still felt that the volume 
augmentation achieved was insufficient. Two patients did not complete a course of 
treatment due to personal or social circumstances therefore full correction of 
lipoatrophy was not achieved. Three patients required a top -up injection 18 -24 months 
following completion of treatment for minor areas of subjective volume loss. 
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Figure 2.11. Pre and 6 -month post- operative result for patient treated with fat 
Figure 2.12.. Pre and 6 -month post- operative result for patient treated with Newfill 
Figure 2.13.. Pre and 6 -month post- operative result for patient treated with 
Bio -alcamid 
2.4. Discussion 
2.4.1. Baseline characteristics of treatment groups 
The 3 groups of patients undergoing treatment for facial lipoatrophy were reasonably 
well matched with regards to age, and haematological parameters. However, there were 
some important differences between the groups which shall be discussed in this section. 
The treatment numbers varied slightly between groups with the smallest number of 
patients undergoing fat transfer and the largest number receiving Newfill injections. 
The clinical pattern of lipodystrophy was a key factor determining choice of treatment. 
Only patients with sufficient autologous donor fat (including areas of lipohypertrophy) 
were selected to the AFT group. Thus, the majority of patients in the AFT group had a 
mixed morphological pattern. This was also reflected in the higher BMI and skin fold 
thickness measurements in this group. Patients with insufficient subcutaneous fat for 
transfer were offered treatment with a filler. Sixty -five percent of the Newfill group and 
50% of the Bio- alcamid group presented with lipoatrophy alone. Although a mixed 
morphological pattern was seen in some patients, the fat distribution was not 
appropriate for fat transfer (e.g. intraperitoneal fat). In addition, 3 patients requested 
Bio- alcamid treatment and 2 patients requested Newfill treatment following complete 
resorption of previously transferred autologous fat. Thus, patient preference was also a 
key factor when considering treatment options. Although all 3 treatments were 
discussed with patients, 9 out of 11 patients recruited from the Glasgow unit requested 
Newfill therapy. This may have been influenced by local resources and bias from the 
referring units as all patients with facial lipoatrophy were treated with Newfill in 
Glasgow prior to the study. 
Overall, a greater number of females with HIV lipodystrophy presented for treatment 
than predicted compared to previous national and local studies. This introduced further 
variability in treatment numbers as differences in clinical pattern were observed 
between genders. Eighty -seven percent of females presented with a mixed morphology 
compared to 48% of males, which explains the slightly larger proportion of females in 
the AFT group. This study may provide some evidence to support the hypothesis of 
different clinical patterns of lipodystrophy observed between genders. It has been 
observed that females tend to develop a mixed pattern of lipodystrophy or 
lipohypertrophy compared to a greater proportion of lipoatrophy in males. This may be 
related to hormonal influences on fat distribution between genders. However, the 
pathogenesis is likely to be multi -factorial and previous studies have not demonstrated 
a direct correlation between morphological pattern and gender. 
A difference in baseline clinical grading of facial lipoatrophy was also seen, with 
significantly higher scores in the Bio- alcamid group compared to the AFT and Newfill 
groups. The study was designed to randomize patients who required a filler to receive 
treatment with either Newfill or Bio- alcamid. However, the majority of patients refused 
randomization and had a preference for their choice of treatment. This was largely due 
to the difference in properties of the two fillers. Consequently, patients with more 
severe facial lipoatrophy tended to favour treatment with Bio- alcamid which can be 
injected in large volumes to achieve a full and permanent correction. 
2.4.2. Complications of treatment 
Clinical follow -up in many patients extended beyond the 12 -month trial interval. This 
was important to evaluate longer -term adverse effects of treatment and the 
complications which emerged following Bio- alcamid injections became a significant 
concern. Early in -vitro studies evaluating the use of Bio- alcamid emphasized the safety 
and biocompatibility of the product (Ramires, Miccoli et al. 2005). The largest 
multicentre study of 2000 otherwise healthy patients reported excellent cosmetic results 
with only 12 complications of S. aureus infection (Pacini, Ruggiero et al. 2002). This 
study also reported no observed cases of migration, dislocation, granulomas, allergic 
response or intolerance of the implant. However, the true incidence of complications 
relating to Bio- alcamid is likely to be underreported due to the large number of patients 
treated by cosmetic practitioners with insufficient follow -up. During the trial period, 
reports have emerged from plastic surgery units which have become referral centres for 
complications relating to the use of this Bio- alcamid. The greatest concern, particularly 
in HIV positive individuals, is the potential for infection. A number of safety studies 
have shown Bio- alcamid® to be non -toxic, non -allergenic, non -reactive, biocompatible 
and non -biodegradable (Pacini, Ruggiero et al. 2003; Formigli, Zecchi et al. 2004). 
However, despite evidence of its biocompatibility, Bio- alcamid® still carries the risk 
associated with implants to provide a favourable environment to harbour bacteria. 
Jones et al have emphasized the late appearance of abscesses months to years after 
injection of the material (Jones, Carruthers et al. 2007). In some cases, the onset of 
infection was triggered by additional revision procedures at or near the site of previous 
injections (Karim, Hage et al. 2006). However, complications may also arise 
spontaneously without any history of trauma or local infection. In most published 
cases, microbacterial cultures have demonstrated streptococcal or staphylococcal 
bacteria. Interestingly, Clostridium perfringens, an anaerobic bacteria commonly 
associated with food borne illness, was isolated in one of our patients. Management of 
infection by antibiotic therapy or attempted aspiration is often unsuccessful. Surgical 
incision and drainage is usually required to remove all infected material resulting in 
undesirable facial scarring. A technique of drainage utilising an irrigation system has 
been described by one institution to minimise skin incisions (Goldan, Georgiou et al. 
2007). The potential for infection- related complications is a disastrous and 
unacceptable result for patients seeking cosmetic enhancement. Because spontaneous 
inflammatory reactions are possible years after injection, it has been suggested that 
Bio- alcamid® may lead to chronic interference with surrounding tissues and enhanced 
susceptibility to infections (Alijotas -Reig, Garcia - Gimenez et al. 2008). Thus, 
immunocompromised patients with HIV infection may represent an even more 
vulnerable patient group. Although warnings against the use of Bio- alcamid® for 
cosmetic indications have been published (Karim, Hage et al. 2006), Bio- alcamid® is 
still considered to have a role in the management of severe reconstructive deficits such 
as HIV lipodystrophy. However, the results of this trial demonstrate that the product 
should be used even more cautiously in this patient group. 
Bio- alcamid® is also prone to other risks associated with prostheses such as migration 
and capsule contraction. Capsule formation around the implant is suggested to prevent 
migration by providing anchorage with surrounding tissues (Formigli, Zecchi et al. 
2004). However, gravitational migration was evident in 3 of our patients and is perhaps 
associated with injection of large volumes of the material into mobile areas. It has been 
suggested that filler migration may occur after manipulation of the product with 
disruption of the surrounding capsule (Ross and Malhotra 2009). However, marked 
migration of Bio- alcamid® was observed in patients who have not undergone revision 
procedures. Areas of excessive capsule formation can also be unpredictable and 
difficult to treat. 
The economic burden of complications relating to Bio- alcamid® must also be 
considered. The requirement for in- patient admission, intravenous antibiotic therapy, 
surgical drainage and further corrective procedures may incur significant costs to health 
trusts. Although private cosmetic practitioners carry out many of these procedures, 
patients with complications often present via acute hospital settings seeking treatment. 
In addition, some cosmetic practitioners lack the facilities or skill to address 
complications requiring surgical removal. 
Therefore, the potential for significant short and long -term complications that have 
emerged as a result of the trial have led to a change in management of patients with 
HIV lipodsytrophy in the Edinburgh unit. Bio- alcamid is no longer offered as a 
treatment option and alternative treatments are being evaluated to rectify some of the 
on -going problems. 
There were no adverse events following treatment with autologous fat transfer. The 
selective randomisation methodology of this study was chosen in the belief that 
autologous fat transfer is the most physiologically compatible filler, and the results of 
the study support the safety of this treatment. No evidence of lipohypertrophy of 
transferred fat was seen in this patient group, despite harvesting fat from the DCFP in 
migration by providing anchorage with surrounding tissues (Formigli, Zecchi et al. 
2004). However, gravitational migration was evident in 3 of our patients and is perhaps 
associated with injection of large volumes of the material into mobile areas. It has been 
suggested that filler migration may occur after manipulation of the product with 
disruption of the surrounding capsule (Ross and Malhotra 2009). However, marked 
migration of Bio- alcamid® was observed in patients who have not undergone revision 
procedures. Areas of excessive capsule formation can also be unpredictable and 
difficult to treat. 
The economic burden of complications relating to Bio- alcamid® must also be 
considered. The requirement for in- patient admission, intravenous antibiotic therapy, 
surgical drainage and further corrective procedures may incur significant costs to health 
trusts. Although private cosmetic practitioners carry out many of these procedures, 
patients with complications often present via acute hospital settings seeking treatment. 
In addition, some cosmetic practitioners lack the facilities or skill to address 
complications requiring surgical removal. 
Therefore, the potential for significant short and long -term complications that have 
emerged as a result of the trial have led to a change in management of patients with 
HIV lipodsytrophy in the Edinburgh unit. Bio- alcamid is no longer offered as a 
treatment option and alternative treatments are being evaluated to rectify some of the 
on -going problems. 
There were no adverse events following treatment with autologous fat transfer. The 
selective randomisation methodology of this study was chosen in the belief that 
autologous fat transfer is the most physiologically compatible filler, and the results of 
the study support the safety of this treatment. No evidence of lipohypertrophy of 
transferred fat was seen in this patient group, despite harvesting fat from the DCFP in 
one patient. The best choice of donor site remains a topic of debate. Some authors 
propose that fat harvested from areas of lipohypertrophy may have some survival 
advantage (Davison, Timpone et al. 2007). However, the only patient in this study who 
had fat harvested from the DCFP underwent complete fat resorption, which may relate 
to the poor quality of fat deposited in these areas. New theories regarding protein 
receptor status of adipocytes within regions of lipohypertrophy have been proposed. 
Guallar et al have demonstrated a high expression of proliferating cell nuclear antigen 
(PCNA), a marker gene of cell proliferation, in adipocytes harvested from the buffalo 
hump region (Guallar, Gallego- Escuredo et al. 2008). The authors suggest that a 
transformed phenotype in cells from these sites develop an intrinsic enhancement in 
cell proliferation, which remains even when transferred to lipoatrophic sites. The study 
also demonstrated variability in PCNA expression, and therefore proliferative capacity, 
in different buffalo hump samples. Although further investigation in this field is 
required, it may explain why buffalo hump deformity may recur following treatment 
with liposuction. It may also provide an explanation for the well -documented `hamster 
cheek' syndrome which may develop following transfer of buffalo hump fat adipocytes 
to treat areas of facial lipoatrophy (Guaraldi, De Fazio et al. 2005). 
Variable degrees of fat resorption were demonstrated post -operatively, but whether this 
is considered a complication or rather an anticipated side -effect of treatment is 
questionable. The degree of resorption of autologous fat grafts also remains a topic of 
debate, and is mainly based on subjective observation of surgically treated areas over 
time. Indeed, studies are difficult to compare due to the wide variability in technique, 
experience of the surgeon and means of evaluating outcome. Compared to other non- 
permanent fillers, the longevity of autologous fat is not as easily predictable. For 
patients with HIV lipodsytrophy, the unpredictable nature of the technique is even more 
apparent due to the underlying systemic lipodystrophic process. 
The perceived success of autologous fat transfer depends on whether one considers 
long -term resorption disappointing or potentially superior to the anticipated longevity 
of other non -permanent fillers. Thus, the less predicable long -term volume 
augmentation achievable with autologous fat must be balanced against the risks of 
allergic responses and other complications relating to synthetic injectable fillers. The 
simplicity and safety of autologous fat transfer also makes it an attractive option 
compared to other surgical options for HIV facial lipoatrophy including the use of 
dermis -fat grafts, flaps and implants. 
Newfill therapy was also found to be a safe treatment in this study. Six patients 
developed palpable subcutaneous nodules, although these were not visible and did not 
require treatment. Subcutaneous nodules are the most commonly reported side -effect of 
Newfill treatment (occurring in 52% of patients in the VEGA study.) Nodules can be 
visible or nonvisible (ie only palpable) and can be temporary or permanent. It has been 
suggested they can arise as a result of technical error, uneven distribution in the 
suspension, or uneven dispersal in the injected areas. Histologically, the nodule consists 
of fluid droplets surrounded by a normal foreign body reaction. Nodules can be further 
subclassified into early and late nodules (Lam, Azizzadeh et al. 2006). All of the 
patients in this study developed early nodules which typically appear within several 
weeks of treatment. They can be disrupted by needle fragmentation of the nodule and 
injection with saline to hydrate and redistribute the particles followed by aggressive 
massage (Lam, Azizzadeh et al. 2006). If the nodules do not resolve over time, they can 
be locally excised. Late nodules that appear several months after injection may be 
treated with an intralesional steroid (triamcinolone, 10 mg /cc) and massage (Vleggaar 
2006). Again, failure to respond to treatment may require local excision of the lesion. 
The guidelines for reconstitution of Newfll have recently been modified by the 
manufacturers to minimise the risk of nodule formation. These include increasing the 
volume of saline when reconstituting the product from 5 to 10 cc. It is also suggested 
that the sterile water should be added 24 -48 hours before injection to allow sufficient 
time for the product to be entirely reconstituted (Vleggaar and Bauer 2004). 
2.4.3. Patient satisfaction 
Mean patient satisfaction was similarly high for all 3 treatments. However, there are 
various weaknesses of the method that should be highlighted. The inclusion of numbers 
as well as the word descriptors on the VAS led to patients indicating their response 
with a number on the horizontal line. Although a numerical value was useful for 
collating scores and calculation of mean values, the scale was not a true VAS as it did 
not capture patient perspective along a continuum. The inclusion of the numbers 
implied specific metric relations and therefore only pre -specified levels could be given 
by the respondent. This was a flaw in the design of the VAS and the numbers should 
have been omitted. One of the limitations of the scale included the `ceiling effect' with 
many patients scoring their satisfaction at the top end of the scale. Patient satisfaction 
scales designed in this way are difficult to interpret because responses are a complex 
sum of expectations that may vary among patients with comparable care. Many factors 
unrelated to the surgery may cloud the perception of patient satisfaction, for example 
unfavourable interpersonal relationships during the treatment period (patient- physician 
or nursing staff). Although an attempt to measure some different elements of patient 
satisfaction was undertaken in this study, these factors were not comprehensive and the 
scales were non -validated. Although some validated and reliable satisfaction 
instruments shave been developed in other fields such as primary care and palliative 
care, these have limited application to aesthetic surgery. Following review of the 
literature (Ching, Thoma et al. 2003), no appropriate tools to directly evaluate patient 
satisfaction in aesthetic surgery were found. Most studies rely on scales developed by 
the researchers themselves. Therefore, there is a need for development of an instrument 
to measure satisfaction with facial appearance and quality of life following aesthetic 
appearance. This is particularly important given that patient satisfaction is the main 
factor in aesthetic surgery that dictates success of the procedure. Technically perfect 
results may be considered a failure if the patient is not satisfied. 
When interpreting the results in this study, there are further elements of bias to 
consider. Firstly, there is a high likelihood of bias from patients reporting satisfaction to 
their surgeons. Indeed, some patients scored satisfaction highly despite development of 
complications or an imperfect aesthetic outcome. This may imply that they found other 
elements of the treatment process satisfactory or that they were motivated by potential 
secondary gain to receive further treatments. An additional factor to consider is that 
patient satisfaction scores were collected 2 to 6 months following treatment so may not 
represent the opinions of the patients who subsequently developed later problems with 
Bio- alcamid. The inclusion of a further patient satisfaction score at the end of the trial 
follow -up or after completion of re- treatments would have been beneficial. 
2.5. Conclusions 
This study demonstrates baseline demographic and clinical data in patients undergoing 
treatment for HIV facial lipoatrophy. High patient satisfaction was seen following 
treatment in each group although scores do not reflect long -term satisfaction. The study 
highlights the complications associated with the chosen treatments, particularly in the 
Bio- alcamid group, and this has led to withdrawal Bio- alcamid as a treatment option in 
the Edinburgh Unit. Further comparison of treatment groups with the addition of 
measured 3 -D and psychological outcome data are provided in the overall discussion 
and conclusions. 
Chapter 3. Three -dimensional facial volume 
analysis in HIV lipodystrophy 
3.1. Aims 
1. To evaluate facial volume change in patients undergoing treatment for HIV 
associated facial lipoatrophy. 
2. To validate the use of the DI3D system as a tool for measuring volumes of 
anatomical areas affected in patients with HIV lipodystrophy. 
3.2. Method 
3.2.1. Design 
A prospective, follow -up study was designed to assess volume change in surgically 
treated areas following 3 different interventions: autologous fat transfer, Newfill and 
Bio- alcamid. 
3.2.2. Sample 
A cohort of 48 patients with HIV facial lipoatrophy were recruited from Plastic Surgery 
clinics in Edinburgh and Glasgow. All patients underwent clinical assessment by 2 
doctors (a Consultant plastic surgeon and the lead researcher) to identify features of 
lipodystrophy and select choice of treatment. Patients with sufficient subcutaneous fat 
were offered treatment with autologous fat transfer. Those patients with insufficient fat 
due to generalized lipoatrophy were offered treatment with either Newfill or Bio- 
alcamid. 
A complete description of the recruitment process and details of surgical technique for 
each treatment is provided in Chapter 2. 
3.2.3. Outcome measures 
Measurement of facial volume was carried out using the Di3D system and software. 
Images were captured on all patients pre -operatively, within a 2 -week interval prior 
treatment. Repeat images were performed at 2, 6 and 12 months following completion 
of treatment. 
In addition, patients underwent clinical follow -up and assessment of psychological 
outcomes at similar time intervals. These outcomes are presented in the relevant 
chapters. 
3.3. DI3D Facial System 
3.3.1. Data Capture 
3.3.1.1. Calibration 
Calibration was carried out prior to each imaging session within an hour of the 
subject's appointment. This calibration was based on photogrammetric techniques and 
allowed the detailed geometric configuration of all the cameras to be determined. A 
calibration target was positioned 91 cm from the DI3D system and comprised a grid of 
accurately known dimensions containing10 x 10 black discs on a white background. 
The calibration target was captured by the cameras in three different positions and at 
two different angles. Images were captured with the calibration target in the Frankfurt 
plane then at an angle of +30 degrees to the Frankfurt plane and the calibration target 
positioned directly facing the base of the unit then repositioned in the horizontal plane 
to face the right and left pods respectively. DI3D then calibrated the system and 
reported a calibration error which was always below 0.4 mm. 
During the calibration process, which took around 5 minutes, images of the target from 
all the cameras were processed to find the central location of the discs and these 
coordinates were used to fit an approximate geometric model of each camera and its 
respective relative orientation to the target. 
3.3.1.2. Subject capture 
Prior to imaging, subjects completed a medical illustration consent form. 
Subjects were asked to remove spectacles and jewellery and to change into a blue 
theatre gown. Subjects with long hair were given a hair band so that all of the face to 
the hairline was visible. Once seated in a wheeled chair in front of a blue background, 
subjects were then positioned 91cm from the DI3D system using a tape measure. The 
measurement was taken from the lateral aspect of the right eye to the base of the 
system. Subjects were asked to look directly at a cross marked on the midpoint of the 
base and levers were used to move the base relative to the tripod stand such that crosses 
viewed through the camera lens were aligned with the subjects' pupil. Subjects were 
asked to adopt a neutral facial expression with lips placed together. 
Using the DI3D Capture application on the laptop computer, the four cameras capture 
the image simultaneously within seconds. An additional flash positioned behind the 
DI3D system and directed at the subject was used to illuminate the scene. 
In most instances, a minimum of two images were captured for each subject. 
3.3.1.3. Data processing 
Following each capture session the calibration file was attached and the photographs 
were processed to create the 3 -D image via the stages described in the above section 
using the DI3D Capture application. The 3 -D image was viewed using the DI3D View 
application which enabled the model to be rotated and magnified. Following selection, 
the data was exported to an OBJ file for analysis using the measurement software. 
3.3.2. DI3D View software 
The DI3D View software can be used to measure linear distances, angles, surface area 
and volume. The software tool for volume analysis was developed by engineers from 
Dimensional Imaging during the course of the study after collaboration with the lead 
researcher. A differential volume tool was developed to measure volume changes 
between pre- operative and post- operative images. 
3.3.2.1. Alignment 
The alignment of two or more 3 -D images requires selection of anatomical landmarks. 
A landmark is a point of correspondence on each object that matches within 
populations (Dryden and Mardia 1998). Many soft tissue anatomic landmarks have 
been defined on the face. The most frequently used definitions are those by Farkas 
(Farkas 1994). Twelve soft tissue landmarks were selected for this study from those 
landmarks considered to be the most reliable in previous studies (Aung, Ngim et al. 
1995; Hajeer MY 2002). Four midline landmarks and 8 bilateral landmarks were 
utilised. In addition, and distinguishing facial markings (such as scars, skin lesions etc) 
can be used as a landmark (Figure 3.1). 
Anatomic landmarks were located and marked on each image by the operator and the 
coordinates were stored. The pre- operative and post -operative images of each patient 
were aligned using a technique known as Procrustes analysis. Generalised Procrustes 
analysis is a mathematical method of manipulating configurations of landmarks so that 
they can be compared independently of size and position. The configurations are first 
scaled to a common size and then rotated and translated to achieve a best fit (Dryden 
and Mardia 1998). 
Following the alignment of images based on landmark localisation, the DI3D software 
permits the operator to further manipulate the images using translation and rotation in 
the x, y and z axes to achieve optimum alignment of the model. 
Figure 3.1. Landmarks for image alignment 
3.3.2.2. Volume measurements 
Volumetric analysis of pre -operative and post -operative images were performed on the 
aligned model a three- dimensional back the of 
analysis (Figure 3.2) The size and orientation of the plane can be manipulated in the x, 
y and z axis around the defined facial area. The cheeks and temples of surgically 
treated patients were selected for analysis. The volume tool then calculates the volume 
enclosed from the back plane to the facial surface. The volume can be calculated 
independently for the pre -operative image and the post -operative image using the same 
plane. The differential volume can also be calculated automatically using a separate 
tool. Thus for each set of pre -operative and post- operative images, 3 volume 
measurements were recorded for each facial area defined by the back plane: the pre- 
operative volume, the post -operative volume and the differential volume. 
Figure 3.2. 3-D backplane 
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3.4. Statistical Analysis 
Facial volumes (as differences, compared to the pre -treatment baseline 3D volume 
measurement), and volumes injected were summarised by treatment at baseline, and at 
2, 6 and 12 months post -treatment. No baseline measurement of volume injected was 
available for the NewFill group. Differences between volume measurements at each 
follow -up visit were summarised by treatment, and within- treatment changes were 
tested using one -sample t- tests. Differences between groups were analysed using 
ANOVA. 
Pearson correlation coefficients were used to test for an association between the 
number of treatments received and facial volumes (compared to baseline) at 2, 6 and 12 
months for patients treated with NewFill. 
In addition, all data was analyzed using equivalent non -parametric tests but no 
differences in results were demonstrated. Thus, data is presented utilizing parametric 
testing as described. 
3.5. Validation of the DI3D system 
The aim of validation was to assess the accuracy and reproducibility of the DI3D 
system to evaluate facial volume changes. Accuracy was defined as the ability of the 
system to measure a given volume as close to the actual volume. Reproducibility was 
defined as the measure of variability between repeated trials of the imaging and 
measuring procedure under the same conditions. Three types of error were evaluated 
during validation of the DI3D system and software: operator error, reproducibility error 
and the DI3D system error. Three experiments were conducted. 
3.5.1. Experiment 1: Measurement Bias 
3.5.1.1. Aim 
The aim of this experiment was to assess the accuracy of measurements of changes in 
facial volume in different regions of the face against known changes in volume. 
3.5.1.2. Method 
The accuracy of the DI3D system to measure facial volume changes was assessed using 
facial casts to eliminate sources of error from facial expression and then on human 
subjects. Each measurement was taken twice, to assess repeatability, and four faces 
were involved to assess variability between faces. 
Process for facial cast and mould preparation 
Facial casts of one male and one female subject were created by a prosthetist using 
plaster. A plaster base was attached to the facial cast to allow the cast to sit upright on a 
solid surface. Twelve facial landmarks were placed on each mould using a black biro 
pen. 
Ten flexible silicone moulds of different areas of the face were prepared from the 
female facial cast. Different sizes and shapes were created to represent the surgically 
treated areas in patients with HIV -associated lipoatrophy. Additionally, moulds of the 
forehead, nose and chin were produced to assess other areas of the face. 
The moulds were created for the following regions of each face: 
1. nose; 
2. nasolabial region 
3. cheek; 
4. temple; 
5. cheek & temple; 
6. forehead (small mould); 
7. forehead (large mould); 
8. malar region; 
9. zygoma. 
10. chin 
The volume of each mould was measured by water displacement based on Archimedes' 
principle. Each mould was immersed in a water container at room temperature placed 
on a digital four -figure balance (model) then the weight of displaced water was 
recorded. Each mould was measured twice and the average weight was calculated. 
The 
volume was then calculated using the formula, volume (m3) = mass (kg) / density, 
assuming a water density of 998.2 kg /m3 at room temperature of 20 degrees celsius. 
Image capture 
Each facial cast was positioned on a table and captured with the DI3D system using the 
method described. An additional image was captured after the placement of each mould 
on the cast using adhesive glue. (Figure 3.3) 
The process was repeated using the same male and female subjects from whom the 
facial casts were modelled. Twelve facial landmarks were placed on each subject using 
a sharp black eyeliner pencil. The face of each subject was then captured with the DI3D 
system using the method described. A further image was captured after the placement 
of each silicone mould and a 3D model was created. 
The following procedure was used to calculate the volume of each mould from the 3 -D 
images of both facial casts and human subjects using the DI3D volume software. 
Figure 3.3. Facial cast with and without placement of malar silicone mould 
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Image alignment 
The 3 -D models without silicone moulds were aligned to each of the 3 -D models with 
silicone moulds using landmarked -based registration (also demonstrated in Figure 3.3). 
The accuracy and reproducibility of landmark localization using the DI3D system was 
previously assessed by comparing measurements on a plaster cast taken using a 
coordinate measuring machine (gold standard). (Khambay, Nairn et al. 2008) The 
DI3D system error was found to be within 0.2mm, which the authors concluded to be 
clinically acceptable. Magnification and rotation of images was performed by the 
operator to achieve accurate placement of 3 -D landmarks corresponding to the 12 
landmarks marked on each cast and human subject prior to image capture. The x, y and 
z co- ordinates of each 3 -D landmark were stored and the software then translated and 
rotated the two models over each other to achieve the best fit (Figure 3.4). Further 
manipulation of images was then performed to achieve optimum image alignment. 
Figure 3.4. Image Alignment 
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3 -D Volume Measurement 
The volume of each mould on the aligned image was measured using the back -plane 
technique previously described. The software utilizes a 3 -D box as the plane which was 
adjusted by the operator in the x, y and z dimensions to fit closely around the mould 
and minimize other areas of the face to be included in the volume calculation. Using 
the volume tool, the differential volume between the model without any moulds and 
each of the 10 models with a mould was measured. Volume measurements for each 
mould were carried out on the male and female cast and the male and female human 
subjects. Each volume calculation was repeated twice and the mean differential volume 
was recorded. 
The accuracy of the system was determined by calculating the difference between 
volumes measured by DI3D and the actual volume of each mould measured by water 
displacement. 
The DI3D system reproducibility and operator error were determined by measuring the 
variability between repeated trials of image acquisition, image alignment and volume 
calculation. 
3.5.2. Experiment 2: Re- Alignment and Re- Measurement 
3.5.2.1. Aims 
To assess the reproducibility of image acquisition and alignment and to assess the 
variability of volume measurements between and within alignments. 
3.5.2.2. Method 
Image acquisition 
To assess the reproducibility of image acquisition with the DI3D system, a mould of 
the malar region was placed on the female cast and was imaged 10 times within the 
same capture session. Each image was aligned to the model of the female cast without 
moulds and the volume of the malar mould was calculated. 
Image alignment 
To assess the reproducibility of image alignment, the same image of the female cast 
with the malar mould was realigned 10 times to the image of the female cast without 
moulds and the volume of mould was measured. 
Volume measurement 
To assess the reproducibility of the volume measurement tool, the model of the female 
cast with the malar mould was aligned to the female cast without moulds and a series of 
ten volume measurements was made using the differential volume tool, but without 
realignment of the image. 
3.5.3. Experiment 3: -Retest Reliability 
3.5.3.1. Aim 
The aim was to assess the repeatability of the measurement process over a short time 
period. 
3.5.3.2. Method 
To assess variation in facial volume in the same human subject between different 
capture sessions, two 3 -D images of 10 human subjects (5 male and 5 female) were 
captured one week apart using the same method. Twelve landmarks were placed on the 
face using a sharp black eyeliner pencil prior to each imaging session, and the 
landmarks were used to align the week one and week two images of each subject. The 
differential volume of three areas of the face between week 1 and week 2 was then 
measured. The areas measured were the forehead, right cheek and nose and the 3 -D box 
back -plane was manipulated to enclose these areas as accurately as possible. 
3.5.4. Statistical Analysis 
3.5.4.1. Experiment 1 
For each measurement, the bias was defined as the difference between the measured 
volume change after adding the mould, and the known volume of the mould. The two 
measurements on each face made up a set of eight measurements of the volume of each 
of the nine moulds (results from only nine of the original 10 moulds were included). A 
maximum likelihood variance components model was used to estimate the components 
of variance due to differences between faces, moulds, time, the second -order 
interaction terms and residual variation. Note that variation due to moulds represents 
true variation; all other sources of variation are due to measurement error. The ratio of 
the variation due to moulds to the sum of all sources of variation therefore represents 
the reliability of the different measurements of the volume of each mould. The same 
method was applied to the eight measurement biases for the nine moulds. 
Figures were produced to investigate factors possibly associated with both the 
magnitude and variability of measurement bias, namely the true volume of the mould 
and the face used. These possible associations were then tested using linear regression 
and ANOVA methods. 
3.5.4.2. Experiment 2 
The two sets of measurements were standardised by subtracting the mean, and 
displayed using a dot plot. The variances of the two set of measurements were 
compared using an F test for equality of variance. 
3.5.4.3. Experiment 3 
Maximum likelihood variance components models were used to estimate the 
components of variance between and within subjects, separately for measurements of 
the forehead, cheek and nose, from which the test -retest reliabilities were 
estimated as 
the ratio of the between -subject variance to the total variance. A Bland- Altman graph 
was produced showing the difference between measurements plotted against the 
average of the two measurements, to assess whether the between measurement 
variation was associated with region or volume. Analysis of variance was used to 
assess whether there were any systematic difference between regions in the average 
differences between measurements. 
3.5.5. Results 
3.5.5.1. Experiment 1 
Figure 3.5 shows the bias for all measurements, first against the true mould volume and 
secondly split by the four faces. 
Variance components models applied to the eight measurements of volume for each 
mould gave an estimated reliability of 97.4 %, whereas the biases gave a reliability 
estimate of 0.0 %. This indicates that the eight different measurements of mould 
volumes were consistent, whereas the measurement biases were essentially random. 
Regression analysis showed the average bias to be -0.30 cc (p= 0.0016), but with no 
evidence of an association with true volume (p= 0.12). There were significant 
differences between faces in mean measurement bias (p <0.0001), due to an average 
underestimation of the true volume for the male face (p <0.0001). 
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3.5.5.2. Experiment 2 
Figure 3.6 shows the variation in measurements about the mean measurement for each 
individual, re- measured either with or without realignment of the image before each 
measurement. Assuming that measurements made with realignment contain error due to 
the realignment as well as due to re- measurement, we would expect the variation with 
realignment to be greater than the variation without realignment. This appears to be the 
case, though a single measurement made with realignment appears to have much 
greater error than all other measurements in this experiment. 
Table 3.1 shows the estimated variances from the two sets of measurements, their ratio 
with a 95% CI and a p -value from an F -test of equality of variances. This information is 
provided for all data and after the exclusion of the outlying measurement amongst the 
realigned measurements. Based on the full dataset there is evidence that the variance of 
the realigned measurements is greater than those made without realignment by a factor 
of approximately 5 (p= 0.028). This finding is, however, sensitive to the inclusion of a 
single observation; after exclusion of this one measurement, the ratio of the two 

































Table 3.1: Estimated variances of measurements made with or without realignment of 
images, their ratio, with 95% CI, and p -value from F -test of equality of variances 
3.5.5.3. Experiment 3 
Figure 3.7 shows the Bland -Altman plot of the differences between the first and second 
measurements made on the forehead, cheek and nose of each individual, versus the 
mean of the two measurements. There is no clear evidence that the variability of 
measurements is associated with the true volume. One -way analysis of variance 
revealed no association between the differences between measurements and facial 
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Figure 3.7. Bland -Altman plot for repeated measurements of forehead, cheek and nose of ten 
individuals, taken one week apart. 
Applying variance components models to measure the test -retest reliability of the 
measurement method found the reliability for measurements of the forehead to be 
99.9 %, for the cheek to be 98.3% and for the nose, 97.7 %. 
3.5.6. Discussion and Conclusions 
3.5.6.1. Experiment 1 
Experiment 1 showed the measurement method to be generally consistent and accurate, 
with the exception of measurements made of the male face, which showed a slight 
underestimation of true volumes. The most likely explanation for this is that the 
silicone moulds created from the female face, although flexible, did not adhere to the 
exact contour of the male face despite adhesive glue. Importantly, the variability in 
measurement did not appear to be associated with true volume, indicating the technique 
to be consistent, or equally accurate at measuring large as small changes in facial 
volume. Attempts to measure 3 -D volume change in the region of the chin following 
application of the chin mould were unsuccessful and therefore the chin mould was 
excluded from the experiment. This was due to distortion of the 3 -D image on the 
inferior aspect of the chin extending to the submental area, particularly in the midline 
where the images merge. Therefore, volume measurements from the periphery of the 3- 
D image e.g. chin, ears may prove problematic and inaccurate for this reason and 
repeated attempts to capture the subject from different angles may be required to 
capture the area of interest without distortion. 
3.5.6.2. Experiment 2 
Experiment 2 showed a greater variability in measurements made with realignment of 
images than without, though this finding is called into question when reanalysed with 
the exclusion of one outlying observation within the realigned measurements. 
Therefore no conclusive inferences can be drawn. 
3.5.6.3. Experiment 3 
Experiment 3 demonstrated measurements taken one week apart to be highly reliable, 
supporting the general conclusion that the method provides consistently accurate 
measurements of facial volume, which does not appear to vary by facial region or the 
overall volume of the facial feature being assessed. 
3.6. Results 
3.6.1. Data completion 
Table 3.2 summarizes the numbers of patients with data collected during the follow -up 
period of the study. Patient recruitment was greatest to the Newfill group. However, 
this group also comprised the largest number of drop -outs. 




3 -D Volume Data 





16 15 8 7 
(43 %) 
20 14 7 5 
(25 %) 
12 7 7 5 
(42 %) 
A missing -value analysis comparing baseline volume measurements between those 
patients with complete data and those patients with incomplete data demonstrated no 
significant differences between the two groups. (Table 3.3) 
Table 3.3. Injected Volumes (Bio- Alcamid and AFT groups only), comparing those 
with or without follow -up volume measurements. Summaries shown are number of 
observations (number of missing values), mean (SD); p- values from two -sample t -tests 
Baseline 
Measurement 
Follow- Follow -up Volume 
up Measurement p -value 


































Table 3.4 shows the number of patients who underwent revision procedures or re- 
treatments during the trial follow -up interval. 











Six patients in the Bio- alcamid group had a minor revision procedure (removal or re- 
injection of 1 cc or less per cheek). In this group, 2 patients underwent a minor revision 
12 months following the original treatment. Therefore follow -up data was completed 
according to the trial protocol prior to revision. One patient who underwent a minor 
revision 2 months following treatment moved away and was lost to further follow -up. 
In the remaining 3 patients, minor revision procedures were performed 6 months 
following initial treatment. Given the difficulty in accurately measuring small volumes 
of Bio- alcamid removed intra- operatively, the residual injected volume of Bio- alcamid 
was uncertain. Therefore, 12 month 3 -D images were not completed in these patients. 
Only psychological data was completed at the defined follow -up intervals. 
Three patients in the Bio- alcamid group underwent major revisions with volumes 
injected ranging between 5 -14cc per cheek. In these patients, the total injected volumes 
were re- calculated and further follow -up 3 -D volume measurements were compared 
with the revised volumes. Follow -up psychological data was recommenced at intervals 
of 2, 6 and 12 months. 
One patient in the fat transfer group with severe lipoatrophy underwent re- treatment 
during the trial follow -up period. A total of 32cc of fat was injected thus the follow -up 
data was completed as for a major Bio- alcamid revision: further 3 -D volume 
measurements were compared with the revised injected volumes and psychological 
data was completed the defined follow -up intervals. 
Two patients in the fat transfer group completed 12 months follow -up but re- entered 
the trial for Newfill therapy. In these 2 patients, baseline 3 -D and psychological data 
was recorded prior to re -entry in the Newfill group and a second follow -up period 
was 
completed. 
3.6.2. 3 -D volume measurement 
i 
The change in facial volume compared to baseline for each treatment group is 
summarised in Table 3.5 and Figure 3.8. 
Additional statistical analysis of the dataset was conducted to investigate the effect of 
the high drop out rate and resultant small sample size at follow -up. Linear mixed 
effects regression (i.e. repeated measures ANOVA) was used to model all volume 
measurements over time. The model included random intercepts for each patient, fixed 
categorical effects of treatment and visit, and a general covariance structure. To 
estimate mean values by treatment and visit, a treatment -by -visit interaction was 
included. To assess the evidence for between -group differences in mean volumes, or 
mean changes in volume, at each visit, Wald tests were applied. 
The results showed little difference when compared with the raw dataset and therefore 
only the raw data is presented for simplicity. A summary of the additional tests 
described are provided in Appendix 3 for reference only. 
Table 3.5. Mean, SD and number of observations of volume injected or volume relative 
to baselineby visit and treatment type. Mean, SD and number of observations of 
changes over baseline, with paired t -test p- values for test of zero change. 
Bio- Alcamid Fat NewFill 
Raw Data Change over p -value 
baseline for change 
Raw Data 
Change over p -value 
baseline for change 
Raw Data 








25.5 (13.4), N=18 
28.3 (13.9), N=15 
26.7 (15.5), N=8 
27.7 (13.4), N=7 
1.1(6.7), N=15 
0.7 (3.1), N=8 




20.1 (9.3), N=10 
17.1 (7.8), N=7 
11.2 (5.2), N=7 
10.0 (7.9), N=5 
-4.9 (5.9), N=6 
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8.7 (7.2), N=14 
12.6 (10.7), N=7 
12.3 (13.5), N=5 
- (-), N=0 
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Month Month Month 
6 12 2 6 12 2 6 12 
Bio-Alcamid Fat NewFill 
The greatest mean injected volume was seen with Bio- alcamid (25.5cc). A paired t -test 
demonstrated no significant difference in mean volume change relative to zero except 
at 12 months. 
The mean injected volume of autologous fat was 20.1cc. Although no difference in 
mean volume change relative to baseline was demonstrated at 2 months, a reduction in 
mean volume to 11.2cc at 6 months (p= 0.03) and 10cc at 12 months following 
treatment was seen (p= 0.1). This represents 66% of injected volume relative to 
baseline remaining at 6 months and 54% at 12 months (Figure 3.9). 
Figure 3.9. Percentage of injected volume remaining at follow -up 
Month 
2 6 12 
Month 
2 6 12 
Bio -Alcamid Fat 
Bio- alcamid Fat 
2 Month 
Mean (SD) 107.3 (21.8 75.4 (31.1) 
Median (IQR) 104.5 (100.2, 75.3 (64.7, 95.0) 
[MIN, MAX] 112.7) [25.5, 113.5] 
[56.4, 157.4] 
6 Month 
Mean (SD) 106.7 (21.2) 66.4 (34.9) 
Median (IQR) 99.1 (92.1, 109.8) 54.1 (48.3, 90.9) 
[MIN, MAX] [90.9, 151.7] [15.3, 116.7] 
12 Month 
Mean (SD) 117.0 (19.3) 56.2 (57.3) 
Median (IQR) 109.6 (106.9, 49.8 (40.7, 106.7) 
[MIN, MAX] 120.1) [ -28.4, 112.1] 
[99.0, 156.5] 
The mean measured 3 -D volume change for Newfill was 8.6cc at 2 months, 12.5cc at 6 
months and 12.2cc at 12 months. The t test (scores at baseline are all equal to 0) 
comparing all follow -up intervals compared to baseline shows that after treatment the 
mean cheek volumes were all significantly different from O. 
Statistical analysis comparing the 3 treatment groups showed a significant difference in 
mean volume at all time intervals. 
No correlation between number of treatment sessions and volume change over time 
was demonstrated (Table 3.6) 
Table 3.6. Correlations between number of treatments and volume changes over time 
for NewFill patients. 
Visit 
Pearson 
Corr' p -value 
Month 2 0.263 p =0.363 
Month 6 0.115 p =0.806 
Month 12 0.059 p =0.924 
3.7. Discussion 
3.7.1. Data completion 
Forty-eight patients received treatment for facial lipoatrophy but only 17 patients (35 %) 
had complete l2 month 3 -D volume data. The number of drop -outs was greatest in the 
Newfill group with only 25% of patients completing follow -up. The fat group 
comprised the smallest number of recruited patients and complete follow -up data was 
also poor (42 %). Complete data in the Bio- alcamid group was 43 %. The large number 
of drop -outs in this study was thus very disappointing but highlights the difficulties of 
clinically -based research which relies on patient motivation. From the outset of the 
study, it was evident that comparison between groups with respect to treatment 
outcomes would be subject to bias due to the non -randomised design of the study and 
the small numbers in each group. Thus the study design was primarily observational. 
However, the declining number of patients at follow -up further confounded the 
difficulties of interpreting results and drawing conclusions within and between groups. 
An attempt to investigate and potentially compensate for drop -outs using regression 
methods was conducted at the outset of data analysis. There were few differences in 
results when compared to the raw data and therefore the more complex statistical 
analysis was not felt to provide a beneficial contribution to the results. Only the raw 
data was used for interpretation of results to provide greater clarity and to avoid 
unnecessary distortions in the data. Statistical analysis of results was performed using 
parametric tests. As an additional measure, equivalent non- paramentric tests were 
applied to all results to investigate any potential differences from assuming a normal 
distribution. Comparison of results using parametric and non -parametric test 
demonstrated no difference. Therefore, only the parametric results were presented in 
this study on the basis that parametric tests are, in general, more powerful and should 
be used if at all possible. 
There are various factors that may account for the high drop -out rate for 3 -D imaging. 
Firstly, patient motivation to complete follow -up after treatment declined, particularly 
by 12 months. Secondly, some patients experienced commuting difficulties as the 3 -D 
system was based in Livingston, approximately 20 miles from where most patients 
lived in Edinburgh. Several patients were reluctant to take time off work, which was 
mainly related to commuting time. This was an even greater obstacle for patients 
recruited from Glasgow (approximately 30 miles from Livingston). In an attempt to 
overcome this practical issue, the DI3D system was transported to an HIV clinic in 
Glasgow on several occasions but unfortunately many patients still failed to attend 
when invited for follow -up. A large proportion of the Newfill group were recruited 
from Glasgow and this accounts for the particularly poor drop -out rate in this group. 
Thirdly, technical issues with the 3 -D system also contributed to incomplete data 
capture. No images could be obtained during one of the capture sessions due to a faulty 
camera. Several patients who had attended for clinical follow -up on that occasion did 
not attend the re- arranged session and were thus lost to follow -up. 
The problem of analysis and interpretation of results therefore requires some reflection. 
Would the results have been different if the data was more complete? Statistical 
analysis of baseline volume and psychological measurements, comparing those patients 
with and without follow -up data, demonstrated no significant difference. However, it is 
likely that those patients who did attend for review had motivation to do so, thus 
biasing the results. In many cases, patients attended for review to discuss a 
complication or concern over the aesthetic result following treatment. Conversely, it is 
likely that those patients who did not attend for review were satisfied with the outcome 
of treatment. Indeed, this appears to be the case for many of the drop -outs in the 
Newfill Glasgow group following communication with the health professionals 
involved in their ongoing HIV management. Frustratingly, the quantification of 
possible facial volume maintenance and improved psychological outcome is lacking in 
the results. It is possible that a greater mean volume of fat remaining at 6 and 12 
months would have been demonstrated in the complete data set. Also, reliability of 
the 12 -month volume data for Newfill therapy would have been more robust. This 
would have been especially useful to demonstrate the delayed volume augmentation 
mechanism of action and duration of effect. 
A further difficulty with the analysis and interpretation of results was the problem of 
revision procedures during the follow -up period, particularly in the Bio- alcamid group. 
Revisions in the Bio- alcamid group were subdivided into minor (lee or less removed or 
re- injected per cheek) or major if larger volumes were re- injected. Although this 
alteration to the original method is not ideal, the total volume injected could 
be 
recalculated for the 3 patients who had a major revision and subsequent volume 
measurements were compared with the revised volumes. The main difficulty arose 
with analysis of follow -up 3 -D data in the minor revision group. Unfortunately, the 
volume of product removed is difficult to measure intraoperatively. Therefore, 
subsequent 3 -D measured volumes could not be compared with an unknown remaining 
injected volume. The dilemma of how to proceed with 3 -D data follow -up was 
applicable to 3 patients in this group. It was decided that subsequent 3 -D measurements 
would be unreliable and therefore inconclusive. This led to incomplete 12 month data 
in these patients and difficulty with subsequent statistical analysis and interpretation. 
For example, the raw data shows similar mean volume measurements at all follow -up 
intervals compared to injected volumes. However, the t -test for change showed 
significance at 12 months which is mostly likely due to the smaller sample size and 
revision procedures performed. All of these patients completed the psychological data 
at the defined trial follow -up intervals and the interpretation of these outcomes is 
discussed in chapter. Although two patients in the fat group switched to the Newfill 
group, 12 month follow -up data was completed prior to the change. 
3.7.2. 3 -D Facial volume results 
For patients with severe facial lipoatrophy, Bio- alcamid® has been advocated as an 
effective treatment option. In this study, patients in the Bio- alcamid group had the most 
severe clinical grade of lipoatrophy and required the greatest injection volumes to 
achieve correction. Therefore, one advantage of Bio- alcamid in reconstructive surgery 
is that it can be injected in large quantities to achieve an immediate correction. The 
product is also considered to be a permanent filler due to the stability of its chemical 
properties and resistance to hydrolysis (Ramires, Miccoli et al. 2005). Indeed, the 
results of this study, utilising 3 -D imaging as a sensitive measure of facial soft tissue 
volume change, demonstrated no significant difference in measured volume post- 
operatively compared to injected volumes. The distribution of volume change in the 
treated areas was not analysed in this study but would be an extremely useful 
investigation of product migration in future. 
The use of autologous fat transfer has also been described in the treatment of HIV - 
lipodsytrophy but the outcome of the procedure is often based on subjective measures 
such as clinical assessment or photographs. One recent study has utilised ultrasound to 
measure dermal and subcutaneous thickness following treatment with fat transfer 
(Guaraldi, Orlando et al. 2005). However, measurements were obtained from only one 
area within the cheek and are operator- dependant. This study provides new, objective 
data on 3 -D measurements of transferred fat in patients with HIV lipodystrophy. The 
results showed no difference in mean volume of transferred fat compared to baseline at 
2 months. Despite a reduction in mean measured 3 -D volume of 7.3cc at 6 months and 
9cc at 12 months, a significant difference compared to baseline was shown at 6 months 
only. Percentage of volume remaining at follow -up compared to injected volume was 
66% at 6 months and 56% at 12 months. The pattern of volume change observed was 
highly variable between patients: some patients retained the injected volume 
throughout follow -up; some patients demonstrated minimal or no change in volume; 
and some patients had a gradual reduction in volume post -operatively. It is possible that 
the variability in results reflects the underlying lipodystrophic process. Indeed, one 
patient who underwent a combined procedure of autologous fat transfer and liposuction 
to the DCFP developed DCFP recurrence coinciding with complete resorption of the 
transferred fat. This suggests that lipodystrophy may be contributing to the success of 
transferred fat in this group of patients. Thus, patients with HIV lipodystrophy should 
be advised about the unpredictable outcome of this procedure. Also, the results of fat 
transfer in this study are very specific to HIV lipodystrophy patients and cannot be 
applied to fat transfer in non -HIV patients. There were no reported changes in HAART 
therapy, haematological parameters, or weight during follow -up although one limitation 
of the study is that these variables were not formally measured. Another important 
factor to consider when analysing the results of fat transfer is that 3 -D measurements 
only represent a change in volume. The composition of the volume change is unknown. 
Therefore, the remaining volume change could either represent survival of the 
transferred fat or simply fibrosis. There is emerging evidence for the role of stem cells 
in transferred fat and this is an interesting area for further investigation. 
Newfill therapy is well -established treatment for HIV -associated facial lipoatrophy and 
previous studies have demonstrated increased ultrasound measurements of dermal 
thickness and improved quality of life up to 96 weeks. However, this study provides 
new information on 3 -D soft tissue volume changes following Newfill therapy. The 
results show a mean change in volume of 8.7cc at 2 months, which increased to 12.6cc 
at 6 months and was maintained at 12 months (12.3cc). Only one paper has been 
published since commencement of the trial which provides 3 -D volume data on Newfill 
therapy for HIV lipodystrophy. In this study, 100 patients with HIV lipodystrophy were 
treated with a mean of 4.85 treatment sessions per patient and follow -up extended to 24 
months (Ong, Clarke et at 2009). The mean volume change was significantly different 
to baseline at all time points and the mean difference per cheek was 2.81cc. The mean 
volume changes in Ong's study were less than the results seen in this trial. However, 
there were some differences in method which could explain these findings. Patients 
were restricted to 4 or 5 treatment sessions on Ong's study, and injections were carried 
out to the cheeks only. In this study, treatment sessions with Newfill were carried out 
until both the patient and practitioner were satisfied that restoration of facial volume 
had been achieved and a wider area extending to the temples was treated. Thus, the 
majority of patients received 7 or more treatment sessions. It is interesting to evaluate 
the relationship between volume augmentation and number of treatment sessions. This 
study demonstrated no correlation between volume change over time and number of 
treatment sessions. However, limitations include small sample size and lack of 
complete follow -up data. Therefore, it is difficult to draw conclusions. From the 
volume data available and clinical impression of patients and practitioners, Newfill 
appears to be an effective treatment for patients with mild to moderate facial 
lipoatrophy but may not provide sufficient volume augmentation for patients with 
severe lipoatrophy. This is related to the mechanism of action of Newfill which 
stimulates neocollagenesis within the dermis. Patients in this study also had a 
variability in mean volume change achieved, unrelated to number of treatment sessions. 
This raises some questions regarding the maximum volume change that can be 
achieved with Newfill and whether this is related to number of treatment sessions or 
individual response to neocollagenesis. This would be a very useful area of further 
investigation and would be helpful in decision -making about choice of treatment in 
patients with severe lipodystrophy. 
3.8. Conclusions 
Based on literature review, this study remains the first to provide objective, 3 -D facial 
volume measurements following 3 different treatments for HIV facial lipoatrophy. 
Comparison between treatment groups, in conjunction with additional outcome 
measures are presented in the overall discussion and conclusions of this thesis. 
In addition, experiments to validate the DI3D system and software have demonstrated 
the accuracy and reproducibility of the system to measure 3 -D facial volume. 
Chapter 4. Evaluation of psychological morbidity 
in HIV lipodystrophy 
4.1. Aims 
1. To evaluate change change in body image assessment, anxiety and depression 
following treatment for HIV -associated facial lipoatrophy. 
2. To compare psychological characteristics between HIV seropositive patients 
with and without lipodystrophy and HIV seronegative men who have sex with men 
(MSM). 
3. To investigate the correlation between psychological distress, clinical grade of 




A prospective, follow -up study was designed to assess change in psychological 
morbidity in a cohort of patients undergoing 3 different treatments for HIV 
lipodystrophy (autologous fat, Newfill and Bio- alcamid). In addition, a case -control 
study with two control groups was designed to investigate variables that may influence 
psychological distress in patients with HIV -associated lipodystrophy. (Figure 4.1) 
Figure 4.1. Flow diagram of Study Design 
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4.2.2. Control groups 
4.2.2.1. Selection of groups 
When considering psychological distress in the cohort group, and particularly the 
impact of a surgical intervention, it is important to identify potential confounding 
variables. To avoid systematic bias in the case control study, the aim should be for the 
groups being compared to be as like one another as possible except for the particular 
difference being examined. Psychological distress associated with development of HIV 
lipodystrophy is the condition under investigation in this study. However, the impact of 
living with HIV infection was considered an important factor contributing to 
psychological wellbeing. A control group comprising HIV patients without 
lipodystrophy was therefore selected to investigate the effect of lipodystrophy alone. In 
order to evaluate the effect of HIV infection to positively or negatively influence body 
image perception, an additional control group of non -HIV patients was required. 
It is also important to consider the influence of factors such as age, sex, and ethnic 
origin on body image assessment. Demographic data was collected on the local 
population of patients with HIV lipodystrophy treated within the Edinburgh Unit from 
March 2003 to March 2006. Thirty -two patients treated were identified using the 
hospital coding system. Thirty patients were male and 2 patients were female with a 
mean age of 46 years. Only one patient was not of Caucasian origin and although not 
all patients volunteered their sexual orientation, it was estimated that approximately 80- 
90% of patients were MSM (men who have sex with men). Consideration was given to 
selection of a control group of healthy volunteers. However, following reflection on the 
demographics of the local treatment population, it seemed appropriate to select a 
control group more closely matched to the likely treatment group with regards to sex, 
age, and sexual orientation. Thus, in anticipation of a similar pattern of referrals to the 
trial, a second control group of men who have sex with men (MSM) was selected to 
evaluate psychological morbidity in this subgroup of the male population. 
4.2.3. Psychological measures 
4.2.3.1. Selection of tools for the study 
The choice of measurement tools selected for the study was based on review of the 
literature and consultation with professionals in psychiatry and psychology. 
Assessment of outcomes in aesthetic surgery is extremely important, as patient 
satisfaction is the predominant factor in determining success. Although various scales 
have been used to assess outcomes, none has achieved widespread use (Ching, Thoma 
et al. 2003). To date, assessment of outcome from aesthetic surgery has involved 
subjective assessment by the patient and surgeon, quality of life outcomes and 
psychological assessments of psychiatric disorders, self -esteem and body image. In one 
review of 43 papers, an attempt was made to identify appropriate instruments to assess 
outcome in aesthetic surgery (Ching, Thoma et al. 2003). The authors discovered that 
assessment tools fell into four categories: satisfaction, objective, psychological and 
quality of life assessments. Each of the instruments was reviewed to evaluate 
practicality, validity, reliability and sensitivity to change. The authors concluded that 
quality -of -life and body -image measures are of greatest value in determining aesthetic 
surgery outcomes. The Derriford Appearance scale was identified as an ideal scale for 
use in aesthetic surgery. 
The DAS 24 was selected as an outcome measure for the study as it was designed 
specifically to measure psychological distress and dysfunction characteristic of 
disfigurements, distress and aesthetic problems of appearance. It is highly sensitive as a 
measure of change following treatment and for evaluating the merits of one treatment 
protocol against another (Harris and Carr 2001). It is psychometrically robust and 
discriminates well between patient groups, between clinical and non -clinical 
populations, and within the general population, between those concerned and not 
concerned about their appearance (Carr, Moss et al. 2005). 
4.2.3.2. Derriford Appearance Scale 
The Derriford Appearance Scale (Appendix 4) is a condition -specific quality -of -life 
measure developed for assessing concern about physical appearance. It seeks to 
measure adjustment to problems of appearance, which the authors define as negative 
emotions of fear, social anxiety, shame, and negative affect along with a behavioral 
response of avoidance and withdrawal that frequently disrupts lifestyle. Initially 
designed as an experimental scale (DAS 136) composed of 136 items, this was refined 
to two user -friendly versions: the DAS 59 composed of 59 items (Harris and Carr 
2001) and the DAS 24 with 24 items. (Carr, Moss et al. 2005) In designing the DAS 
24, 
items were selected from the DAS 136 to include as broad a range of behavioural and 
emotional responses to being visibly different as possible. 
The first page of the DAS 24 collects demographic information and identifies the body 
part(s) about which the respondent may be self -conscious. Then in a series of 24 items, 
respondents are asked to choose from a range of responses. Response categories of 
`extremely' to `not at all' are used when items relate to an emotional response (e.g. 
`How distressed do you get when you see yourself in the mirror'). An `almost always' 
to `never /almost never' response category is used for items relating to particular 
behaviours (e.g. `I avoid going out of the house'). For items that include a not 
applicable (N /A) option, N/A always scores zero. The remaining response categories 
score one to four and the response category indicating more distress scores the highest. 
Items one to twenty four inclusive are summed to provide the total score. The minimum 
score is 11 and the maximum is 96. There is no threshold score to indicate `caseness' as 
the authors of the scale believe that adjustment to appearance concerns is a continuum. 
The DAS 24 has been administered to clinical and non -clinical populations.(Harris and 
Can 2001) Data was collected from 535 participants in a multi -centre trial. Around half 
were recruited from plastic surgery clinics and the remainder from waiting lists. The 
DAS 24 was sent by post to a non -clinical population and 1170 responses were 
received. The results were compiled to provide norm tables. To evaluate validity of the 
DAS 24, five additional scales to measure psychological outcome were completed by 
participants. The internal consistency of the scale was high (Cronbach alpha = 0.92). 
The reliability of the scale, indicated by test -retest correlation, was good (r= 0.82 -0.88). 
Concurrent validity, measured by comparison with a range of established scales, 
revealed a good relationship with the DAS 59 (Pearson correlation 0.88) and moderate 
positive correlation with subscales of the Crown Crisp Experimental Inventory 
(Pearson correlation 0.5 - 0.66). 
To date, there are no published studies to evaluate the DAS -24 in a cohort of patients 
with HIV lipodystrophy. 
Research indicates that individuals with disfigured appearance are prone to depression, 
anxiety, shame and interpersonal difficulties. Newell and Marks suggested that the 
difficulties experienced by those with facial disfigurements might be due to phobic 
anxiety specific to social situations. Indeed, research has shown that people with facial 
disfigurements exhibit similar anxiety and depression scores to individuals with 
agoraphobia and social phobia (Tebble, Thomas et al. 2004). Thus a `fear avoidance' 
model has been proposed and suggests that the fear of response of others perpetuates 
social anxiety and the subsequent avoidance of social interactions. In a study by Sen et 
al, symptoms of anxiety or depression were reported in over 30% of patients with 
severe maxillo- facial trauma (Sen, Ross et al. 2001). In particular, symptoms of anxiety 
and depression have been reported in patients with HIV lipodystrophy, although 
quantification utilizing validated methods is lacking. 
A measure of anxiety and depression was therefore considered to be an important 
outcome for the study and the Hospital Anxiety and Depression Scale was selected on 
this basis. 
4.2.3.3. Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) was developed in 1983 to detect 
states of depression and anxiety among patients in non -psychiatric hospital clinics 
(Zigmond, Snaith et al. 1983). It is divided into an anxiety subscale and depression 
subscale, each containing seven items (Appendix 5). Assessment of severity of anxiety 
and depression is rated on a four -point (0 -3) scale. Scores of 0 -7 in respective subscales 
are considered normal, with 8 -10 borderline and 11 or over indicating clinical 
'caseness'. The authors state that the scale may be a useful devise for assessing 
change 
in a patient's emotional state as well as for assessing the presence of clinically 
significant degrees of anxiety and depression. 
In a comprehensive review of the literature, the validity of the Hospital Anxiety and 
Depression Scale was assessed based on 747 studies which used the scale Reiland, 
Dahl et al. 2003). The internal consistency of the scale was found to be good in all of 
the reported studies. As a case finder for anxiety and depression, optimal sensitivity and 
specificity was achieved when caseness was defined by a score of 8 or above for 
HADS -A and HADS -D. The concurrent validity of HADS was also found to be good. 
The authors conclude that HADS performs well in screening for the separate 
dimensions of anxiety and depression and ` caseness' of anxiety and depression in 
patients from non -psychiatric hospital clinics. 
4.2.3.4. Evaluation of selected tools in HIV lipodysotrophy patients 
Although both of the instruments chosen are well established and reliable, data to 
support their application to HIV lipodystorphy is lacking. In order to investigate 
whether the selected tools address the psychological issues associated with HIV 
lipodystrophy, a series of informal, semi -structured interviews were designed. A 
sample of 7 patients with HIV lipodystrophy treated within the Edinburgh Unit was 
selected. A set of reference interview questions was devised to prompt discussion 
(Appendix 6) but most patients volunteered information about their individual 
experiences. Finally, patients were asked to complete the psychological scales selected 
for the study and provide feedback. 
The qualitative interviews raised several psychological issues, some which were 
common to all patients and others experienced only by individuals. The stigmatization 
of HIV lipodystrophy was one of the most apparent issues. Patients felt that their HIV 
diagnosis was apparent from their appearance, particularly amongst the HIV and MSM 
communities where awareness is increased. This led to some perceived difficulties 
in 
social interactions and forming relationships. Patients were often misjudged because 
of 
their appearance and described public perception of facial wasting as a consequence 
of 
severe illness or intravenous drug abuse. Subsequently, patients felt members of the 
public treated them with trepidation. Most patients regarded their face as their most 
important physical feature. Although they were able to disguise other body parts with 
clothing, their face was always exposed. Many patients had negative feelings about the 
change in their appearance, and some felt depressed. Several patients admitted to 
concerns about appearance prior to the development of lipodystrophy and feel this 
reflects pressure from the MSM community which places emphasis on physical 
attractiveness. One patient was concerned that his gaunt appearance conjured similar 
negative images of HIV or AIDS portrayed in the media. For some patients who feel 
systemically well and have good HIV control, the morphological features of 
lipodystrophy are a visible reminder of their HIV status. Most patients felt self - 
conscious about their appearance, particularly in public places; however, for the 
majority it did not affect their work or social life. Some factors such as increasing age 
and a stable relationship appeared to influence concern over appearance in a positive 
way. Although most patients did not complain about physical symptoms related to 
lipodystrophy, one patient felt that peripheral wasting of his limbs caused weakness and 
shortness of breath on exertion. 
Both psychological scales were acceptable to all of the patients questioned. Some 
patients provided useful feedback on some of the items in the DAS24. Overall, the 
selected psychological measures were considered appropriate to address the aims of the 
study in this patient group. 
4.2.4. Recruitment 
HIV -seropositive patients with lipodystrophy were recruited from referrals to plastic 
surgery clinics in Edinburgh and Glasgow. Participants in the control groups were 
recruited from Infectious Diseases and Genito -Urinary Medicine clinics. A medical 
history and lipodystrophy- specific examination using the patient and physician 
assessment of lipodystroph (Carr, Law et al. 2003) was carried out on all HIV - 
seropositive patients by 2 doctors. This assessment records independently any 
lipoatrophy or fat accumulation in each of the face, neck, dorsocervical spine, arms 
breasts, abdomen, buttocks, and legs, as well as the presence of any lipomata. Other 
data collected included the patients' age, ethnic status, date of diagnosis, mode of HIV 
acquisition, current medication and treatment history, viral load/ CD4 count, and 
fasting glucose, cholesterol and triglycerides. 
Patients were recruited to the trial if the eligibility criteria were satisfied. A patient 
information sheet was provided and informed consent was obtained. 
4.2.4.1. HIV -seropositive with lipodystrophy (HIV LD) group 
Inclusion Criteria 
1. Patients over 18 years of age. 
2. HIV seropositive. 
3. Patient and physician agreed body changes attributable to lipodystrophy and 
amenable to surgical treatment. 
4. Undetectable viral load and CD4 count > 200 cells /mm3 
Exclusion Criteria 
1. Pregnancy. 
2. Inflammation/ infection of skin at site of treatment. 
3. Concurrent illness/ medical problems precluding general anaesthetic. 
4. Concurrent treatment with anti -coagulants 
4.2.4.2. HIV -seropositive without lipodystrophy (HIV non LD) group 
Inclusion Criteria 
1 Age 18 -60 years 
2 No morphological features of lipodystrophy as agreed by patient and physician 
3 Time since HIV diagnosis > 6 months 
Exclusion criteria 
1. Any known psychiatric disorder 
4.2.4.3. HIV -seronegative men who have sex with men (MSM) group 
Inclusion Criteria: 
1 Age 18 -60 years 
2 MSM 
3 HIV -seronegative test within past 6 months 
Exclusion criteria: 
1. Any known psychiatric disorder 
4.2.5. Data Collection 
4.2.5.1. HIV LD Cohort 
Demographic data was collected including the patients' age and ethnic status. Data 
relating to the patients' HIV status was recorded including; date of diagnosis, mode of 
HIV acquisition, current medication and treatment history, viral load/ CD4 count. 
Information on the patients' past medical history, drug history and relevant social 
history were also collected. 
Clinical grading 
The HIV Outpatient Study (HOPS) scoring system (incorporated in the lipodystrophy- 
specific assessment utilized for patient recruitement) was used to rate the degree of 
lipoatrophy as absent = 0, mild =1 (noticeable on close inspection), moderate = 2 
(readily noticeable by patient and physician) or severe = 3 (readily noticeable to a 
casual observer) by both the patient and lead investigator. 
Psychological measures 
The DAS -24 and HADS were completed by all patients pre -operatively and repeat 
measures were obtained at 2, 6 and 12 months following completion of treatment. 
3 -D imaging 
Measurement of 3 -D facial volume change in HIV LD patients undergoing treatment 
for facial lipoatrophy was performed at 2, 6 and 12 months post -operatively. The 
details of this study are provided in chapter 3. 
4.2.5.2. Control groups 
Demographic data was recorded on the age, sex, ethnic origin, and sexual orientation of 
all participants. For the HIV non LD group, data was collected on the patients' HIV 
history including; date of diagnosis, mode of HIV acquisition, treatment history, and 
viral load/ CD4 count. 
Psychological measures 
All participants completed the DAS -24 and HADS scales at the time of recruitment to 
the trial. No repeat measures were performed. 
4.2.6. Statistical analysis 
4.2.6.1. Case control study 
Baseline patient demographics (age, treating unit, ethnicity) were summarised by study 
group (HIV LD, HIV non -LD and MSM), as a whole and by gender, where 
appropriate. Subgroups were compared by analysis of variance (ANOVA). For the two 
HIV groups, disease -related factors (main HIV risk factor, duration of HIV, duration of 
HAART, viral load, CD4 count and BMI) were summarised as a whole and by gender. 
Subgroups were compared by analysis of variance ( ANOVA). 
Baseline patient demographics (age, treating unit, ethnicity) were summarised by study 
group (HIV LD, HIV non -LD and MSM), as a whole and by gender, where 
appropriate. Subgroups were compared by analysis of variance (ANOVA). For the two 
HIV groups, disease -related factors (main HIV risk factor, duration of HIV, duration of 
HAART, viral load, CD4 count and BMI) were summarised as a whole and by gender. 
Subgroups were compared by analysis of variance (ANOVA). Baseline DAS -24 and 
HADS depression and anxiety (HADS -D and -A) scores were summarised by study 
subgroup. Mean scores were compared between study subgroups using analysis of 
variance ( ANOVA). Mean scores were compared between study subgroups as a whole, 
and following exclusion of non -MSM and non -Caucasian individuals from each 
subgroup, using analysis of variance ( ANOVA). 
Comparative reference values were extracted from the published norm tables for the 
DAS -24 based on large multi -centre trials. Reference values were presented by gender 
for DAS -24 scores in a general population and in a clinical population (including 
subgroups with concerns relating to the head and neck region. The norm tables supply 
data on 3 different age ranges: 18 - 30 years, 31 -60 years and 61+ years. To 
approximate the age distribution of the study population, reference values were derived 
from individuals aged 31 -60 years. Study subgroups were compared to the reference 
populations using two -sample t- tests. 
4.2.6.2. Prospective study of HIV LD treatment groups 
Patient demographics, HIV -related factors and clinical features were summarised by 
treatment group, and compared using analysis of variance (ANOVA) for continuous 
measures and Fishers exact test for categorical variables. 
To assess the potential for bias due to loss to follow -up, the baseline characteristics of 
those with or without follow -up volume measurements at 2, 6 and 12 months were 
summarized, and compared with two sample t- tests. 
Psychological measures (DAS -24, HADS -A and HADS -D scores) at baseline and at 2. 
6 and 12 months post -treatment, are summarized for all HIV LD patients undergoing 
treatment for facial lipoatrophy, as a whole and by treatment group. Changes over 
baseline were tested with paired t- tests, within treatment groups. 
Correlations between changes in psychological measures over baseline and facial 
volumes at 2, 6 and 12 months were tested using Pearsons correlation coefficient. 
Differences between psychological scores for DAS and HADS within patients 
subdivided according to clinical grade of lipoatrophy (assessed by both patient and 
physician) were tested using ANOVA. The percentage agreement of patient versus 
physician grading of severity was calculated and tested using McNemar's test. 
4.3. Results 
4.3.1. HIV LD cohort versus control groups 
4.3.1.1. Demographic data 
The DAS -24 and HADS were completed by 56 patients with HIV -associated 
lipodystrophy referred for plastic surgery, and similar numbers of HIV- seropositive 
patients without lipodystrophy and HIV -seronegative MSM volunteers (Table 4.11) 
Differences in baseline demographic data between groups are summarized as follows. 
There was a significant difference in mean age between participants in the MSM and 
HIV LD group (10 years) and HIV non -LD group (6 years). A greater proportion of 
patients in the HIV LD group were recruited from Edinburgh (80 %) compared to a 
larger number of patients in the HIV non -LD group who were recruited from Glasgow 
(81 %). The majority of patients in both the HIV LD and MSM groups were Caucasian 
compared to a slightly more variable ethnic mix in the HIV non -LD group. Whilst the 
majority of patients in the HIV LD and non -LD groups were MSM 
(83% and 76% respectively) some other risk factors were seen including intravenous 
drug abuse, heterosexual contact and blood contamination. 
Table 4.1. Demographics of HIV LD, HIV non -LD and MSM subgroups. 
HIV LD HIV non -LD 
MSM p-value 
Male Female Total Male Female Total 
N 
Recruited 41 15 56 49 13 62 54 <0.001 
Age (years) 45 41 44 41 33 39 35 <0.001 


















Ethnicity N ( %) 
Caucasian 41 (100) 14 (93) 55 (98) 43 (88) 8 (62) 51 (82) 53 (98) 
African 0 1 (7) 1(2) 3 (6) 5 (38) 8 (13) 0 
0.013 
Thai 0 0 0 2 (4) 0 2 (3) 1 (2) 
Malaysian 0 0 0 1 (2) 0 1 (2) 0 
Risk Factors N ( %) 
MSM 34 (83) 0 34 (61) 37 (76) 0 37 (60) 
IVDA 2 (5) 5 (33) 7 (13) 2 (4) 1 (8) 3 (5) 
Heterosexual contact 4 (10) 10 (77) 14 (25) 9 (18) 11 (85) 20 (32) 0.472 
Mother to child 0 0 0 0 1 (8) 1 (2) 
Blood contamination 1 (2) 0 1 (2) 1 (2) 0 2 (3) 
Duration of HIV (years) 10.7 15.7 11.9 6.5 4.1 6.2 <0.001 
Duration of HAART 
(years) 8.3 
8.2 8.2 2.3 1.7 2.2 <0.001 
Viral load (HIV copies /ml) 
N ( %) 
Undetectable 39 (95) 12 (80) 51 (91) 44 (89) 12 (92) 56 (90) 0.768 
Detectable 2 (5) 3 (20) 5 (9) 5 (11) 1 (8) 7 (10) 
Mean detectable 1100 18933 10016 104263 24700 64481 
CD4 count, cell /mm3 
(mean +- SD) 
482 596 514 465 459 464 0.26 
BMI 22.1 20.5 21.3 24.1 26.6 25.3 <0.001 
Thus, analysis of psychological scores was performed on the groups as a whole, and 
following exclusion of non -MSM and non -Caucasian individuals. Patients in the HIV 
LD group had a longer duration of HIV infection (5 -year difference) and treatment with 
Highly Active Antiretroviral Therapy (6 -year difference) than HIV non -LD patients 
although no difference in viral load and CD4 count were seen. The mean BMI of HIV 
LD group was also slightly lower than the HIV non -LD group. 
Due to the small number of females recruited to each group, females were excluded 
from statistical comparison of psychological measures between groups. This was 
decided on the basis that no meaningful conclusions could be drawn from comparison 
of such small samples. Comparison of the psychological scores (DAS -24, HADS -A and 
HADS -D) for the groups as a whole and following exclusion of non -MSM and non- 
Caucasian individuals demonstrated no difference in results. Therefore, results for 
analysis of subgroups excluding non -MSM and non -Caucasian individuals are 
presented. 
4.3.1.2. Derriford Appearance Scale 
Baseline DAS -24 scores for the HIV LD cohort and control groups are summarized in 
Table 4.2. Dotplots of the DAS and HADS results are provided in appendix x and 
demonstrate that, despite a large range and standard deviation for some groups, there is 
reasonable spread of the data with no particular outliers. Analysis using ANOVA tests 
demonstrated significantly increased scores for the HIV LD group compared to male 
HIV non -LD patients and the MSM group. There was no significant difference in 
scoring between male HIV non -LD and MSM subgroups (p= 0.83). 
Table 4.2. DAS -24 scores by subgroup with p- values from ANOVA tests 
HIV N 41 
LD Mean (SD) 55.5 (16.5) 
HIV N 49 
non- Mean (SD) 35.3 (12.7) 
LD 
N 54 
MSM Mean (SD) 35.8 (11.0) 
p-value p<0.001 
The DAS -24 reference data for males aged 31 -60 years in the general population and in 
a clinical population of head and neck patients were extracted for comparison with the 
study population groups (Figure 4.2). 




FIN LD HIV nonLD MSM General Clinical Population Mean Values 
Mean scores for HIV LD patients (55) were higher than males in the general population 
(27) and clinical population of head and neck patients (41) (p <0.001). Mean scores for 
the HIV non -LD group (35) and MSM group (35) were also significantly higher than 
the general population (p <0.001) but lower than the clinical head and neck population 
(p = 0.03). 
4.3.1.3. Hospital Anxiety and Depression Scale 
HADS -D and HADS -A scores are summarized in Table 4.3 and Figure 4.3. 
The male HIV LD group had higher depression scores than the male HIV non -LD and 
MSM groups (p <0.001). There was no difference in scoring between male HIV non -LD 
and MSM subgroups (p= 0.92). A similar pattern was seen for anxiety scores, though 
the statistical evidence for differences between the male subgroups was not significant 
(p= 0.070). 
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Figure 4.3. Boxplots (median, quartiles and range) of HADS -D and 
HADS -A scores for all subgroups 
4.3.2. Psychological outcome in HIV LD treatment cohort 
Forty -eight patients from the HIV LD cohort underwent treatment for HIV facial 
lipoatrophy: 16 patients had Bio- alcamid augmentation, 20 patients received Newfill 
injections and 12 patients underwent fat transfer. The demographic and clinical data for 
patients in each treatment group is summarized in table and discussed in Chapter 2. 
4.3.2.1. Data completion 
The number of HIV LD patients who completed psychological data at each follow -up 
interval is shown in Table 4.4. 
Table 4.4. Number of patients treated and follow -up psychological data completed 
Psychological data 
Treatment Patients 2 6 




16 15 12 13 (81 %) 
Newfill 20 16 8 8 (40 %) 
AFT 12 9 12 9 (75 %) 
A missing -value analysis comparing baseline psychological measurements between 
those patients with complete data and those patients with incomplete data (using two - 
sample t- tests) demonstrated no significant differences between the two groups. 
4.3.2.2. Psychological outcome in HIV LD cohort as a whole 
The overall change in DAS -24, HADS -A and HADS -D for all patients undergoing 
treatment for facial lipoatrophy (irrespective of treatment group) is shown in Figure 
4.4. A dotted line on the graph indicates `caseness'scores greater than 11 for HADS. 
Summary statistics for the DAS -24 show an overall mean baseline score of 54 with a 
significant reduction in scores to 39, 42 and 43 at 2, 6 and 12 months respectively (all 
p <0.001; paired t -tests vs. baseline). There was some improvement in overall HADS -A 
scores compared to baseline although results did not reach significance at 12 months 
(m2 p= 0.058, m6: p= 0.082, m12: p= 0.184). There was a significant improvement in 
overall HADS -D scores compared to baseline (p= 0.004, 0.003, 0.027 at months 2, 6 
and 12 respectively, vs. baseline). 
Figure 4.4. Summary of psychological measures of all HIV LD patients undergoing 
treatment for facial lipoatrophy (dotted line indicates `caseness' scores for HADS 
greater than 11). 
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4.3.2.3. Psychological outcome in each HIV LD treatment group 
Derriford Appearance Scale 
Table 4.5 provides summary statistics for DAS scores by treatment and follow -up 
interval. In addition, the change in scores relative to baseline with t -test p- values for 
test of zero change is shown. 
Table 4.5 Mean, SD and number of observations of DAS, HADS -A and HADS -D, by 
visit and treatment type. Mean, SD and number of observations of changes over baseline, with 
paired t -test p- values for test of zero change. 
Outcome Visit 
Bio -Alcamid Fat NewFill 
Raw Data 
Change over p -value 
baseline 
for Raw Data 
change 
Change over p -value 
Raw Data 
Change over p -value 








































56.2 (19.8), N=20 
37.6 (15.3), N=16 
38.1 (18.4), N=8 


















































9.8 (5.4), N=20 
9.0(4.7),N=16 
9.0 (5.4),,N=8 


















































7.2 (5.0), N=20 
5.7 (4.9), N=16 
6.0 (3.0), N=8 










Comparison of psychological measures between treatment groups using ANOVA 
demonstrated no significant difference in DAS -24 scores at baseline or throughout 
follow -up (Table 4.6). 
Table 4. 6. p- values for tests of no difference between groups in mean value or mean 
change over baseline using ANOVA 
Follow -up Mean Change 
DAS 2 month p =0.701 p =0.610 
DAS 6 month p =0.821 p =0.256 
DAS 12 
month 
p =0.891 p =0.145 
HADS -A 2 p =0.225 p =0.330 
month p =0.336 p =0.258 
HADS -A 6 
month 
p =0.576 p =0.110 
HADS -A 12 
month 
HADS -D 2 p =0.210 p =0.508 
month p =0.915 p =0.220 
HADS -D 6 
month 
p =0.513 p =0.108 
HADS -D 12 
month 
To investigate the effect of the high drop out rate and resultant small sample size at 
follow -up, linear mixed effects regression models were applied to each psychological 
measure, in the same manner as for facial volumes. Model- predicted values at each 
time point for each treatment group, with 95% confidence intervals demonstrated little 
difference compared to the raw data and are therefore provided in Appendix 3 for 
reference only. 
For Bio- alcamid, a significant difference in DAS scores compared to baseline was 
found at all time intervals. In the fat group, improvements in DAS scores were also 
demonstrated at all follow -up visits, although the values did not reach significance as a 
consequence of small sample size. Significant improvements in DAS scores were found 
at all time intervals in the Newfill group, although there was in increase in scores at 12 
months. 
Figure 4.5. Box plot of DAS -24 results for each treatment group over time 
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Bio- Alcamid Fat NewFill 
Hospital Anxiety and Depression Scale 
Mean HADS -A and HADS -D scores are summarized by treatment group and follow -up 
interval (including patient numbers) in Table 4.5. No significant difference in HADS -A 
or HADS -D scores between the 3 treatment groups at baseline or throughout follow -up 
(Table 4.6). Figures 4.6 and 4.7 show boxplots of HADS -A and HADS -D for each 
treatment group over time. 
Figure 4.6. HADS -A results for each treatment group over time 
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Figure 4.7. HADS -D results for each treatment group over time 
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Bio- Alcamid Fat NewFill 
In the Bio- alcamid group, post -treatment scores reached significance for HADS -D at 2 
months only. Some improvement in HADS -A and HADS -D scores was found in the fat 
group, although values only reached significance for HADS -D at 6 months. No 
significant improvement in HADS -A or HADS -D scores was demonstrated for the 
Newfill group. 
4.3.2.4. Correlation between psychological outcome and facial volume 
change 
Table 4.7 illustrates that no correlation between change in psychological measures 
compared to baseline and change in facial volume measured by 3 -D imaging was seen 
at any time point. 
Table 4.7: Correlations between changes in volume and changes in psychological factors. 
[N] 
Pearson Corr" (p- value) 
Rank Corr" (p- value) 
DAS Change HADS -A Change HADS -D Change 
2 months - 
Baseline 
[32] 
0.212 (p= 0.244) 
0.146 (p= 0.416) 
6 months - 
Baseline 
[20] 
0.139 (p= 0.560) 
0.050 (p= 0.829) 
[32] 
-0.121 (p=0.509) 
-0.161 (p= 0.369) 
[20] 
-0.010 (p= 0.968) 
-0.068 (p= 0.764) 
[32] 
-0.053 (p= 0.775) 
-0.062 (p= 0.728) 
[20] 
0.118 (p= 0.621) 
0.107 (p= 0.644) 
12 months - 
Baseline 
[16] 
0.036 (p= 0.894) 
-0.046 (p= 0.855) 
[16] 
-0.067 (p= 0.805) 
0.083 (p= 0.752) 
[16] 
0.168 (p= 0.535) 
0.082 (p= 0.756) 
4.3.2.5. Clinical grading of facial lipoatrophy and correlation with 
psychological measures 
The correlation between patient and physician grading of facial lipoatrophy is shown in 
Table 4.8. Overall, patient grading was higher than physician grading and the 
correlation between these measures was poor (63 %). The correlation between 
psychological outcome and both patient and physician grading of severity is 
summarised in Tables 4.9 - 4.10. A pattern of greater psychological scores for DAS, 
HADS -A and HADS -D was found with higher grading of facial lipoatrophy, 
(particularly patient grading) although this only reached significance for HADS -D. 
Table 4.8. Patient vs. Physician Grading of severity. 
Physician Grading 
1 2 3 
1 6 0 0 
Patient Grading 2 3 12 0 
3 2 11 9 
Percentage Agreement 62.8% 
McNemar's Test p <0.001 
Table 4.9. Psychological Scores vs. Patient Grading of severity. 
Patient Grading ANOVA 
1 2 3 
p-value 
[N] [6] [15] [22] 
DAS Mean 44.67 49.53 59.32 p=0.107 
(SD) (13.08) (17.62) (18.24) 
HADS- 
[N] [6] [15] [22] 
Mean 
A 
8.50 9.00 10.23 p=0.669 
(SD) (5.17) (5.36) (4.94) 
HADS- [N] [6] [15] [22] 
Mean 
D 
4.33 5.20 8.91 p=0.043 
(SD) (2.42) (4.13) (5.93) 
Table 4.10. Psychological Scores vs. Physician Grading of severity. 
Physician Grading ANOVA 
p-value 
1 2 3 
[N] [11] [23] [9] 
DAS Mean 51.55 53.26 58.22 p=0.703 


























4.4.1.Selection of control groups 
The psychological distress caused by HIV -associated lipodystrophy is a well - 
recognised problem. This study attempted to quantify the effect of various factors 
influencing body image assessment and psychological outcome in this group. A group 
of HIV patients without lipodystrophy, but matched to the cohort group with respect to 
other variables was required to evaluate the impact of lipodystrophy on psychological 
distress. In addition, a control group of non -HIV patients was a requirement to 
investigate the effect of HIV infection as an independent variable. Given that a 
significant proportion of referrals made to the Plastic Surgery Unit in Edinburgh since 
the introduction of treatment funding for facial lipoatrophy were MSM, sexual 
orientation was also hypothesized to potentially influence body image perception. 
Therefore, in an attempt to keep the non -HIV group matched to the cohort group with 
respect to this variable, the inclusion of an MSM group was devised. The authors of the 
DAS scale provide reference tables based on large population studies, which account 
for age, sex and ethnic status. However, the impact of sexual orientation, hypothesized 
to influence body image perception and referral for treatment has not pi eviously been 
assessed using this scale. This rationale formed the basis for selection of the control 
groups as discussed in the methods section. 
Consideration should be given however to the baseline demographics of patients 
recruited to each study group. When analyzing the results, the risk factors were more 
variable than anticipated. Although the greatest proportion in each group was MSM 
(83% of HIV LD and 76% of HIV non -LD), there were other risk factors displayed in 
the patient demographics such as IVDA (5% in the HIV LD and 4% in the HIV non- 
LD) and heterosexual contact (10% in the HIV LD and 18% in the HIV non -LD). 
Therefore, the results of this study are skewed, given that one of the control groups is 
comprised of only MSM patients and cannot be compared to the other control groups 
who demonstrate variable risk factors. Considering IVDA patients for example, 
different levels of psychological distress or body image perceptions may exist 
compared to MSM patients due to the complex interplay of social and lifestyle factors. 
Analysis of psychological measures in this study with exclusion of non -MSM and non- 
Caucasians demonstrated no difference compared to the groups as a whole. However, 
the sample size may be too small to detect a difference between groups. Inclusion of a 
control group matched for these other risk factors would have been helpful. However, a 
much larger sample size would be required to test the difference between the risk factor 
variables statistically. 
4.4.2. Psychological characteristics of cohort versus control 
groups at baseline and confounding variables 
In summary, comparison of all three male subgroups, demonstrated significantly higher 
scores for the DAS -24 and RADS -D in patients with HIV lipodystrophy patients 
compared to controls. Scores for HADS -A were also higher, although not significant. It 
is interesting to note that no difference in DAS -24, HADS -D or HADS -A scores was 
evident between the HIV non -LD males and MSM group. However, when interpreting 
these findings, consideration of other confounding variables influencing body image 
perception such as age, gender and ethnic origin of subjects is particularly relevant. The 
mean age of the patients in the HIV LD group was similar to the HIV non -LD group 
but 10 years older than the MSM group. The published norm tables for the DAS -24 
show greater scores for the general male population in a younger age group (median = 
26 in 18 -30 yrs) compared to the older age groups (median = 25 in 31 -60 years, median 
= 20 in 61 years and over). If using the norm tables for comparison then the mean age 
of all 3 male subgroups falls into the 31 -60 year age range. Therefore, one drawback of 
the reference tables is the relatively wide range of this age subdivision. It would be 
useful to know if a 10 -year age difference (such as that displayed between the MSM 
group and the other control groups) has any effect on DAS scores. Therefore, the DAS- 
24 scores for the younger MSM group may not be comparable to the other subgroups. 
It is possible that selection of an MSM group matched for age would display lower 
DAS -24 scores. 
All of the male patients in the HIV LD group were Caucasian and similar numbers of 
Caucasian patients were recruited to the control groups. A small number of patients of 
different ethnic origins were recruited to the HIV non -LD and MSM group but 
exclusion of these patients did not affect results. However, it is possible that a larger 
sample size would demonstrate differences between ethnic groups for the selected 
scales. For example, the features that determine attractiveness and importance placed 
on body image may vary be subject to cultural variation. The morphological changes 
attributable to HIV lipodystrophy may therefore be therefore be associated with 
different levels of psychological distress depending on cultural perceptions of 
attractiveness. In addition, there Rumsey reports evidence for increased appearance 
related concern in `non -White' ethnic origin living in the UK is based on difficulties 
with social encounters and employment issues (Rumsey, Clarke et al. 2004). 
The effect of gender on psychological outcome has not been investigated in this study 
but is another important variable to consider. Further investigation of psychological 
measures in a larger female population of HIV -seropositive patients with and without 
lipodystrophy would be useful as the number of participants in this study were limited. 
Indeed, one study has found that women may be more sensitive than men in terms of 
psychological difficulty following disfigurement (Anderson and Maksud 1994). 
When comparing baseline demographics between groups, the proportion of patients 
recruited from Edinburgh and Glasgow differed significantly. Thus, geographical 
variation between groups may be an additional source of bias. It is possible that socio- 
economic factors differ in patients recruited from these different sites. The general 
health literature suggests that those at a lower socio- economic level are more affected 
by their health status (Marmot, Smith et al. 1991). It has also been found that the 
unemployed are at a greater risk of developing psychological distress following acute 
injury (Joy, Probert et al. 2000). 
Although the limitations of the control groups have been discussed, the results of the 
study do highlight the significantly greater levels of the psychological distress in the 
HIV LD group. The DAS -24 scores for the HIV LD group were also markedly higher 
than for a clinical population with other facial disfigurements, which reinforces the 
significant stigmatizing nature of this condition. Utilizing the reference tables for DAS- 
24, mean scores for all male subgroups in this study were higher than the general male 
population. This suggests that there may be greater concern over appearance in the 
MSM group compared to males in the general population. However, the reference 
values do not represent the local population and a further, larger study with matching of 
other confounding variables would be required to draw conclusions on the significance 
of sexual orientation on body image perception as an independent variable. 
4.4.3. Psychological measures 
4.4.3.1. Selection of psychological measures 
The HADS scale was selected for this study for several reasons: 
established reliability and validity 
the scale is limited to 14 items which makes it easy to administer and 
well accepted 
 the scale has no items relating to somatic symptoms that may confound the diagnosis in 
patients who also have physical illness and therefore reduce the sensitivity in screening 
for depression 
ability of the test to detect change over time 
availability of reference values for a variety of medical and non -medical populations. 
The RADS has gained widespread use in clinical practice and has demonstrated 
excellent acceptability, reliability and validity, particularly in 2 large meta -analysis 
reviews of the scale based on 747 and 200 papers in each review respectively 
(Herrmann 1997; Bjelland, Dahl et al. 2003). There has been some discussion about 
whether the anxiety and depression subscales really measure different aspects of mood. 
Some investigators have preferred the HADS total score as a general measure of 
distress (Chaturvedi 1991), others have found no significant correlation between the 
two subscales. (Aylard, Gooding et al. 1987). In fact, the mean correlation between 
anxiety and depression subscales from 18 separate studies with n =8160 is r =0.63. Thus, 
subscale scores are clearly correlated in most patient groups. Given the extensive co- 
morbidity between anxiety and depression, the moderate to strong correlations between 
HADS -A and HADS -D subscales reported are to be expected. Thus the total HADS 
scale could have been used as an alternative method of analyzing results in this study. 
A further analysis could also have incorporated the correlation between HADS -A, 
HADS -D and DAS scores. However, the results of the literature review support the 
two - factor structure of HADS and there is sufficient evidence that both subscales differ 
in a clinically meaningful way. Although there is some overlap, it is recommended that 
both subscales should therefore be used separately for most purposes. In addition, 
presentation of the data in separate subscales facilitates comparison of results with 
reference data in different clinical studies. Interestingly, no differences in HADS -A 
scores were demonstrated either between the HIV LD cohort and controls or when 
comparing the three different treatment groups. This may represent a real finding but 
could also result from inadequacy of the scale to detect anxiety symptoms in these 
groups. However, the excellent sensitivity and specificity of the HADS as a case finder 
for anxiety and depression was also reported in the review papers (Herrmann 1997; 
Bjelland, Dahl et al. 2003). The optimal threshold values for `case -finders' has been 
shown to be 8+ as suggested in the original paper on HADS. In this study, values above 
this threshold were seen for HADS -A in the HIV LD group but not for HADS -D at 
baseline. Post -treatment HADS -A values fell below the threshold at 2 and 12 months. 
Although results were not found to be statistically significant, a reduction in scores 
below the `caseness' cut -off may represent a positive clinical intervention. 
Finally, the benefits and drawbacks of HADS in this study over other psychological 
measures should be highlighted. Several studies have demonstrated high correlation of 
the HADS subscales with scales used as gold standards for depression and anxiety such 
as the Beck Depression Inventory (BDI) and the State Trait Anxiety Inventory (STAI). 
(Michopolous, Douzenis et al. 2008) 
Meta- analysis comparing HADS with additional scales revealed that HADS exhibited 
similar sensitivity and specificity as longer versions of the General Health 
Questionaire. When compared to other questionnaires for anxiety and depression in 
common use such as BDI, STAI, CAS, and SCL -90 Anxiety and Depression subscales, 
the 
correlation to HADS -D and HADS -A, respectively, were between .60 and .80, which 
should be characterised as medium to strong correlations (Bjelland, Dahl et al. 2003). 
Thus, the concurrent validity of HADS is considered to be very good. An additional 
benefit to the use of HADS in this study is the exclusion of somatic items. Because 
there is a large overlap between HIV manifestations and somatic 
symptoms of anxiety 
and depressions, it is crucial to use measures that do not contain 
somatic items to 
validly and reliably assess these psychological states in HIV -infected patients. One 
study evaluated the psychometric properties of the HADS in 162 HIV -seropositive 
patients, who, in addition to the HADS, also completed the Beck Depression Inventory 
(BDI) and the State -Trait Anxiety Inventory (Savard, Laberge et al. 1998). In contrast 
to the BDI, HADS scores were found to be unconfounded by the presence of HIV 
symptomatology. The authors conclude that the HADS appears to represent the best 
currently available self -report scale, to reliably and validly assess anxiety and 
depression in HIV -infected patients. 
Therefore, the choice of HADS as a measure of anxiety and depression in this study 
was good overall. The addition of a total HADS score may have been beneficial. It is 
possible that the total score may have demonstrated a more convincing improvement 
following treatment intervention than either sub -scale individually. 
The advantages of utilizing the DAS -24 scale in this study were: 
the short form is quick to complete thus more acceptable to patients and scores can easily 
be collated 
the scale is condition -specific, developed specifically for assessing concern about 
physical appearance 
the scale has been validated and tested in a large population of plastic surgery patients 
reference data is available for general and clinical populations based on age and sex 
However, several drawbacks of the scale emerged during the study. The greatest 
disadvantage of the DAS -24 is that the scale is not specific to facial lipoatrophy. One 
systematic review of 442 articles of patient- reported outcome measures developed and 
validated for patients undergoing surgical and non -surgical facial aesthetic procedures, 
identified the Derriford Appearance Scale as one of only 9 favourable measures 
(Kosowski, McCarthy et al. 2009). However, the authors also highlight the central 
difficulty in using this measure for facial aesthetic surgery patients given 
its purpose as 
a generic measure relevant to various surgical procedures. This deficiency was 
particularly important when analyzing the scores of patients with a mixed clinical 
pattern of lipodystrophy. Although patients may have been satisfied with treatment for 
facial lipoatrophy, they had ongoing concerns regarding body fat distribution. Indeed, 
patients may become more dissatisfied with other body areas following successful 
treatment to the face which was previously their primary concern. Thus, improvement 
in concern over facial appearance may not be reflected in the DAS scores if this is the 
case. In retrospect, an additional measurement scale to grade facial appearance and 
satisfaction would have been useful in this study. However, valid, reliable and 
responsive instruments to measure outcomes following facial aesthetic procedures are 
lacking. One review of 442 articles and 47 patient- reported outcome measures for 
assessing facial appearance after cosmetic procedures found only 9 measures which 
adhered to international guidelines for the development of validation of health outcome 
questionnaires (Kosowski, McCarthy et al. 2009). Most of these measures are tailored 
to a specific procedure such as the Rhinoplasty Outcomes Evaluation or Facial Lines 
Treatment Satisfaction so could not be adopted in this study. Only one of the identified 
measures, the Facial Appearance Sorting Test, may have been appropriate for the study. 
This is a card -sorting test where patients are asked to rank their own personal 
appearance on a spectrum of attractiveness. The instrument was able to detect an 
improvement in appearance and psychiatric symptomology in a prospective study of 22 
patients accepted for rhinoplasty. However, psychometric analysis of the test was not 
performed and availability of reference data are lacking. 
In addition, there are some important elements lacking in all of these measures which 
focus only on appearance outcome. Namely, procedure- related symptoms and 
procedural satisfaction are not addressed. Clearly issues such as facial 
pain, erythema 
and swelling or the impact of complications on quality of life are relevant. 
In this study, 
an attempt to address some of these issues was made by specifically asking about 
procedure- related symptoms and complication during clinical follow -up. However, this 
was not quantified by formal means. In addition, patient satisfaction was assessed using 
a rating scale devised for the study although there were weaknesses with this measure 
which are discussed in chapter 2. 
The authors of another comprehensive review of aesthetic surgery outcome measures 
recommend the use of a generic, utility -based quality of life instrument in conjunction 
with specific quality of life measures such as the DAS (Ching, Thoma et al. 2003). The 
reason for this is that condition -specific measures such as the DAS, which are 
specifically tailored to the cosmetic surgery population, cannot be used to compare 
different health states. In planning the study, consideration was given to use of a 
general quality of life scale such as the Health Measurement Questionnaire or Short 
Form 36 but these instruments were rejected on the basis that they may not be able to 
detect significant change in patients undergoing procedures predominantly cosmetic in 
nature. In retrospect, the inclusion of a general scale, in addition to a body image 
specific scale, may have been advantageous to the study. Such a scale may have better 
reflected the multidomain construct which defines quality of life including physical, 
social, psychological, emotional and spiritual domains. This may have been particularly 
useful to measure the psychological impact of HIV infection, especially when 
comparing the cohort group with controls. Interestingly, no difference was noted in 
psychological outcome between the HIV non -LD group and the MSM group. When 
interpreting this fording, consideration should be given as to whether the chosen 
instruments adequately assessed the relevant psychological issues. The rationale for the 
inclusion of only 2 short questionnaires was to minimize time in the belief that this 
would be more acceptable to the patient and encourage completion. 
However, the 
measures may not have adequately addressed the psychological 
issues pertaining to the 
HIV population. The qualitative interviews performed prior to this study were helpful 
to identify psychological issues specific to the HIV LD cohort and to determine 
whether these issues were adequately assessed using the selected psychological scales. 
Although, the questionnaires were found to be relevant and acceptable to patients 
during informal interviews prior to the study, only a small number of patients were 
involved. Therefore, the opinions of this group and problems experienced may not 
represent the HIV population as a whole. However, the interviews created an 
environment for patients to provide and honest account of the impact of HIV on various 
aspects of life such as relationships, work, and social activities. Most importantly, the 
effect of disfigurement on body image perception was uncovered, and the 
stigmatization of this particular condition was emphasized. Thus, the importance of 
incorporating psychological and quality of life measures to evaluate treatment outcome 
was confirmed. Some additional insight into the multiple factors affecting adjustment 
to disfigurement was revealed. For example, the importance of a stable relationship in 
acceptance of body image was emphasized by some patients. Indeed, these are also 
factors that have been demonstrated to affect adjustment to disfigurement in clinical 
research. Tebble showed that psychological sequelae of facial lacerations were 
influenced by external factors such as social support and indicated that patients in long- 
term relationships are less concerned about their appearance (Tebble, Thomas et al. 
2004). Patient assessment of the selected psychological scales for the main study was 
also useful. On the whole, the content of the scales was satisfactory, although a small 
number of items from the DAS -24 were felt to be less appropriate by some patients. 
For example, `How distressed do you get when you go to the beach ?' if patients never 
go to the beach, or `How distressed do you get whilst playing sports ?' if the patient 
doesn't play sports. However, after communication with the author of the DAS 
24, it 
was felt that the content should not be altered, as this would affect the scoring and 
validity of the scale. 
4.4.3.2. Comparison of study results with published clinical trials using 
assessment tools 
The Derriford Appearance Scale (DAS -59) and short form (DAS -24) have been used as 
psychological measures in several studies of different patient groups. One of the largest 
studies by Rumsey et al reported the extent of psychosocial needs of outpatients 
attending for treatment of a wide range of disfiguring conditions (Rumsey, Clarke et al. 
2004). Data for the DAS -24 and HADS was collected from 15 outpatient clinics in a 
cross -sectional survey of 458 patients. The scores for the DAS -24 were highest in 
patients attending two general plastics clinics for elective procedures and in patients 
with tattoos (mean scores 49, 52 and 48 respectively). Scores were lowest in patients 
attending burns, hands and eye clinics (mean scores 32, 36 and 37 respectively). 
Unfortunately the results are not sub -divided according to age or gender, so it is 
difficult to compare directly with the HIV LD cohort. However, mean scores for HIV - 
LD men (55) and HIV -LD females (64) appear to be higher than all of the other patient 
groups studied. The main drawback of Rumsey's study is the cross -sectional design. 
Apart from the general plastics clinics, where all of the patients are seeking elective 
plastic surgery, the stage of treatment for patients attending the other clinics is 
undisclosed. Thus, some patients may have already received treatment for 
disfigurement, resulting in a lower score. Also, within the general plastics groups, no 
information on the body areas of concern or types of procedures sought is given. 
Therefore, no inferences about the causality of these associations are possible. 
Rumsey's study also included a semi -structured interview which highlighted the 
importance of social support as a factor associated with reduced impact of appearance 
concerns on lifestyle, and reduction in perceived worry and 
noticeability of the 
disfigurement. This was also a factor associated with reduced concern over appearance 
in HIV LD patients which emerged during the semi -structured interviews in Study 1. 
According to Rumsey, the implication of this finding could be instrumental in 
rehabilitation of social difficulties relating to disfigurement by inclusion of relatives in 
graded exposure techniques. 
Jackson et al have also utilised the DAS -24 and HADS to evaluate the psychosocial 
benefits of corrective surgery for adults with strabismus (Jackson, Harrad et al. 2006). 
A cohort of 46 patients completed the psychological measures preoperatively and 3 
months postoperatively following treatment for strabismus. There was a significant 
reduction in mean DAS -24 scores from 40.2 preoperatively to 30.8 postoperatively. 
The preoperative score for this group as a whole were lower than the HIV LD group. 
However, the results of the strabismus group are not subdivided according to age or 
gender, so direct comparison with the HIV LD group is difficult. Another drawback of 
the study is the lack of long -term follow up data. 
The DAS -24 has also been used to study appearance issues in patients following 
surgery for oral and oro- pharyngeal squamous cell carcinoma (Katre, Johnson et al. 
2008). A postal questionnaire was sent to disease free patients identified over a 13 -year 
period with a 66% response rate (252 patients). The study provides useful data for 
mean DAS -24 scores according to age and sex. In the 31 -60 years group, males scored 
32 and females scores 34 (lower than reference clinical population values). Scores in 
the 61 year and above age group were 26 for both males and females. However, the 
main disadvantage of this study is the cross -sectional design and lack of preoperative 
DAS -24 data to compare with other groups such as the HIV LD cohort. The study also 
assessed the correlation between various clinical factors with appearance. 
Age (younger 
patients), T stage 3 and 4 and adjuvant radiotherapy were 
key factors in patients 
reporting problems with appearance. Thus, the relatively low 
DAS -24 scores in this 
cohort may be influenced by age (mean 66 years) and the fact that the study is weighed 
towards longer -term disease free survivors. The authors also speculate that head and 
neck cancer patients may have fewer pre- treatment appearance concerns compared to 
published norms due to factors such as lower levels of self care and higher 
consumption of alcohol and nicotine products. Interestingly, this study also utilised the 
University of Washington quality of life questionnaire and found that appearance was 
less of a concern than other oral functional issues such as saliva, swallowing, speech 
and chewing. Therefore, although appearance was an important issue, it was overall a 
relatively lesser issue compared to function in this patient group. 
The 59 -item Derriford Appearance Scale was utilised as a measurement tool in Ong's 
study of 100 patients with HIV lipodystrophy undergoing treatment with polylactic acid 
(Ong, Clarke et al. 2009). The study provides useful reference data for male patients 
with HIV lipodystrophy at baseline and up to 24 months following treatment. There is a 
paucity of published reference DAS -59 data for female patients with HIV 
lipodystrophy. The DAS -59 comprises 6 subscales examining general self - 
consciousness, social self -consciousness, self -consciousness of body and sexual self - 
consciousness, negative self -consciousness, self -consciousness of facial appearance, 
physical distress and dysfunction as well as a whole scale score. Ong reports a 
statistically significant improvement in all measures of well being 6 months following 
treatment except for physical distress. However, at the 24 -month review, all measures 
of well being except for social self -consciousness and physical distress returned to 
baseline values which Ong attributes to anticipatory anxiety over recurrence of 
lipodystrophy. In general, the scores provided in Ong's study are considerably higher 
than published studies utilising the DAS -59 in other patient groups. Litner et 
al utilised 
the scale as an outcome measure in patients undergoing cosmetic 
facial or nasal plastic 
surgery (Litner, Rotenberg et al. 2008). The overall score (81.2) 
was less than the HIV 
lipodystrophy group (122.4) in Ong's study. Interestingly, this study demonstrated 
elevated baseline levels of dysfunction for males compared with females, especially 
those males undergoing rhinoplasty. However, the sample size of male patients was 
relatively small (only 12% of the 93 patients included in the study were male). The 
study reports significant declines from baseline postoperatively for the full scale and 
for all subscales and the authors conclude that quality of life is enhanced by facial 
cosmetic surgery. However, only 3 months post- operative data was collected. It would 
be very interesting to investigate long -term psychological outcomes in patients 
undergoing cosmetic facial procedures, especially given the tendency for scores to 
return to baseline measures in the HIV lipodystrophy groups studied. 
The psychological impact of minor facial lacerations has also been investigated using 
the DAS -59, although only 2 of the 6 subscales were selected: general self - 
consciousness (GSC) and social self -consciousness (SSC) (Tebble, Thomas et al. 
2004). For males aged 31 -60 years, scores were 24.5 for GSC and 22.3 for the SSC. 
These results are lower than the HIV lipodystrophy group in Ong's study (GSC 29.2 
and SSC 35.6) but higher than the general population reference values. Follow -up data 
collected 6 months after injury demonstrated an improvement in GSC but not for SSC, 
highlighting the longer term psychological consequences of even minor facial 
lacerations (Tebble, Adams et al. 2006). 
One further study of quality of life after breast reduction utilised the DAS -59 as a 
measurement tool (Hermans, Boeckx et al. 2005). Unfortunately the scores are not 
presented in the paper therefore comparison with other patient groups is not possible. 
However, the authors report that insecurity, pain, shame and unattractiveness 
were 
significantly scored higher in the non -operated group. 
HADS data from Rumsey's cross -sectional study of 15 outpatient clinics 
is useful for 
comparison with HIV LD patients (Rumsey, Clarke et al. 2004). 
Mean anxiety scores 
were greatest in general plastics (17) and rhinoplasty (12) clinics, although the mean 
score across all clinics was 7.9. Thus, mean anxiety scores were higher for HIV LD 
males (9.8) and females (9.9) compared to the mean score of all the clinics but lower 
than some of the individual clinics highlighted. The mean depression score across all 
clinics was 5.2, which was also lower than HIV LD males (7.6) and females (8.2). 
Similarly high scores were seen for depression in the general plastics clinic (16.4) 
compared to other clinics and the HIV LD groups. The explanation for the high anxiety 
and depression scores in the general plastics group may be related to the fact that this 
group are selectively more concerned with appearance as they are seeking treatment for 
a perceived disfigurement compared to other groups who may have already received 
treatment or be attending clinics for different reasons. Direct comparison with the HIV 
LD group is difficult as the study does not subdivide the general plastics clinic scores 
into age, sex or type of disfigurement. In addition, there are only 11 patients in the 
general plastics group studied which may be an additional source of bias. Compared to 
a group of patients undergoing corrective treatment for strabismus (Jackson, Harrad et 
al. 2006), the preoperative mean anxiety (6.4) and depression (3.7) scores were lower 
than the HIV LD group. 
4.4.4. Psychological outcome in HIV LD treatment group 
4.4.4.1. Data completion 
Overall completion of psychological outcome data (62 %) was greater than for 3 -D 
volume data (35 %). Repeat psychological measures were posted to patients who did not 
attend follow -up and this accounts for the higher completion rate. The drop -out rate 
was greatest in the Newfill group with only 40% completing follow -up compared to 
81% in the Bio- alcamid group and 75% in the fat group. As discussed in the volume 
study chapter, the weaknesses of this study relate to the small numbers in each 
treatment group, confounded by incomplete follow -up data and lack of randomization. 
Therefore, several sources of bias exist which makes comparison between groups 
difficult. When considering patient motivation for completing follow -up, it was 
observed that those patients who attended were more likely to discuss an aesthetic 
concern or complication of treatment. Thus, it is possible that those patients who fail to 
attend are satisfied with the surgical outcome. This is an important source of bias when 
interpreting the psychological data. The results may be skewed, representing patients 
who are less satisfied with treatment. Furthermore, the potential for secondary gain 
must be considered. Some patients who desired re- treatment or revision procedures 
may have score more highly in the belief that this measure would secure further 
treatment using limited NHS funding. Indeed, many patients were denied treatment 
before funding was made available prior to the study. Another difficulty encountered 
was analysis of psychological data in patients who underwent revision procedures 
during the trial follow -up period. For these patients, completion of psychological data 
was continued at the defined follow -up intervals following the primary procedure. This 
was decided on the basis that re- commencing the follow -up period from baseline in 
every patient who underwent revision would further fragment the results within the 
small treatment groups and thus complicate statistical analysis. In addition, it would 
further extend the duration of the trial and most likely result in further incomplete data. 
However, the decision to complete the psychological data according to the follow -up 
period after the initial procedure introduces further bias. Repeat measures of 
psychological outcome in patients who were re- treated are more likely to be positively 
or negatively influenced by the intervention. Therefore, no inferences can be drawn 
about the long -term outcome of the primary procedure. The high number of revision 
procedures and complications with Bio- alcamid was not anticipated prior to the study. 
The emergence of these problems during the study created a dilemma: although 
adherence to the follow -up protocol prior to re- treatment would benefit the statistical 
analysis, this had to be weighed against duty of care to the patient. Unfortunately, those 
patients who were dissatisfied with the surgical result or developed a complication 
required earlier intervention, particularly as treatment was carried out using NHS 
resources. 
4.4.4.2. DAS and HADS scores 
Given the difficulty of comparison between groups described, it may be more useful to 
evaluate the HIV LD cohort as a whole when considering whether treatment 
intervention for HIV LD is associated with an improvement in psychological outcomes. 
In this way, patients provide their own control group, overcoming some of the 
additional weaknesses of non -randomization to treatment groups. Overall results 
showed a significant improvement in DAS and HADS -D scores following treatment. 
Although some increase in scores for both scales was demonstrated at 12 months, 
values were still significantly different compared to baseline. This study therefore 
supports the hypothesis that treatment for HIV LD can be associated with improvement 
in body image perception and psychological distress. However, the conclusions that can 
be drawn from analysis of individual treatment groups are less reliable and should be 
interpreted with caution as follows. 
Despite differences in baseline clinical grading between treatment groups, 
psychological measures demonstrated no difference in either DAS or HADS scores 
between the treatment groups at baseline or at follow -up. Improvements in DAS scores 
compared to baseline were seen for all 3 treatments, although results only reached 
significance in the Bio- alcamid and Newfill groups. This may be related to the 
relatively small sample size in the fat group. However, 11 out of 12 patients (92 %) in 
the fat group had a mixed morphological pattern of lipodystrophy. Thus, treatment for 
facial lipoatrophy may result in some improvement in body image perception but 
patients may also have ongoing concerns regarding body fat distribution. 
Unfortunately, this is not reflected in the DAS scores as the scale is not specific to 
facial lipoatrophy and reflects overall quality of life related to body image. The graphs 
also demonstrate a small increase in DAS scores (although not significant) for Newfill 
at 12 months. This is a finding replicated in the study by Ong et al, which demonstrated 
a return of DAS and HADS -A scores to baseline values between 12 and 24 months 
follow -up. The explanation for this may relate to anticipatory anxiety. Patients are 
aware that the effects of Newfill are temporary and may become increasingly worried 
about the recurrence of lipoatrophy. As a consequence, patients may scrutinize their 
face and develop self -perceived changes in treated areas, despite evidence of ongoing 
3 -D volume augmentation. However, current literature demonstrates high chronicity 
and recurrence of major anxiety disorders following treatment intervention. Although 
various treatment modalities including medication, cognitive therapy etc may lead to 
acute symptom reduction, maintenance in the long -term may not be sustained. 
Therefore, this pattern of ̀ bounce back' in anxiety symptoms may be echoed following 
plastic surgery interventions in patients exhibiting anxiety trait. 
The results for HADS -A and HADS -D demonstrate a similar pattern for each treatment 
group, with initial improvements in scores at 2 or 6 months, followed by an increase in 
scores at 12 months. The bounce back phenomena may account for the recurrence of 
symptoms following treatment, as anxiety about other issues returns. Some issues, 
particular to each treatment group, may also be postulated to contribute to symptom 
recurrence. A significant improvement in both HADS -A and HADS -D scores was seen 
in the Bio- alcamid group at 2 months and may represent a short-term effect following 
treatment in this group with the most severe facial lipatrophy at baseline. However, the 
high rate of revision procedures and subsequent complications with Bio- alcamid may 
account for a return of anxiety and depression in this group. Interestingly, the DAS 
scores remain significantly improved throughout follow -up. In the fat group, 
improvements in HADS -A and HADS -D reach significance by 6 months. Scores then 
increase at 12 months, although do not reach baseline values. This pattern may be 
related to fat resorption and loss of facial volume in this group (although no statistical 
correlation between facial volume and psychological measures was found). 
Alternatively, the mixed morphology explanation described for the DAS results and 
ongoing dissatisfaction with body image may be relevant. The changes in HADS -A and 
HADS -D scores are smallest in the Newfill group and do not reach significance at any 
follow -up interval. One possible explanation may relate to the mechanism of action of 
Newfill which leads to a subtle and gradual volume augmentation. Therefore, the 
psychological impact of a delayed treatment effect may not be so evident compared to 
the immediate post- operative effect of surgical treatments such as fat transfer and Bio- 
alcamid. However, no statistical difference was demonstrated for HADS -A and HADS- 
D scores between Newfill and the other treatment groups. This is a finding also 
replicated in 2 prospective, comparative studies of fat transfer, polylactic acid and 
polyalcrylamide gel in the treatment of HIV lipodystrophy. The Medical Outcomes 
Study -HIV questionnaire was utilised in one study to evaluate psychological outcome 
up to 48 weeks following treatment (Negredo, Higueras et al. 2006). Significant 
improvements in scores were demonstrated in all 3 treatment groups compared to 
baseline but no difference in outcome between treatment groups was seen. However, 
one major limitation of this scale is that it does not assess the aesthetic appearance of 
the face. In another study by Guaraldi et al, psychological outcome measures included 
the Adult AIDS Clinical Trial Group Assessment of Body Change and Distress 
(ABCD) questionnaire and a non -validated visual analogue scale to assess Facial 
Aesthetic Satisfaction (Guaraldi, Orlando et al. 2005). Improvements in both measures 
were found in all treatment groups at 24 weeks compared to baseline although no 
statistically significant differences were noted between the 3 interventional arms. 
Therefore, neither this study nor any published comparative studies have been able to 
demonstrate a psychological advantage of one type of treatment for facial lipoatrophy. 
In this study, no correlation between facial volume with DAS or HADS was found. 
This lack of correlation is consistent with previous studies which have demonstrated a 
dissociation between physical deformity and psychosocial distress (Ong, Clarke et al. 
2007). 
4.4.4.3. Correlation between psychological outcome, facial volume and 
clinical grading 
Interestingly, there was a relationship observed between patient grading of severity and 
all psychological outcomes: grade 1 lipoatrophy was associated with the lowest scores; 
grade 2 lipoatrophy was associated with intermediate scores and grade 3 lipoatrophy 
was associated with the highest scores. A much weaker relationship was seen between 
physician clinical grading and psychological scores. Intuitively, the belief that more 
severe disfigurement is associated with greater psychological distress is prevalent. 
However, the majority of published literature on disfigurement reports a lack of 
relationship between severity of disfigurement and resulting distress (Bryant and 
Harvey 1996; Bisson and Shepherd 1997). Research from Changing Faces (a UK -based 
self -help organization) has shown that a `small mark' can lead to as many difficulties as 
a major disfigurement (Smith 2000). McGrouther has also reported that the impact of 
an injury is not proportional to the severity of the disfigurement but that other 
psychological factors are involved (McGrouther 1997). It is suggested that how a 
person reacts to a change in appearance is important rather than the change itself 
(Tebble, Adams et al. 2006). Also, Moss et al propose that the perceived severity of a 
condition provides the best predictor of distress (Moss 2005). This is an important 
factor to consider when assessing patients with facial disfigurements and is particularly 
relevant to patients with HIV lipodystrophy who feel stigmatized by their condition. 
Thus, in this study, increased psychological scores were demonstrated in patients who 
perceived their faces to be severely affected by lipodystrophy. This was despite 
physician grading being less severe for many patients. This is also an important 
consideration given that the basis for reconstructive surgery is predicted on the 
assumption that improved appearance will lead to improved psychological functioning 
and better quality of life. Pruzinsky has suggested that the impact of surgery may 
involve a complex interplay between physical, social and psychological variables, 
which makes it difficult to predict who will benefit from surgery (Pruzinsky 2002). 
Ong et al have demonstrated dissociation between subjective and objective measures of 
appearance during treatment for facial lipoatrophy, with only subjective assessment 
predicting psychological outcomes (Ong, Clarke et al. 2007). Although the results of 
this study suggest that treatment for HIV -associated facial lipoatrophy is associated 
with improvements in measured psychological outcome (for DAS -24 measures and 
depression), the relationship predicting severity of lipoatrophy and resultant distress (at 
baseline and following treatment intervention) is less well defined. Indeed, this study 
also demonstrated no correlation between change in facial volume following treatment 
and psychological outcome. Assuming that greater volume change was required to 
achieve restoration of facial volume in patients with greater severity of facial 
lipoatrophy, this finding supports the body of literature on treatment for disfigurement. 
Therefore, treatment of more severe clinical grade of lipoatrophy is not associated with 
greater improvement in psychological outcome. Moss proposes that the change in 
perceiving oneself as a member of a stigmatized group to a member of a `normal' 
group is a crucial factor. This may also provide an explanation for discrepancy in 
clinical outcome and patient satisfaction, where patients may be satisfied with a less 
than optimum surgical result or dissatisfied with a good surgical result which was also 
found in this study. 
The lack of correlation between objective 3 -D data and patient reported outcomes in 
this and other studies calls also calls into question the usefulness of 3 -D data for 
measuring the success of aesthetic procedures. Whilst many surgeons strive to 
introduce objective data for analysis of aesthetic outcome, it is unknown whether these 
measurements correlate with beneficial patient outcomes. In addition, there is likely to 
be little consensus between surgeons in the types of measurements that are considered 
important. This finding was also highlighted in a study by Meier et al who performed 
3 -D measurements of facial volume following fat grafting for facial rejuvenation in 33 
patients (Meier, Glasgold et al. 2009). Patient satisfaction remained high despite only 
31% of injected volume remaining at follow -up. Thus, the small measured volume 
change could be considered a technical failure using objective data but was still 
associated with a successful aesthetic outcome as rated by the patient. 
A significant difference between patient and physician grading of facial lipoatrophy 
was demonstrated (62.8% agreement). This may represent greater perceived severity of 
facial lipoatrophy by the patient due to social stigma. Alternatively, bias relating to 
surgeon grading may be present as scoring was performed by a single surgeon. Another 
drawback of the study is that clinical grading was measured at baseline only. In one 
study, clinical grading by the surgeon has been used as an outcome measure to evaluate 
Newfill treatment for HIV lipodsytrophy (Ong, Clarke et al. 2009). Interestingly, an 
increase in clinical grade by the examining doctor was seen at the end of the 24 month 
follow -up period, despite no statistically significant difference in mean 3 -D laser scan 
volume measurements. The authors suggest a clinical bias towards placing a patient 
who may be of borderline grade in a worse clinical grade particularly if a change is 
perceived by the patient. Therefore, clinical grading by a surgeon (which may be 
perceived as a more objective measure than patient grading) is a subjective and 
unreliable outcome measure. However, if clinical grading is utilized, there may be an 
argument in favour of patient grading given that the success of aesthetic surgery is 
driven by the patient's perception of improvement in appearance. Indeed, Ong et al also 
concluded that clinical grading was more sensitive than laser scanning in predicting 
change in psychological functioning. 
4.5. Conclusions 
The case -control study has shown significantly higher levels of concern over body 
image and depression in patients with HIV associated lipoatrophy compared to HIV - 
seropositive patients without lipodstrophy and HIV -seronegative MSM control groups. 
Treatment for HIV facial lipoatrophy was associated with a significant improvement in 
appearance related concern and depression for the cohort as a whole. 
In addition, a lack of correlation between psychological measures, facial volume and 
clinical grading was seen. 
Chapter 5. Discussion 
5.1. Limitations of the case control study 
The limitations relating to the design of this case -control study include the potential for 
sampling bias and differential measurement bias. Sampling bias exists in the selection 
of the case group as the cases in this study may not represent psychological morbidity 
in patients with HIV lipodystrophy in general but rather those who present for surgical 
treatment. It is possible that those patients who desire surgical correction of 
lipodystrophy have greater concern over body image and associated psychological 
morbidity than those patients who do not wish treatment. Alternatively, those patients 
who are eligible for surgery may represent a healthier group of cases with well - 
controlled HIV parameters. Thus, it is possible that increased levels of psychological 
morbidity exist in HIV patients who do not present for surgical treatment due to other 
health or social concerns. Therefore, the design of the study could have, included 
another control group of HIV patients with lipodystrophy who are not undergoing 
surgical treatment. However, the sample size of this group would be very small as the 
majority of patients with HIV lipodystrophy in Glasgow and Edinburgh were included 
in the trial or have previously undergone treatment for lipodystrophy. Sampling bias 
may also exist in selection of control groups. Clinic -based controls were used in this 
study mainly for convenience. This has the potential advantage of compensating for the 
potential selection bias of obtaining cases from a clinic. However, health concerns 
underlying clinic attendance in either control group may be positively or negatively 
associated with the risk factor under investigation. When assessing eligibility for the 
trial, patients with known psychiatric illness were excluded. However, increased 
anxiety associated with clinic attendance may influence results, and psychological 
morbidity may not be accurately represented in the MSM or non -LD HIV seropositive 
groups. A population -based sample is a measure that could have been adopted in this 
study. For example, a disease registry could have been used to obtain a representative 
sample from the general population in the area with HIV infection. However, a clinic 
setting was considered to encourage greater response to questionnaire completion. In 
addition, bias from the individuals choosing to respond may exist. Indeed, another 
control group of healthy subjects from the general population within the area was 
considered. When designing the study, this group was not considered to provide a good 
match to the case group with respect to confounding variables such as sexual 
orientation. However, following analysis of the demographic mix recruited to the case 
group, a local, general population sample may have been a useful addition to the study. 
The DAS -24 reference tables provide very useful data on both general and clinical 
populations which were used for comparison in this study. However, the sample of 
reference participants may not match the Glasgow or Edinburgh population. 
Matching of control groups is another strategy to avoid sampling bias. As discussed in 
the relevant chapters, control groups were well matched with regards to some predictor 
variables such as HIV parameters but less well matched with regards to age, risk factors 
and ethnicity. Formal matching of controls with regards to these predictor variables was 
not carried out and is a limitation of the study. Patients in the case group were recruited 
over a 2 -year interval and analysis of demographics was not possible until the end of 
this period. Due to time constraints, participants in the control groups were recruited 
simultaneously. Therefore, matching of variables such as age, sex ethnicity etc in the 
control groups was difficult as the demographic data for the case group was not 
available. 
The second particular weakness of case -based studies is differential measurement bias. 
The method of measurement of psychological morbidity in the control groups is subject 
to bias as the psychological questionnaires were carried out at only one time interval. 
Performing repeat outcome measures in controls and obtaining average values may 
have better represented psychological morbidity in these groups over the same time 
interval as values obtained for cases. One other variable to consider when comparing 
cases with controls is potential bias relating to the strong desire for surgical treatment 
in the HIV LD group and how that may influence psychological scoring. Some HIV LD 
patients were previously denied treatment due to lack of NHS resources for aesthetic 
procedures. Therefore, patients may exaggerate the psychological impact of 
lipodystrophy and select high scores in the outcome measures in order to secure 
treatment. This is a difficult aspect of bias to compensate for but is worth discussion. 
The use of blinding in case -control studies is a strategy used to avoid bias in measuring 
risk factors. However, this was an impractical solution in this study as the 
morphological nature of HIV lipodystrophy was evident to the observer and the 
patients were aware of the treatment intervention. So, neither the observer nor the 
specific risk factor being studied could be blinded. 
Following treatment for HIV lipodystrophy, there was a significant improvement in 
DAS -24 and HADS -D scores, to a level almost comparable with the HIV non -LD and 
MSM groups at 2 months. Thus treatment for HIV LD may go a long way towards 
restoring psychological morbidity to baseline values for HIV non -LD patients. 
However, longer -term follow up at 12 months demonstrated some return of 
psychological symptoms. This study provides comparable data for this patient group, 
which are not represented in the published norm tables. 
5.2. Limitations of the prospective study 
There are several limitations of the 3 -D volume and psychological studies relating to 
the observational design. The inference that an association represents a cause -effect 
relation in an observational study is subject to both spurious associations and real 
associations that do not represent cause -effect, especially those due to confounding. To 
rule out spurious associations due to chance, calculation of sample size is important. In 
this study, calculations of sample size proved difficult due to the lack of published 
studies relating to 3 -D stereophotogrammic facial volume change or data for the 
psychological scales chosen in HIV -lipodystrophy patients. Referral numbers of 
patients with HIV lipodystrophy to the plastic surgery units in Edinburgh and Glasgow 
in the 2 -year interval prior to the trial was considered when estimating the size of 
patient group that could be recruited. Thus, the sample size of 50 HIV lipodystrophy 
patients was chosen to allow the study to be completed within a reasonable timescale 
whilst providing useful information for future studies. However, lack of statistical 
calculation of sample size is a weakness of this study. 
Spurious associations due to bias must also be considered in this type of study and 
strategies to minimise these systematic errors in both the design and analysis phase of 
the research must be performed. Three concerns relate to the design phase. Firstly, does 
the sample of study subjects represent the population of interest? A discussion on 
potential bias and representativeness of the HIV lipodystrophy cohort is provided in the 
case -control discussion. Secondly, does the measurement of the predictor variable 
sufficiently represent the predictor of interest? Difficulties in defming HIV -associated 
lipodystrophy exist and are explained in the introduction of this thesis. In this study, a 
medical history and lipodystrophy- specific examination (using the patient and 
physician assessment of lipodystrophy by Carr et al) was carried out to define the 
presence and severity of HIV- associated lipodystrophy. However, the subjective nature 
of this assessment is demonstrated in the poor correlation between patient and 
physician assessment. Patients were assessed by at least 2 physicians who agreed that 
the morphological appearance was related to HIV -lipodystrophy (the referring HIV 
physician and the lead researcher). In addition, all new referrals were also assessed by a 
consultant plastic surgeon. Thirdly, does measurement of the outcome variables 
sufficiently represent the outcomes of interest? In this study, the measurement of facial 
volume utilising the DI3D system was validated and found to be accurate and 
reproducible. Validated psychological measures were also selected and tested in a 
semi -structured interview to assess suitability of the scales to a group of patients with 
HIV lipodystrophy. Thus, the selected scales seemed appropriate to measure the 
outcome of interest when designing the study. However, some weaknesses of the scales 
to quantify outcome following facial aesthetic surgery emerged during the study. In 
addition, the complex interplay of variables influencing psychological morbidity before 
and after surgery, particularly in an HIV cohort, may not have been fully addressed 
although these variables are acknowledged and discussed in chapter 4. 
There are also several potential sources of bias in the analysis phase of the study. 
Firstly, there were a large number of patients who did not complete follow -up, 
particularly in the Newfill group. In addition, some patients underwent re- treatments 
during the follow -up interval. A detailed discussion relating to the effect of drop -outs 
and re- treatments on both the 3 -D volume and psychological data is provided in the 
relevant chapters. Secondly, the majority of patients were not randomised to either the 
Newfill or Bio- alcamid group. Therefore, bias exists in the selection of patients to 
treatment type. The 3 treatment groups were also not matched. Indeed, differences in 
baseline characteristics between groups were observed and the potential sources of bias 
when analysing the measurement outcomes have been discussed. Thus, weaknesses of 
the study relating to incomplete follow -up, small sample size, and lack of 
randomisation limit the extent of comparison that can be made between treatment 
groups. Therefore, conclusions from the study can only be based on observation of the 
cohort and caution must be exerted when drawing conclusions about the advantage of 
one treatment type over another. 
Finally, real associations that do not represent cause -effect, such as confounding 
variables must be considered in an observational study. Many of the potential 
confounding variables and weakness of the study have been highlighted in the relevant 
sections of the discussion on volume measurements and psychological outcomes. For 
example, progression of lipodystrophy or changes in weight may affect facial volume. 
During the study follow -up patients were questioned about changes to antiretroviral 
medication or weight. However, haematological parameters such as viral load and CD4 
count were not measured throughout the follow -up interval. In addition, objective 
measurements of body fat such as DEXA scanning or BMI measurements were not 
carried out at follow -up. Confounding variables that may influence psychological 
outcomes such as dissatisfaction with other body areas, particularly in patients with 
mixed morphology, or development of complications has also been considered. 
Although the DAS -24 is a useful tool to measure quality of life relating to body image, 
perhaps an additional scale to specifically measure concern over facial appearance 
would have been useful to assess outcome of treatment to the face. 
5.3. Comparison of treatment results and directions for future 
research 
Although conclusions relating to comparison of treatment groups must be made 
cautiously due to the limitations of the study, some advantages and disadvantages of 
each treatment were observed. 
Autologous fat transfer continues to remain the preferred treatment option in those 
patients with sufficient donor fat due to the safety of this technique and low rate of 
complications. A more natural volume augmentation was achieved as the treatment 
replaces what is anatomically deficient. The study demonstrated a mean reduction in 
volume compared to baseline at 6 and 12 months post -operatively. However, the 
individual response following treatment was highly variable. Thus, the major drawback 
of this technique is the unpredictable nature of fat resorption, related to both graft 
survival of the transferred fat and ongoing lipodystrophy. Further studies with larger 
patient numbers and extended follow -up are required to evaluate the long -term success 
of fat transfer. Also, further investigation utilizing histological and biological 
assessment of fat graft survival is needed, particularly in patients with HIV 
lipodystrophy. These studies would also be useful to determine the merits of fat 
harvested from different donor sites in HIV lipodystrophy patients. Other disadvantages 
of this treatment include lack of sufficient donor fat in HIV patients and the 
requirement for the treatment to be performed in an operating theatre, which has both 
practical and financial implications. Although the treatment was associated with high 
patient satisfaction, the long -term improvement in psychological outcome in this 
patient group was questionable. 
Treatment with Newfill was associated with a moderate but progressive volume 
augmentation throughout follow -up. However, the magnitude of volume change 
demonstrated between individuals was variable and was not associated with total 
number of treatment sessions in this study. Therefore, Newfill therapy may be 
insufficient to fully restore facial contour in patients with severe facial lipoatrophy. 
Newfill appears to be a safe and effective treatment for patients with mild to moderate 
facial lipoatrophy. Further assessment of 3 -D volume change beyond 12 months in a 
larger group of patients is required to determine duration of effect. Also it would be 
useful to further investigate the relationship between number of treatments and change 
in volume to better predict treatment outcome. Treatment was associated with 
improved quality of life relating to overall body image assessment but minimal 
improvement in anxiety and depression symptomatology. 
Bio- alcamid treatment was able to achieve the greatest facial volume augmentation and 
a permanent result was maintained. The early follow -up results were also associated 
with improved psychological outcomes and high patient satisfaction. Therefore, this 
product appeared to be a good reconstructive option for patients with severe 
lipoatrophy. However, the complications that have emerged during the extended 
clinical follow -up of these patients have led to the discontinued use of this product as a 
treatment option for facial lipoatrophy. 
Some patients appear to shift the goals of treatment from restoration of lipoatrophy to 
cosmetic enhancement. Therefore, establishing realistic patient expectations and 
reinforcing the goals of treatment during follow -up may be important. 
CHAPTER 6 - Conclusions 
6.1. HIV LD treatment cohort versus control groups 
This study demonstrated that patients with HIV lipodystrophy have greater distress 
relating to body image and depression compared to HIV -seropositive patients without 
lipodstrophy and HIV -seronegative MSM control groups. This study provides baseline 
demographic psychological data for these sub -groups of the population, which are not 
represented in the published norm tables. This provides useful comparative data when 
considering the effects of confounding variables such as HIV infection and sexual 
orientation on psychological outcome in patients undergoing treatment for HIV 
lipodystrophy. Investigation of psychological measures in a larger female population of 
HIV -seropositive patients with and without lipodystrophy and in a general population 
including non -MSM participants would be useful further research. 
6.2. Prospective study of HIV LD treatment group 
This study has provided objective, measured 3 -D volume data for patients undergoing 
treatment for HIV facial lipoatrophy. Changes in facial volume compared to baseline 
were observed in all 3 treatment groups. Bio- alcamid was associated with the greatest 
volume change which was maintained throughout follow -up, confirming the permanent 
nature of this product. Measured 3 -D volume augmentation was maintained in the AFT 
group at 2 months post -operatively, but the mean volume remaining at 6 and 12 months 
was 66% and 54% respectively. A progressive 3 -D volume enhancement was 
demonstrated following Newfill therapy (from 8.6cc at 2 months to 12.3 cc at 12 
months) with results showing significant change compared to baseline throughout 
follow -up. 
In addition, experiments to validate the DI3D system and software have demonstrated 
the accuracy and reproducibility of the system to measure 3 -D facial volume. 
The results of this study demonstrated no difference in psychological outcome between 
groups. Overall, treatment was associated with improved body image quality of life but 
only a moderate improvement in depression and a minimal effect on anxiety levels 
were seen. Therefore, reconstructive treatment may be associated with an improvement 
in appearance- related concerns but may not improve symptoms of anxiety and 
depression in this patient group. 
No correlation between facial volume change or clinical grade of lipoatrophy and 
psychological outcome was demonstrated in this study which supports current evidence 
which also reports a lack of relationship between severity of disfigurement and 
resulting distress. 
The short and long term complications from each treatment type have been evaluated 
and a resultant change in management protocol has been established, with the 
discontinued use of Bio- alcamid. Reported patient satisfaction was high for all 3 
treatments. 
In conclusion, this study has provided quantification of both objective, 3 -D volume 
data and subjective, patient- reported outcomes for patients undergoing treatment for 
HIV facial lipoatrophy. However, the study highlights the discrepancy between 
objective measures and beneficial patient outcomes when evaluating the success of an 
aesthetic procedure. Whilst further development of objective tools to aid surgical 
planning and monitor outcome are required, there is also a need for a well -developed 
patient- reported outcome measure designed to measure satisfaction with facial 
appearance and quality of life following aesthetic procedures. This is crucial for the 
introduction of more evidence -based practice to the field of aesthetic surgery and in 
setting standards for clinical decision -making among aesthetic patients. 
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APPENDIX 1. Patient and physician assessment 
of lipodystrophy 
APPENDIX 2. Patient Satisfaction Scales 
Patient satisfaction questionnaire 
1. On the following scale from 1 -10, how would you rate your satisfaction with the 













3. To what extent would you recommend the treatment you received to others: 
I would definitely I would defmitely 
not recommend it recommend it 
10 
4. How would you rate the result of your surgery compared with what you 
expected? 
Much worse than Much better than 
I expected I expected 
10 
Please circle the response that applies to you: 
5. What treatments did you receive? 
Fat injections Bio- alcamid injections Newfill injections Liposuction 
6. Have the effects of treatment lasted? Yes No 
If not, how long after surgery did you notice a return of the problem? 
0 -3 months 3 -6 months 6 -9 months 9 -12 months 12 -18 months 
7. Did you have any complications following surgery (e.g. bleeding, bruising, 
wound infection? Yes No 
If you answered yes, please give details: 
If you have any other comments about your surgery (good or bad) please write them in 
the space below. 
Thank you very much for completing this questionnaire. Your help is very much 
appreciated! 
APPENDIX 3. Linear mixed effect regression 
models 
Mean, SD and number of observations. Linear mixed effects (LME) model predicted mean (95% CI) of volume injected or volume relative to 
baseline, DAS, RADS -A and RADS -D, by visit and treatment type and mean (95% CI) change over baseline with p- values for test of zero 
change, and p- values for tests of no difference between groups in mean value or mean change over baseline. 
LME Mean (95% CI) LME Change (95% CI), p 
Between -Group p- 
Outcome Visit value 




Injected 26.9 (21.8, 
2 Months 32.0) 
6 Months 26.1 (20.9, 
















4.3 ( -1.9, 
10.4) 
1.4 (-1.9, 4.8), 
p=0.395 
0.7 (-2.3, 3.6), 
p.651 
3.2 (-0.1, 6.6), 
p=0.058 













55.5 (46.5, 59.9) 56.2 (48.1, 
64.5) 41.2 64.2) 
Baseline 41.6 (32.5, (30.6, 40.2 (31.7, 
2 Months 50.7) 51.7) 48.8) 
6 Months 43.1 (33.7, 42.8 39.9 (30.3, 
12 Months 52.5) (32.3, 49.5) 
41.4 (32.1, 53.2) 46.2 (36.5, 
50.7) 42.7 55.9) 
(32.0, 
53.3) 
-13.9 (-21.5, - 
6.4), p<0.001 
-12.4 (-20.5, - 
4.3), p=0.003 
-14.1 (-21.6, - 
6.6), p<0.001 

















9.4 (6.8, 9.9 (7.1, 9.8 (7.5, 
11.9) 12.8) 12.1) 
Baseline 6.8 (4.3, 8.3 (5.3, 9.3 (6.9, 
2 Months 9.4) 11.3) 11.6) 
6 Months 8.7 (6.0, 7.5 (4.6, 8.9 (6.1, 
12 Months 11.4) 10.5) 11.7) 
7.9 (5.3, 8.9 (5.9, 9.6 (6.8, 
10.5) 11.9) 12.4) 
-2.6 (-4.3, -0.8), -1.6 (-3.- 8, 0.6), -0.5 (-2.2, 1.2), 
p=0.005 p=0.155 p=0.545 
-0.7 (-2.6, 1.2), -2.4 (-4.6, - -0.9 (-3.1, 1.3), 
p=0.487 0.2), p1).033 p=0.425 
-1.5 (-3.3, 0.4), -1.0 (-3.3, 1.2), -0.2 (-2.5, 2.0), 






7.6 (5.2, 5.8 (3.1, 
10.1) 8.6) 
Baseline 4.6 (2.2, 4.2 (1.3, 
2 Months 7.1) 7.1) 
6 Months 6.3 (3.7, 3.5 (0.7, 
12 Months 8.8) 6.4) 










-3.0 (-4.6, -1.4), -1.6 (-3.- 6, 0.4), -1.2 (-2.8, 0.4), 
p<0.001 p=0.118 pa.129 
-1.3 (-3.1, 0.4), -2.3 (-4.3,- -1.3 (-3.3, 0.8), 
p=0.132 0.3), p=0.027 p=0.224 
-1.4 (-3.1, 0.3), -1.1 (-3.1, 0.9), -0.7 (-2.7, 1.4), 
p=0.100 p=0.293 p=0.515 





THE DERRIFORD APPEARANCE SCALE (DAS 24) 
YOUR NAME: DATE: 
YOUR DATE OF BIRTH: SEX: Male / Female 
OCCUPATION: Yours Partners /Spouse's 
YOUR FAMILY STATUS (please tick the option closest to your situation) 
Married /Living with partner [ ] 
Living alone [ ] 








Bangladeshi [ ] 
Indian [ ] 
ROUND (please tick) 




Other (please specify) Black - other (please specify) 
This questionnaire is concerned with how you feel about your appearance 
The first part of the scale is designed to find out if you are sensitive or self- conscious about any 
aspect of your appearance (even if this is not usually visible to others). 
(a) Is there any aspect of your appearance (however small) that concerns you 
at all? Yes / No 
If No, please turn to the next 
page If Yes, please continue: 
(b) The aspect of my appearance about which I am most sensitive or self- conscious is 
From now on, we will refer to this aspect of your appearance as your `feature' 
(c) The thing I don't like about my feature is 
(d) If you are sensitive or concerned about any other features of your body or your 
appearance, please say what they are 
Please turn over 
a. 1996. 
Instructions: The following questions are concerned with the way you feel or act. They are 
all simple. Please tick the answer that applies to you. If the item does not apply to you at all, 
tick the N/A (not applicable option). Don't spend long on any one question. 
a. How confident do you feel? 
Not at all .... Slightly .... Moderately .... Extremely .... 
b. How distressed do you get when you see yourself in the mirror /window? 
Extremely Moderately.... A Little .... Not at all Distressed .... 
c. My self- consciousness makes me irritable at home: 
N/A Never /Almost never .... Sometimes .... Often .... Almost alw 
d. How hurt do you feel? 
Extremely .... Moderately .... Slightly .... Not at all .... 
e. At present my self- consciousness has an advers ct on m . 
Almost always .... Often .... Sometimes .... Neve s.:` : n N/A 
f. How distressed do you get when you g 
N/A Not at all .... A little .... Moderately -ly .... 
Other people mis -judge me bec -- - y fe e: 
' ! r /almost never ...... N/A Almost always .... Often .. 
h. How feminine /masculine do yo 
Not at all .... Sf -;A; Mrately Extremely .... 
g 
j 
I am self - .onsc feature: 
N/A er .... Sometimes .... Often .... Almost always .... 
u feel? 
htly .... Moderately .... Extremely .... 
k. c ain gestures (e.g. folding my arms in front of other people, 
covering my 
P m my hand): 
1996 
ver /almost never .... Sometimes .... Often .... Almost always ... 
I avoid communal changing rooms: 
Almost always .... Often .... Sometimes.... Never /almost 
never N/A 
m. How distressed do you get by shopping in department stores /supermarkets? 
N/A Not at all .... Slightly .... Moderately .... Extremely .... 
n. How rejected do you feel? 
Not at all .... Slightly .... Moderately .... Extremely .... 
o. I avoid undressing in front of my partner: 
N/A Never /almost never .... Sometimes .... Often .... Almost always .... 
p. How distressed do you get while playing sports /games? 
Extremely .... Moderately .... Slightly .... Not at all .... N/A 
q. I close into my shell: 
Almost always .... Often .... Sometimes.... Never /Almost never ... 
r. How distressed are you by being unable to wear your favourit 
Extremely .... Moderately .... Slightly .... Not at all .... 
s. How distressed do you get when going to social even 
N/A Not at all Moderately .... A fag a ely .... 
t. How normal do you feel? 
Not at all .... Slightly .... Moderat: Extre 
u. At present my self- consciousnes a se effect on my sex life: 
Almost always .... Often .... ver /almost never .... N/A 
v. I avoid going out of the house: 
Almost alw_, ften.Sometimes.... Never /almost never .... 
218 
w. How distressed er people make remarks about your feature? 
. Moderately .... A fair amount .... Extremely .... 
x. I av ' _:: ' '; /restaurants: 
(ways .... Often .... Sometimes.... Never /almost never .... N/A 
y es me physical pain /discomfort: : 
er /almost never .... Sometimes .... Often .... Almost always .... 
My feature limits my physical ability to do the things I want to do: 
Almost always .... Often .... Sometimes....Never/ almost never ... 















1. I wake early and then sleep badly for the 
rest of the night. 
2. I get very frightened or have panic 
feelings for apparently no reason at all. 3 2 1 0 
3. I feel miserable and sad. 3 2 1 0 
4. I feel anxious when I go out of the 
house on my own. 3 2 1 0 
5. I have lost interest in things. 3 2 1 0 
6. I get palpitations, or sensations of 
`butterflies' in my stomach or chest. 3 2 1 0 
7. I have a good appetite. 0 1 2 3 
8. I feel scared or frightened. 3 2 1 0 
9. I feel life is not worth living. 3 2 1 0 
10. I still enjoy the things I used to. 0 1 2 3 
11. I am restless and can't keep still. 3 2 1 0 
12. I am more irritable than usual. 3 2 1 0 
13.1 feel as if I have slowed down. 3 2 1 0 
14. Worrying thoughts constantly go 
through my mind. 3 2 1 0 
Anxiety 2, 4, 6, 8, 11, 12, 14 
Depression 1, 3, 5, 7, 9, 10, 13 
Scoring 3, 2, 1, 0 (For items 7 & 10 the scoring is reversed) 
GRADING: 0 - 7 = Non -case 8 -10 = Borderline case 11+ = Case 
221 
APPENDIX 6. Reference qualitative interview 
questions 
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